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Genome-wide studies have suggested that NRF1 regulates transcription of ~5-6% of 
human genes, including nuclear genes encoding mitochondrial products. My thesis focus is in 
neural systems in which NRF1 is a master regulator. 
Prader-Willi syndrome (PWS) results from genetic loss of function of an imprinted 
domain in human chromosome 15q11.2. I confirmed NRF1 regulation of ~83% of PWS-region 
genes using chromatin immunoprecipitation (ChIP). Further studies focused on evolution of this 
region. Uniquely in marsupials, SNRPN and the ancestral SNRPB’ gene are adjacent each with an 
intronic snoRNA paralog. Based on molecular phylogenetics, a model is proposed for origin of 
each PWS snoRNA from a single ancestral snoRNA. Thus, most extant eutherian PWS genes 
originated by stepwise duplication and divergence over the past ~180 million years. 
Circadian rhythms regulate organismal physiology in a 24 hour day-night cycle. 
Functional NRF1 binding sites in promoters/enhancers were found for ~56% of circadian 
regulatory genes using bioinformatics, ChIP, NRF1 siRNA assays, and luciferase reporter 
constructs having significantly reduced transcriptional activity on mutation of NRF1 sites. 
Further, co-immunoprecipitation showed that NRF1 and the phosphorylated, active form of 
CLOCK interact in a molecular complex. In serum-induced NIH3T3 cells with circadian 
oscillations of Dbp and Nr1d1 mRNA, Nrf1 mRNA and protein levels show ultradian 
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oscillations. Hence, NRF1 regulates numerous circadian regulatory genes and interacts with 
CLOCK, suggesting multiple roles in circadian biology.  
Additional studies included finding that NRF1 regulates ~45% known hereditary spastic 
paraplegia (HSP) genes, that NRF1 activates its own transcription, and that the number of NRF1 
sites determine the degree of transcriptional activation.  
In summary, NRF1 is a master regulator in PWS, circadian rhythms, and HSP. 
Identification of NRF1 target genes and mechanisms will lead to an understanding of the 
evolution, functions, disease processes, and therapeutic targets within gene regulatory networks 
involving NRF1. Circadian rhythms are disrupted by travel, shift-work, and in illness, including 
infection, psychiatric and sleep disorders, obesity, diabetes, and cancer. Consequently, 
understanding body clocks will provide insights into the pathogenesis of these disorders and 
potentially lead to improved treatment and prevention options, which will have enormous public 
health impact.  
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1.0  INTRODUCTION 
1.1 NUCLEAR RESPIRATORY FACTOR 1 
1.1.1 Gene and protein 
Nuclear respiratory factor 1 (NRF1, also originally named α-Pal) is a highly conserved, 
phosphorylated nuclear protein (Figure 1.1). It is encoded by a gene with 11 exons including a non-
coding first exon. NRF1 was first found to regulate genes in mitochondrial respiratory function 
(Scarpulla, 2008). Subsequent research has found that NRF1 recognition sites occur in many 
nuclear genes encoding factors involved in mitochondrial function and biogenesis (Evans & 
Scarpullar, 1989; 1990; Virbasius et al., 1993; Scarpulla, 2008; Kelly & Scarpulla, 2004), cell cycle 
regulation (Cam et al., 2004; Efiok & Safer, 2000), and neuronal functions (Smith et al., 2004; 
Chang et al., 2005). As a transcription factor (TF), NRF1 forms homodimers and recognizes a 
unique DNA binding sequence, YGCGCAYGCGCR, (Scarpulla, 2006). This motif consists of a 
palindromic, direct repeat, and (PyPu)n sequence structure, but the relative contributions of each of 
these alternative components to binding affinity are not known. In virtually all described 
circumstances, NRF1 functions as a positive TF to upregulate gene expression (Scarpulla, 2008), 
although binding of chicken NRF1 at the transcription start site (TSS) of the histone H5 gene 
inhibits transcription (Gómez-Cuadrado et al., 1995), as may regulation by the sea urchin NRF1 
2 
(P3A2) at the CyIIIa gene (Bogarad et al., 1998). The regulatory roles of NRF1 may thus be 
complex and depend on the context of the regulatory elements. 
NRF1 has an ancient origin in animals, with orthologs identified in mouse (Nrf1), chicken 
(NRF1) (Gómez-Cuadrado et al., 1995), zebrafish (nrf1) (Becker et al., 1998), sea urchin (P3A2) 
(Calzone et al., 1991; Höög et al., 1991), and Drosophila (EWG) (DeSimone & White, 1993), all 
that share a highly conserved DNA binding region (Figure 1.1). Recent molecular phylogenetic 
studies have identified NRF1 orthologs in all animals with whole genome sequences except for the 
worm C. elegans (R.D. Nicholls unpublished data). The DNA binding domain of NRF1 is unique 
and not shared with any other TF class. The constrained amino acid sequence of the DNA binding 
domain of NRF1 suggests that a similar binding site is recognized across the animal kingdom. 
Indeed, Drosophila EWG binds to an identical DNA motif as mammalian NRF1 (Fazio et al., 2001).  
Knock-out and mutation studies in animals indicate that NRF1 has irreplaceable functions in 
animal development and differentiation. In mouse, a homozygous Nrf1 knockout mutation is lethal 
between embryonic days E3.5 and E6.5 (Huo & Scarpulla, 2001). Although Nrf1 -/- blastocysts 
appear normal in morphology, these could not grow in vitro in cell culture and had significantly 
reduced amounts of mitochondrial DNA as well as decreased mitochondrial staining with a 
fluorescent dye that measures mitochondrial membrane potential (Huo & Scarpulla, 2001). 
Disruption of zebrafish nrf1 is lethal at the larval stage and also shows a specific retinal phenotype 
with loss of all photoreceptor neurons and their precursors (Becker et al., 1998). Similarly, loss of 
the sea urchin P3A2 is embryonic lethal (Bogarad et al., 1998). Partial loss-of-function mutations of 
EWG in fly show severe neuronal and muscle defects while complete loss-of-function mutations are 
embryonic lethal (Fleming et al., 1989; DeSimone & White, 1993; Haussmann et al., 2008).  
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Figure 1.1. Structure of the NRF1 polypeptide. NRF1 from human, mouse, and chicken are 99-
100% identical over the entire sequence, compared with the orthologs (not shown) from sea urchin 
(P3A2; 67.5% identity in the DNA binding domain) and Drosophila (EWG; 59.7% identity in the 
DNA binding domain). The position of polypeptide structural domains are indicated, including 
alanine (Ala)-rich (hatched box), nuclear localization signal (NLS, black vertical box), DNA 
binding (black horizontal box), dimerization (small black horizontal bar) and transcriptional 
activation (grey box) domains. NRF1 has 5 serine residues that are phosphorylated (P), and four of 
these serines are conserved in P3A2 and EWG. Other symbols are: interaction domains (i.d.) for 
dynein light chain and PPARGC1A/PRC; Gt: position of the RRF126 gene-trap β-geo fusion 
truncating the mouse Nrf1 polypeptide. Modified from: Höög et al., 1991; Efiok et al., 1994; 
Gómez-Cuadrado et al., 1995; Gugneja et al., 1996; Gugneja et al., 1997; Herzig et al., 2000; 
Andersson & Scarpulla, 2001; Huo & Scarpulla, 2001; Nicholls RD, unpublished data. 
 
 
 
4 
1.1.2 NRF1 and mitochondria 
The mitochondrion is a membrane-enclosed organelle found in most eukaryotic cells. 
Known as “cellular power plants”, mitochondria produce energy, adenosine triphosphate (ATP), 
which is used as a major source of chemical energy. Mitochondria are also involved in pyruvate and 
fatty acid oxidation, nitrogen metabolism, and oxidative phosphorylation (Scarpulla, 2008). A 
unique feature of mitochondria is that they contain their own genetic system, mitochondrial DNA 
(mtDNA), which encodes a number of gene products that contribute to the structure and function of 
the organelle (Scarpulla, 2008). Although the mitochondrion has its own genetic information, the 
limited capacity of mtDNA requires nuclear genes to provide major respiratory subunits and to 
support mtDNA transcription and replication (Gopalakrishnan & Scarpulla, 1995). These nuclear 
genes encode most of the structural and catalytic components involved in the electron transport 
chain and oxidative phosphorylation system, as well as genes that control mitochondrial 
transcription, translation and DNA replication (Scarpulla, 2008). NRF1 is one of several key TFs 
that regulate transcription of nuclear genes encoding mitochondrial products. Other key TFs in 
nuclear control of mitochondrial biogenesis include GABP (GA binding protein transcription factor, 
alpha subunit, also known as NRF2), ESRRA (estrogen-related receptor alpha, also known as 
ERRα), PPARs (peroxisome proliferator-activated receptors), CREB1 (cAMP responsive element 
binding protein 1, also known as CREB), Sp1 and YY1 (Yin Yang 1, Scarpulla, 2008). As noted 
above, NRF1 was first identified and cloned in studies on transcriptional regulation of cytochrome c 
and cytochrome oxidase subunit genes (Evans & Scarpulla, 1989; Gopalakrishnan & Scarpulla, 
1994; Virbasius et al., 1993). Bioinformatics analysis and chromatin immunoprecipitation (ChIP) 
using cancer cell lines showed that NRF1 binds to the promoters of many nuclear genes that are 
5 
involved in mitochondrial biogenesis and regulates transcription of these genes, including TFAM 
(mitochondrial transcription factor A), and others (Cam et al., 2004; Scarpulla, 2006).   
Mitochondrial function is hypothesized to be associated with exercise and aging, NRF1 and 
its coactivators (e.g., PPARGC1A, also known as PGC-1α) have also been studied in these 
important physical conditions (Scarpulla, 2008). Under the normal situation in some cell types, 
NRF1 function involves co-activation by PPARGC1A to recruit RNA polymerase to promoters of 
nuclear target genes. It has been shown that exercise induces an increase in PPARGC1A and NRF1 
in skeletal muscle as well as mitochondrial biogenesis (Murakami et al., 1998; Baar et al., 2002). In 
aging, reports have shown PPARGC1A and NRF1 expression levels are different comparing young 
versus aged subjects (Lezza et al., 2001, Viña et al., 2009), suggesting changes in mitochondrial 
biogenesis, but the answers are not yet definitive and the mechanism underneath is still obscure.  
Studies of the function of NRF1, its coactivators, and other interacting TFs and regulators 
will help us better understand the mechanism of mitochondrial biogenesis, oxidative stress and 
aging, as well as how physical exercise can improve the activity of mitochondria to prevent its 
impairment by aging.  
1.1.3 NRF1 in neuronal development 
Although most of the early studies on NRF1 focused on mitochondrial functions, it is 
becoming increasingly clear that NRF1 not only regulates nuclear genes in mitochondrial 
biogenesis but also regulates numerous genes in neuronal and other systems.   
For example, NRF1 was found to up-regulate transcription of the human IAP (Intergrin-
associated protein or CD47) gene, involved with processes of memory formation in the rat 
hippocampus and regulation of dendritic outgrowth and synaptic transmission in developing 
6 
cortical neurons through the activation of MAPK (Huang, et al., 1998; Chang & Huang, 2004; 
Numakawa, et al., 2004). Subsequently, NRF1 was found to increase neurite outgrowth in part 
through the regulation of IAP (Chang, et al., 2005). NRF1 is also important for expression of FMR1, 
the fragile X mental retardation syndrome gene (Smith et al., 2004). More recent studies showed 
that NRF1 regulates gene expression of Synapsin I, a phosphoprotein that plays a role in regulation 
of axonogenesis and synaptogenesis (Wang et al., 2009), as well as several NMDA receptor (NR) 
genes which play important roles in neuronal plasticity and synaptic transmission associated 
neuronal functions (Dhar & Wong-Riley, 2009). The same group also investigated NRF1 regulation 
of cytochrome c oxidase (COX) subunits (Dhar et al., 2008; Dhar et al., 2009) to perhaps provide a 
link between energy generation and synaptic transmission. Additionally, studies of the NRF1 
ortholog in zebrafish showed that loss of function led to a specific loss of photoreceptor neurons 
and their precursors (Becker et al., 1998) and expression of EWG, the Drosophila ortholog, is 
neuronal specific (Haussmann et al., 2008). 
The above experimental data implies that NRF1 may play additional roles in neuronal 
systems and could be involved in neural-related disease pathways. My major focus has been to 
identify which systems are regulated by NRF1 and the mechanisms of action by NRF1. 
1.1.4 Genome-wide studies of NRF1 binding sites 
Transcription is initiated or repressed by the assembly of TFs at their binding sites in cis-
acting DNA elements, usually in the promoter region of a gene, with the TSS defining where the 
gene begins to be transcribed into RNA (Wasserman & Sandelin, 2004). Besides promoters, other 
cis-acting DNA elements include enhancers (activation elements), silencers (repression elements) 
and insulator (boundary elements, Villard, 2004; Riethoven, 2010). These elements can be hundreds 
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or thousands of base pairs from 5’ or 3’ of the TSS (Villard, 2004; Riethoven, 2010). According to 
their function, TFs can most simply be divided into two groups. One group is the basal TFs that are 
necessary for transcription to occur, e.g., RNA polymerase II, and the other group includes the gene 
specific TFs which promote (as an activator) or suppress (as a repressor) basal transcription (Villard, 
2004). Studying the exact mechanisms of how a TF regulates gene expression will be helpful in 
understanding gene functions and gene regulatory networks (GRNs), and how these operate in 
normal development as well as the roles in disease.   
One of the approaches to understand the functions of a TF is to identify the target genes and 
regulated gene networks. In finding such a GRN, one can use the data to analyze TF function in 
certain diseases and identify new genes and mechanisms in disease regulation. In order to search for 
candidate TF binding sites in the genome, a suitable first step in the era of genome sequences is a 
computational approach for specific binding site sequences to identify candidate genes. Next, 
several genome-wide experimental methods have been established to prove functional TF binding 
sites: 1) microarray analysis, e.g., Chromatin immunoprecipitation on chip (ChIP-chip); 2) gene 
silencing by RNA interference (siRNA) or TF overexpression (a complementary approach to 
siRNA); and 3) next generation sequencing, e.g., ChIP-seq and RNA-seq (Goutsias & Lee, 2007; 
MacQuarrie et al., 2011; Pareek et al., 2011). With these approaches, a list of target genes will be 
identified and can be focused on for more in depth functional studies. To date, many experimental 
methods, including in vitro assays such as electrophoretic mobility shift assay (EMSA) (Fried & 
Crothers, 1981), reporter assays in cell culture, and in vivo methods such as ChIP (Kuo & Allis, 
1999) have been applied to elucidate the interaction of a TF and DNA sequences. Nevertheless, 
these studies can only be performed when the location of regulatory element is known or predicted. 
In large and complex genomes, discovery of bona fide TF binding sites are challenging due to 
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factors such as 1) poor definition of gene promoters; 2) the distance between TF binding sites (e.g., 
in enhancers) and promoters can be 1 kb or more and up to a megabase; 3) the degeneracy in TF 
recognition motifs around a consensus nucleotide sequence; and 4) the variety of mechanisms, such 
as spacing and arrangement of TF binding sites, that are involved in transcriptional regulation 
(Hallikas et al., 2006; Villard, 2004).   
Recent approaches have used computational bioinformatics to develop algorithms capable 
of searching genome sequences for potential TSS and TF binding sites. Typically, several classes of 
computational programs have been applied to the search for potential TF binding motifs in a 
genome and each has strengths and weaknesses (Wasserman & Sandelin, 2004). With the 
availability of representative mammalian genome sequences, comparative genomics provides a 
powerful tool to systematically discover functional elements in a genome (Wasserman et al., 2000; 
Dubchak et al., 2000; Xie et al., 2005). In particular, the NRF1 motif has been found to be the most 
highly conserved putative TF binding motif in the human genome (Xie et al., 2005). The basis for 
this is likely to have several explanations including 1) NRF1 has a longer recognition motif than 
most TFs; 2) the NRF1 binding site allows less degeneracy than most TF binding sites which can be 
highly degenerate; and 3) NRF1 gene regulation, once established by evolutionary processes, may 
be associated with stronger selective pressure and/or reduced compensatory changes in TF 
regulation than for other TF-target gene interactions. The first two of these explanations are 
involved while the third is a hypothesis that remains to be tested. Experimentally, these 
considerations provide a strong rationale for inclusion of bioinformatics studies to identify and 
understand NRF1 functions in GRNs.  
To date, genome-wide studies in human by ChIP-chip found NRF1 binding sites in 5.3% of 
~13,000 gene promoters (Cam et al., 2004). Nevertheless, this study used a karyotypically highly 
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rearranged cancer cell line, and thus many epigenetically regulated or tissue-specific target genes 
would not have been identified (including virtually all the target genes identified in this thesis). A 
strictly bioinformatics study examining the distribution of 8-mer nucleotide sequences (FitzGerald 
et al., 2004) found that a sequence (CGCVTGCG) similar to NRF1 binding sites was found in 6% 
of the 13,010 promoters analyzed, although the result may be slightly overestimated since the core 
of the consensus NRF1 binding site is longer (GCGCANGCGC). Indeed, a GCGCatGCGC motif 
was found in 5.3% of 10,577 promoters (Xi et al., 2007). Using comparative analysis of the human, 
mouse, rat and dog genome sequences to identify conserved regulatory motifs in promoters of ~ 
17,700 genes, Xie et al. (2005) found 6.1% had conserved NRF1 binding sites. These studies 
provide a preliminary estimate of the frequency of NRF1 target genes in the human genome, 
although as no experimental confirmation was done it is unknown what percentage of identified 
sites are functionally relevant. Furthermore, none of these studies examined non-promoter 
sequences, so the potential contribution of NRF1 to long-range gene regulation is completely 
unknown.  
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1.2 PRADER-WILLI SYNDROME 
1.2.1 Clinical phenotype and diagnosis 
Prader-Willi Syndrome (PWS) is a complex congenital disorder that involves genetic 
abnormalities in chromosome 15q11-q13, with an incidence of ~1:15,000-1:25:000 births (Holm et 
al., 1993; Buiting, 2010; Wattendorf & Muenke, 2005). It is the most common form of obesity 
caused by a genetic syndrome (Wattendorf & Muenke, 2005). The clinical phenotype of PWS 
includes severe hypotonia, respiratory distress, feeding difficulties and failure-to-thrive in early 
infancy, followed by hyperphagia and development of obesity in later infancy or early childhood 
(Holm et al., 1993; Nicholls & Knepper, 2001; Gunay-Aygun et al., 2001). Patients are delayed in 
early motor and language development, as well as having some degree of cognitive impairment and 
hypogonadism (Holm et al., 1993; Gunay-Aygun et al., 2001). Other common features include 
short stature, characteristic facial features, strabismus and scoliosis (Holm et al., 1993; Wattendorf 
& Muenke, 2005). Patients also have common behavioral abnormalities, e.g., temper tantrums, 
stubbornness, manipulative behavior and obsessive-compulsive characteristics (Holm et al., 1993; 
Nicholls & Knepper, 2001). A prevalence rate of 25% for non-insulin-dependent diabetes mellitus 
was found in PWS adults due to obesity (Butler et al., 2002).    
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1.2.2 Genetics and epigenetics 
At the molecular level, genes within the 2 Mb PWS region are regulated by the process of 
genomic imprinting. Genomic imprinting is an epigenetic mechanism leading to uniparental 
expression of certain genes in mammals and is established by a genetic element called the 
imprinting center (IC) during gametic and early preimplantation development (Nicholls & Knepper, 
2001; Morison et al., 2005). The most common cause of PWS is a 5-6 Mb de novo deletion 
exclusively on the paternally-inherited allele. There are two classes of deletions in PWS patients, 
with two proximal breakpoints 1 and 2 (BP1, BP2) in 15q11 and a single distal BP3 in 15q13. PWS 
patients can also have maternal uniparental disomy (UPD) of chromosome 15, or in rare cases 
imprinting defects generating a maternal imprint on the paternally-derived chromosome (Nicholls 
& Knepper, 2001; Horsthemke & Buiting, 2006). In each circumstance, PWS arises from the 
functional loss of a set of paternally-expressed genes.  
To date, at least 13 paternally-expressed genetic loci have been identified in the PWS-region 
in human, six of which encode polypeptides, including MKRN3 (Jong et al., 1999a; 1999b), 
MAGEL2 (Boccaccio et al., 1999; Lee et al., 2000), NDN (Jay et al., 1997; MacDonald & Wevrick 
1997), C15orf2 (Buiting et al., 2007), and the bicistronic SNURF-SNRPN [Gray et al., 1999a, 
Figure 1.2(a)]. A second imprinted disorder, Angelman syndrome (AS), is a neurological disease 
associated with genetic mechanisms that lead to a loss of function of a maternally-expressed 
imprinted gene, UBE3A, located telomeric to the PWS domain [Figure 1.2(a)]. Most PWS genes 
have an exclusive or predominant expression pattern in neurons (Cavaillé et al., 2000; Nicholls & 
Knepper, 2001; Runte et al., 2001), and their functions are only partially understood. The 
bicistronic locus SNURF-SNRPN encodes two polypeptides. SNRPN encodes a brain-specific 
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spliceosome protein, SmN, which replaces the otherwise constitutive SmB’/B protein during late 
fetal and postnatal brain development (Sharpe et al., 1990, McAllister et al., 1989), while the 
upstream SNURF encodes an independent nuclear protein of unknown function (Gray et al., 1999a). 
SNURF-SNRPN is also the host gene of five classes of box C/D small nucleolar RNAs (snoRNAs). 
The snoRNAs include SNORD107 (previously HBII-436, 1 copy), SNORD64 (previously HBII-13, 
1 copy), SNORD109A (previously HBII-438A, 1 copy), SNORD116 (previously HBII-85, 29 
copies), SNORD115 (previously HBII-52, 47 copies) and SNORD109B (previously HBI-438B, 1 
copy, Cavaillé et al., 2000; Runte et al., 2001; Buiting, 2010; Zhu, et al., in preparation), most of 
which have unclear function and targets, except that SNORD115 has been identified to regulate 
serotonin receptor 2C mRNA splicing (Kishore & Stamn, 2006).  
The complex genetic locus encoding the polycistronic SNURF-SNRPN-snoRNA loci 
appears to play a major role in PWS, based on the location of the imprinting regulatory region at its 
5’ end [Figure 1.2(a); Nicholls & Knepper 2001; Horsthemke & Buiting 2006], its disruption by 
two classes of balanced translocations (Wirth et al., 2001), and the finding that mice with a deletion 
of Snurf-Snrpn and the snoRNA clusters have a “partial mouse PWS” phenotype (Tsai et al. 1999). 
More recent studies showed that NECDIN (a MAGE-family protein, encoded by NDN) and 
MAGEL2 bind to several proteins in the region of the centrosome, and that axonal outgrowth is 
abnormal in Ndn-deficient embryos (Lee et al., 2005), while other studies suggest that in 
preadipocytes NECDIN inhibits a TF, E2F4, to prevent adipogenesis which is consistent with its 
long-postulated role in post-mitotic cells (Tseng et al., 2005). NECDIN also appears to play a role 
in the neuronal function of respiration (Ren et al., 2003; Zanella et al., 2008). Magel2 is a clock-
controlled circadian output gene (Kozlov et al., 2007). All PWS genes have similar expression 
patterns with highest or exclusive expression in neurons, especially during development (Cavaillé et 
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al. 2000; Runte et al., 2001; Lee et al., 2003; Watrin et al., 2005), and a common regulatory 
element specific for neurons has been proposed (Watrin et al., 2005).  
The PWS region has an intriguing evolutionary history in mammals and shows clear 
evidence of relatively rapid and recent evolutionary change. SNRPN and the PWS region snoRNAs 
derive from an ancestral duplication of a SNRPB’ gene in a therian ancestor (Gray et al., 1999; 
Rapkins et al., 2006; unpublished data). Mrkn3, Magel2, Ndn, and Frat3 in rodents are all 
intronless genes and acquired by retrotranposition events in a eutherian or rodent ancestor, 
respectively (Jong et al., 1999a; 1999b; Gray et al., 2000, 2001; Chai et al., 2001). C15orf2 shows a 
predominantly testis-specific expression pattern (Färber et al., 2000), with low expression in fetal 
brain and originates from a retrovirus in an ancestral primate (Buiting et al., 2007). In mouse, the 
homologous PWS region is in chromosome 7C [Figure 1.2(b)], except that mouse doesn’t have 
C15orf2 and PWRN1 (Buiting et al., 2007), but gained Frat3 by retrotransposition (Chai et al., 
2001). The rodent locus also does not have Snord109 copies and has a rodent specific microRNA 
(miRNA), miR-344 [Figure 1.2(b)]. Loss of imprinted gene expression in mouse 7C leads to a 
similar but more severe neonatal phenotype as human (Nicholls & Knepper, 2001; Stefan et al., 
2005; Stefan et al., in preparation). 
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Figure 1.2. Prader-Willi syndrome (PWS) imprinted domain in (a) human chromosome 
15q11.2 and (b) mouse chromosome 7C. Genes in blue are paternally expressed, while genes in 
red are maternally expressed. Circles indicate genes encoding proteins, ovals indicate RNA genes, 
and arrows indicate the direction of gene transcription. cen, centromere; tel, telomere; IC, 
imprinting center. Modified from Stefan, et al., in preparation. 
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1.3 CIRCADIAN RHYTHMS 
As the word “circadian” was first derived from the latin word “circa diem”, it means “about 
a day” (Roenneberg & Merrow, 2005; Toh, 2008). Circadian rhythms exist in virtually all living 
organisms and function as an internal body clock that regulates the metabolic, physical and 
behavioral paces of the body (Panda et al., 2002; Roenneberg & Merrow, 2005; Toh, 2008). The 
fundamental trigger of circadian rhythms is environmental cues, such as light and temperature 
(Roenneberg & Merrow, 2005).  It is hypothesized that circadian oscillators are an advantage for 
living organisms to adjust internal physiology to adapt to environmental changes (Panda et al., 
2002).  
1.3.1 Physiology and behavior 
The daily sunrise and sunset are considered to be the ultimate force for circadian rhythms 
(Roenneberg & Merrow, 2005). The central mammalian circadian pacemaker resides in the 
suprachiasmatic nucleus (SCN) of the hypothalamus (Maywood et al., 2007; Takahashi et al., 
2008). The SCN is composed of bilateral nuclei, each comprising approximately 10,000 neurons 
which are autonomous cells (Takahashi et al., 2008).When these neurons in the SCN are entrained 
by projection from retinal neurons, they use neuronal and hormonal mechanisms to coordinate 
rhythmic physiology and behavior. Studies have shown that damage to the SCN eliminates 
endogenous circadian rhythms, which supports its role as circadian pacemaker (Inouye & 
Kawamura, 1979). In addition to the SCN, peripheral organs, such as liver and heart, have circadian 
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rhythms that receive neural and hormonal output signals from the SCN (Rutter et al., 2002; 
Hastings et al., 2007) and additionally can also be entrained by food or energy balance (Mendoza, 
2007). 
In mammals, circadian rhythms influence many aspects of physiology and behavior, 
including sleep-wake cycles, energy metabolism, hormonal regulation, heart rate, blood pressure 
and body temperature (Triqueneaux et al., 2004; Gallego & Virshup, 2007). Therefore, it is 
reasonable to consider the goal of circadian rhythms is to optimize metabolism and energy balance 
for sustaining life of a living organism (Levi & Schibler, 2007). 
1.3.2 Molecular clocks in human 
In animals, the cellular circadian cycle is determined molecularly by oscillations of positive 
and negative transcriptional and post-transcriptional feedback regulation. In the positive feedback 
loop, CLOCK and BMAL1, two basic helix-loop-helix (bHLH)-PAS TFs, form a heterodimeric 
complex and function as a transcriptional activator in the circadian pacemaker to activate the 
transcription of circadian core genes, period (PER) and cryptochrome (CRY), as well as other 
circadian output genes, through E-box DNA binding elements (5’- CACGTG-3’, Steeves et al., 
1999; Gekakis et al., 1998; Kondratov et al., 2003). On the other hand, PER and CRY also 
heterodimerize and mediate the negative limb of a transcriptional feedback loop in the circadian 
system (Sun et al., 1997; Darlington et al., 1998; Hastings et al., 2007; Brown et al., 2005). In this 
feedback system, the CLOCK/BMAL1 complex binds to E-boxes in the promoters of the PER and 
CRY genes and stimulates transcription, but as the concentration of PER/CRY increases, they 
inhibit CLOCK/BMAL1 function. Subsequently, PER and CRY are degraded and cycling of this 
system generates the circadian oscillations (Reppert & Weaver, 2002). In addition, NR1D1 (also 
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known as REV-ERBα) forms an ancillary feedback loop by being a repressor of BMAL1 
transcription (Takahashi et al., 2008). Another circadian regulator is DBP, which encodes a TF that 
regulates many clock output genes as well as PER1 (Yamaguchi et al., 2000).  
Post-translational modifications such as phosphorylation, ubiquitination, sumoylation, and 
acetylation have been shown to play important roles in the regulation of circadian expression 
(Cardone, et al., 2005; Takahashi et al., 2008). Circadian timing of PERs is controlled through 
progressive phosphorylation by kinases, CSNK1A1 (also known as CKIα, Hirota et al., 2010), 
CSNK1D (also known as CKIδ, Lee et al., 2009) and CSNK1E (also known as CKIε, Akashi et al., 
2002; Takahashi et al., 2008; Lee et al., 2009). The stability and cellular localization of PER is also 
regulated by phosphorylation (Akashi et al., 2002; Blau, 2008). For CRY1, phosphorylation and 
protein stability are rhythmically regulated by AMPK, an adenosine monophosphate (AMP)-
activated protein kinase (Lamia et al, 2009). BTRC (also known as β–TrCP1) and FBXL3, both F-
box proteins and subunits of ubiquitin protein ligase complexs, can target phosphorylated PER and 
CRY proteins, respectively, and promote polyubiquitylation for the 26S proteosomal degradation 
pathway (Reischl et al., 2007; Busino et al., 2007). In the circadian system, sumoylation was first 
found in a lysine residue (Lys259) of BMAL1 by SUMO1 to enhance the circadian expression of 
BMAL1 (Cardone et al., 2005). Such a process is induced by CLOCK (Cardone et al., 2005). In 
addition, CLOCK protein can rhythmically acetylate BMAL1; subsequently, acetylation of BMAL1 
facilitates recruitment of CRY1 to CLOCK/BMAL1 for transcription repression (Hirayama et al., 
2007). SIRT1 (histone deacetylase sirtuin 1), on the other hand, can interact with CLOCK to 
deacetylate BMAL1 and PER2 (Nakahata et al., 2008; Asher et al., 2008). 
Additionally, histone acetylation and methylation are also crucial in circadian regulation 
(Takahashi et al., 2008; Katada & Sassone-Corsi, 2010). Rhythmic expression of mouse Per1 and 
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Per2 are regulated by histone H3 acetylation and deacetylation (Etchegaray et al., 2003; Curtis et 
al., 2004; Naruse et al., 2004). Similarly, rhythmic histone acetylation was reported in circadian 
transcription of Dbp by the binding of CLOCK/BMAL1 to an intronic Dbp enhancer (Ripperger & 
Schibler, 2006). Later studies showed that CLOCK protein has histone acetyltransferase (HAT) 
activity (Doi et al., 2006; Hirayama et al., 2007), while SIRT1 is a NAD+-dependendent 
deacetylase to histone H3 (Nakahata et al., 2008; Asher et al., 2008). Circadian expression of 
SIRT1 was found in mouse liver and fibroblast cells with a constant level of Sirt1 mRNA, 
indicating posttranscriptional regulation involved in circadian regulation of SIRT1 (Asher et al., 
2008). Since the function of SIRT1 depends on NAD+, it provides a link between cellular 
metabolism and circadian rhythms. Finally, recent studies indicated that a chromatin activator 
MLL1 is part of the CLOCK/BMAL1 complex and plays a crucial role in circadian transcription 
and H3K4 trimethylation (Katada & Sassone-Corsi, 2010). Overall, these findings in post-
translational regulation and histone modification for chromatin remodeling change the traditional 
view of the control of molecular clock purely by a transcriptional feedback loop. The network of 
transcriptional and post-transcriptional regulation shows how complex and hierarchical the 
molecular control of circadian regulation is. Together, these processes create the dynamic changes 
of chromatin structure in circadian expression and thus reflected by rhythmic changes on mRNA 
and protein levels of circadian input and output genes.   
During the past decade, studies in circadian rhythms have made remarkable progress. One 
piece of evidence is that many new genes have been studied and found to play roles in circadian 
regulation (Asher et al., 2008; Lee et al., 2009; Katada & Sassone-Corsi, 2010, Hirota et al., 2010). 
However, more evidence indicated that new regulatory genes may involve different levels of 
regulation to fine-tune circadian regulation (Bozek et al., 2010).  
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1.3.3 Circadian rhythms and disease 
Circadian rhythms direct neural and hormonal control of daily activity, feeding, and sleep 
cycles. They are disrupted by travel, shift-work, and in disease including sleep, eating and 
psychiatric disorders, obesity, diabetes, cardiovascular disease, infection, and cancer (Kondratov & 
Antoch, 2007; Weldemichael & Grossberg, 2010; Wulff et al., 2010; Gravotta et al., 2011).  
Since circadian rhythms are highly correlated to body metabolism, many studies showed 
association between circadian clock and metabolic abnormalities (Bass & Takahashi, 2010; Huang 
et al., 2011). Glucose concentrations in the blood are highly rhythmic (Bass & Takahashi, 2010). 
Patients with type II diabetes have abnormal circadian insulin secretion (Boden et al., 1999). Clock 
and Bmal1 mutant mice have impaired glucose tolerance, reduced insulin secretion and other 
phenotypes that lead to the development of diabetes mellitus and obesity (Turek et al., 2005; 
Marcheva et al., 2010).   
Another common feature for disease associated with circadian rhythms is an abnormality in 
sleep. The timing of sleep is controlled by the circadian clock with the release of melatonin and a 
reduction of body temperature. It has been reported that more than 80% of patients with depression 
or schizophrenia have sleep complaints (Wulff et al., 2010). Decrease of melatonin secretion is 
often found in patients with Alzheimer’s disease and phenotypic features of day time agitation, 
night-time insomnia and restlessness (Weldemichael & Grossberg, 2010; Wulff et al., 2010). 
Similarly, for patients with Parkinson’s disease, it is common to have night-time sleep disturbances 
and daytime sleepiness (Wulff et al., 2010). 
At the molecular level, the first disorder that linked directly to core circadian genes is 
familial advanced sleep phase syndrome (FASPS), which has missense mutation in PER2 
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(Takahashi et al., 2008). Insomnia is one of the most common sleep disorders and affects 
approximately 10-15% of the adult population (Ban et al., 2011). A cohort study has linked 
insomnia to SNPs in ROR1 and PLCB1, genes that have previously been associated with bipolar 
disease and schizophrenia, respectively (Ban et al., 2011). A mutation has been found in DEC2, 
encoding a repressor to the CLOCK/BMAL1 complex, in a family-based study of lifelong shorter 
daily sleep time (He et al., 2009). Subjects with the DEC2 mutation have a short sleep phenotype 
(He et al., 2009).  
Interestingly, clinical studies show that disease treatment is often sensitive to the time of 
administration (Levi & Schibler, 2007). Consequently, rhythmic processes in the body should be 
considered in personalized pharmacotherapy for more effective treatment (Ohdo, 2010), including 
in cancer treatment (Kondratov & Antoch, 2007). Therefore, a better understanding of how body 
clocks work will not only provide insights into the pathogenesis of these and other common 
disorders, but also improve treatments for disease. 
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2.0  TRANSCRIPTIONAL AND EVOLUTIONARY MECHANISMS IN PRADER-
WILLI SYNDROME 
2.1  INTRODUCTION 
2.1.1 Regulation of the PWS imprinted domain in somatic cells 
As described in Chapter 1.2., PWS is an inborn disease that involves chromosomal 
abnormalities of human chromosome 15q11.2. In the 2 Mb human PWS domain (Figure 2.1), our 
laboratory has identified 14 NRF1 binding sites in the SNURF-SNRPN promoter (2 sites), SNURF- 
SNRPN intron 1 enhancer (2 sites), a CpG-islet site 3.7 kb 5’ of MKRN3 (intergenic in mouse), the 
NDN promoter, the U1A and U1B promoters, putative enhancer elements upstream of U1A and 
U1B, and in an element termed the “NRF1 cluster”. The “NRF1 cluster” element is located between 
a cluster of intronless genes in proximal 15q11.2 and the U1-SNURF-SNRPN-snoRNA region and 
consists of four conserved NRF1 binding motifs (Figure 2.2, Stefan et al., in preparation). The 
stereospecific arrangement of 4 clustered NRF1 motifs suggests binding to the same face of the α-
helix and potential for cooperative interactions similar to known enhancer elements (Stefan et al., in 
preparation). Studies by our laboratory also found that the “NRF1 cluster” element shows brain-
specific DNA methylation, and has strong enhancer function in reporter assays (Stefan et al., in 
preparation). The “NRF1 cluster” element also shows NRF1 binding and an enhancer-pattern 
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(Heintzman et al., 2007; Schübeler, 2007) of histone H3K4 methylation based on ChIP studies 
(Stefan et al., in preparation). Similarly, in the mouse orthologous region, chromosome 7C, we 
found 18 NRF1 cis-binding sites in 11 gene promoters, two enhancers, and the “NRF1 cluster”, all 
differentially methylated and bound in vivo by NRF1 within active chromatin [acetylated histone 
H4 and dimethylated histone H3 (Lys4)] on the paternal allele only (Stefan et al., in preparation). 
Combined, the human and mouse studies indicated that NRF1 is a “master” regulator of the PWS 
region (Stefan et al., in preparation). However, the previous human studies used SK-N-SH cells 
which do not express MAGEL2, PWRN1, or C15orf2, and only express a low level of MIRH1 
(Stefan et al., in preparation).  
In order to confirm and extend analysis of the role of NRF1 in regulating PWS genes, my 
study has used ChIP assays to examine NRF1 binding in the GM11715 mouse/human somatic 
hybrid cell line. The GM11715 cell line was derived by microcell fusion of human diploid fetal 
lung fibroblasts with mouse A9 cells (Ning et al., 1992) and is Hprt- (Cos et al., 1974), which can 
be used in drug selection by HAT for gene targeting (Capecchi, 2005). Similarly, A15 (and its 
derivative, A15-1, which has a truncated version of chromosome 15) is also a somatic cell hybrid 
derived from mouse A9 cells (McDaniel & Schultz, 1992) but has a more active, hypomethylated 
epigenetic state in 15q11.2 than does GM11715 (Gabriel et al., 1998), which provides alternative 
cell line(s) for such studies. Expression studies have found that all of the human PWS genes are 
expressed robustly in the GM11715 cell line with the exception of MKRN3; in contrast, the 
homologous mouse genes are not expressed (Figure 2.3). Because the three somatic cell hybrids all 
express apparently robust levels of PWS genes and contain only one paternally-derived human 
chromosome 15 (Figure 2.3, Gabriel et al., 1998), these provide an apparently ideal system for the 
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study of NRF1 regulation in the PWS domain by gene targeting of a single copy of the “NRF1 
cluster”. 
Gene targeting is based on the principle of homologous recombination, and has been applied 
to many studies using mouse embryonic stem (ES) cell studies to examine gene function and 
phenotype, and a few studies in gene regulation (Sedivy & Dutriaux, 1999), as well as studies in 
somatic cells (Porter & Itzhaki, 1993). If the disruption of the “NRF1 cluster” by gene-targeting 
was successful, it would allow testing the hypothesis that this element has long-range cis-regulatory 
function in gene expression across the PWS domain. Importantly, this approach will allow analysis 
of gene expression and changes in chromosomal structure of the entire PWS domain in a 
chromosome setting. 
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Figure 2.1. NRF1 is a master regulator of the human Prader-Willi syndrome (PWS) 
imprinted domain in chromosome 15q11.2. Genes in blue are paternally expressed, while genes 
in red are maternally expressed. Circles indicate genes encoding proteins, ovals indicate genes 
encoding small RNAs, and arrows indicate the direction of gene transcription. Gold stars indicate 
verified NRF1 binding sites. cen, centromere; tel, telomere; Modified from Stefan et al., in 
preparation. 
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Figure 2.2. Multi-sequence alignment of the “NRF1 cluster” in mammals. NRF1 sites are 
highlighted in bold red. Sp-family site is highlighted in bold purple. 
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Figure 2.3. Expression studies on GM11715 cells. Abbreviations: “+”: RT positive; “-“: RT 
negative; 5.8S rRNA as a positive control (Li, S & R. D. Nicholls). 
 
 
2.1.2 Genomic imprinting and disease 
Genomic imprinting is a type of epigenetic modification that has roles in mammalian 
development, especially placental and fetal development, childhood and adult behavior (Hall, 1990; 
Li & Sasaki, 2011). It results in the differential expression of genetic material from the maternally- 
and paternally-derived alleles. Consequently, genomic imprinting does not show Mendelian 
inheritance and provides an explanation for some of the genetic events that do not follow single-
gene inheritance (Hall, 1990). 
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Imprinting was first identified during nuclear transfer experiments in mice in the 1980’s. By 
transplantation of either the haploid androgenetic or the gynogenetic nucleus to haploid recipient 
eggs, only the ones with each copy of paternal and maternal pronuclei resulted in development to 
term, suggesting the existence of imprinting mechanisms (Surani et al., 1986; Ciccone & Chen, 
2009). The establishment and removal of genomic imprinting occurs primarily during 
gametogenesis (but is not completed until early preimplantation development) by epigenetic 
modification, including DNA methylation by DNA methyltranferases (DNMTs) and DNA 
demethylases (DMEs), and histone modification by lysine methyltransferases (KMTs) and lysine 
demethylases (KDMs) (Kota & Feil, 2010; Law & Jacobsen, 2010). Most imprinted genes have 
regulatory sequences that are differentially methylated regions (DMRs, Uribe-Lewis et al., 2011). 
Once genomic imprinting is established, it is then passed to the zygote through fertilization and 
maintained throughout somatic development and adult life (Wood & Oakey, 2006; Li & Sasaki, 
2011). Only in the formation of primordial germ cells are such modifications erased and new 
imprints set for the next gametogenesis cycle (Li & Sasaki, 2011). As a result, imprinting maintains 
permanent genetic features within a generation, but may alter genetic features between generations. 
The first identified imprinted genes were the paternally expressed insulin-like growth factor 2 (Igf2, 
DeChiara et al., 1991) and the maternally expressed insulin-like growth factor type-2 receptor 
(Igf2r, Barlow et al., 1991) in mice. To date, 41 transcriptional units (TUs) in human and 71 TUs in 
mouse have been reported to be imprinted, in which 29 TUs are shared by human and mouse 
(Morison et al., 2001, http://igc.otago.ac.nz/home.html). Among these TU, 30% (25/83) of them 
encode noncoding RNAs.   
Defects in genomic imprinting are associated with different types of disease. Uniparental 
disomy (UPD) is a condition in which an individual inherited both copies of a chromosome from 
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one parent only (Yamazawa et al., 2010). Usually UPD is not associated with a phenotype unless 
imprinted genes are present on the chromosome with UPD (or, if UPD results in homozygosity for 
a recessive mutation). Lack of either paternal or maternal imprinted genes in UPD causes certain 
inborn diseases. So far, nine types of UPD (Morison et al., 2001; Hirasawa & Feil, 2010; 
Yamazawa et al., 2010) have been reported, among which four types are maternal UPD, including 
Russell-Silver syndrome (or Silver-Russell syndrome, chromosome 7p11-13 and 7q31-qter, 
Hannula et al., 2001; Eggermann, 2010), maternal UPD14 syndrome (MUPD14 syndrome, 14q, 
Kayashima et al, 2002; Ogata et al., 2008), PWS (15q11-13, Nicholls et al., 1989; Nicholls & 
Knepper, 2001) and maternal UPD20 (MUPD 20, only three cases, among which one is mosaic 
trisomy 20 (Chudoba et al., 1999; Eggermann et al., 2001; Salafsky et al., 2001). In addition, five 
types have paternal UPD, including transient neonatal diabetes mellitus (6q24, Shield, 2000; 
Aviram et al., 2008), Beckwith-Wiedemann syndrome (BWS, 11p15, Smith et al., 2007), paternal 
UPD14 syndrome (14q32, Ogata et al., 2008; Yamazawa et al., 2010), Angelman syndrome (AS, 
15q11-13, Robinson et al., 2000; Nicholls & Knepper, 2001) and pseudohypoparathyroidism type 
1b (20q13, Morison et al., 2001; Amor & Halliday, 2008; Fernández-Rebollo et al., 2010). 
Imprinting abnormalities have also been associated with cancers, which have characteristics of 
global hypomethylation and site-specific hypermethylation, as well as loss of imprinting in certain 
types of cancer (Feinberg, 2007). For examples, congenital loss of imprinting at the IGF2-H19 
locus occurs in Wilms tumor and BWS individuals have an increased risk for Wilms tumor and 
hepatoblastoma (Uribe-Lewis et al., 2011). Therefore, a better understanding of the mechanisms of 
genomic imprinting will not only improve the current functional studies of imprinted genes during 
gametogenesis and embryonic cell development (Li & Sasaki, 2011), but also improve 
understanding of mechanisms for some complex diseases. 
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2.1.3 Evolutionary insights and relationships of the PWS SNRPN imprinting locus 
and snoRNAs 
Genomic imprinting is widespread in placental mammals (eutherian mammals) and also 
occurs in marsupials (metatherian mammals, Renfree et al., 2009). These two branches of mammals 
diverged from a common ancestor about 173-190 million years ago (mya, Kumar & Hedges, 1998; 
van Rheede et al., 2006). The first complete genome sequence of a metatherian, Monodelphis 
domestica (gray short-tailed opossum), revealed that non-protein-coding sequences between 
metatherians and eutherians were up to 80% conserved (Mikkelsen et al., 2007) indicating the high 
sequence conservation in the gene regulatory elements and their origins from a common ancestor. 
The study of the metatherian genome provides great insights in understanding the evolutionary 
history of human genes. As a relatively young genetic mechanism in evolutionary terms, imprinting 
in mammals has been found to be acquired by a combination of ancient gene functions present in 
non-mammalian vertebrates and evolutionary young gene loci without clear lower vertebrate 
ancestors. It has been shown that chicken doesn’t have imprinted genes (O’Neill et al., 2000). 
Metatherian imprinted genes include IGF2 (O’Neill et al., 2000; Lawton et al., 2008), PEG1/MEST 
(Suzuki et al., 2005), IGF2R (Killian et al., 2001) although it is hypomethylated compared to 
mouse Igf2r (Weidman et al., 2006), and PEG10 (Suzuki et al., 2007). The unique and expanded 
stage of postnatal embryonic development in metatherians provides a good model to study the 
origin of imprinting from non-placental mammals to placental mammals, since the development of 
the placenta in eutherians has been suggested to relate to the origin of genomic imprinting (Suzuki 
et al., 2007).  
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PWS is a genomic imprinting disorder that occurs in approximately 1 per 15,000 newborns. 
The clinical features of PWS include neonatal failure-to-thrive with childhood-onset severe obesity 
and other endocrine and behavioral abnormalities. PWS arises from functional loss of multiple 
imprinted, paternally-expressed genes, which are located on human chromosome 15q11.2 (Nicholls 
& Knepper, 2001). So far, there are at least thirteen paternally expressed genes that have been 
identified, including five protein coding genes, MKRN3, MAGEL2, NDN, and a bicistronic SNURF-
SNRPN. The bicistronic locus SNURF-SNRPN normally encodes two polypeptides: SNRPN 
encodes a brain-specific spliceosomal protein, SmN, which replaces SmB’/B protein during 
postnatal brain development (Sharpe et al., 1990; McAllister et al., 1989), while the upstream 
SNURF encodes an independent nuclear protein with an unclear function (Gray et al., 1999a). 
MKRN3, MAGEL2 and NDN are all intronless genes (Chai et al., 2001) and their function remains 
largely unknown. In mouse, the homologous PWS region is on chromosome 7C, except that mouse 
doesn’t have the testis-specific C15orf2 (Färber et al., 2000), but gained Frat3 by retrotransposition 
(Chai et al., 2001). The loss of imprinted gene expression on mouse 7C showed similar neonatal 
defects as in human (Stefan et al., 2005). In the PWS gene region, SNURF-SNRPN also serves as 
the host of five classes of C/D-box small nucleolar RNAs (snoRNAs), SNORD107, SNORD64, 
SNORD109, SNORD116 and SNORD115 (Cavaillé et al., 2000; Runte et al., 2001). SnoRNA is a 
group of RNA that guides chemical modification of ribosomal RNA (rRNA) or other RNAs. There 
are two classes of snoRNAs, C/D-box snoRNAs and H/ACA-box snoRNAs. Named by conserved 
sequence motifs box C/C’ (5’-CUGA-3’) and D/D’ (5’-RUGAUGA-3’), the C/D-box snoRNAs 
contain one or two 10-21 nucleotide long antisense elements 5’ of box C/C’, which are 
complementary to the mature ribosomal RNA and direct site-specific 2’-O-methylation (Tyc & 
Steitz, 1989; Kiss-Laszlo et al., 1996; 1998).  The C/D-box snoRNAs can be coded either by exonic 
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sequences (Cavaillé et al., 1996) or by intronic sequences (Tycowski et al., 1996); however, the 
latter is more commonly found in vertebrates (Kiss, 2002). For the PWS C/D-box snoRNAs, the 
function of only SNORD115 has been identified in the regulation of alternative splicing for the 
serotonin receptor 2C mRNA (Kishore & Stamn, 2006), and the function of the other four classes of 
snoRNAs remains unknown. Therefore, understanding the evolutionary origins of PWS genes could 
provide significant insight for studies of gene function and imprinting mechanism. Previous studies 
suggested the evolutionary origin of SNRPN was ~95-125 mya (Rapkins et al., 2006). During 
evolution, MKRN3 was derived from MKRN1 by retrotransposition about 80-120 mya (Gray et al., 
2000, 2001). MAGEL2 and NDN were derived by retrotransposition from an ancestral X-
chromosomal MAGE gene (Chai et al., 2001; Rapkin et al., 2006). The C15orf2 gene was derived 
~40 mya by retroviral insertion and is a primate-specific and intronless gene (Chai et al., 2001). 
Finally, the maternally expressed UBE3A and ATP10C genes were translocated to the current 
location (Chai et al., 2001). As a model system to understand the acquisition of new gene functions 
and the origin of genomic imprinting, we have focused on understanding the phylogenetic history 
of the key gene, SNRPN, associated with PWS (Nicholls & Knepper, 2001). 
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2.2 MATERIALS AND METHODS 
2.2.1 Gene expression studies of 3 somatic cell hybrids 
RNA was extracted from GM11715, A15, and A15-1 cell lines, and reversed transcribed 
into cDNA by Super Script®III reverse transcriptase (Invitrogen) according to the manufacturer’s 
instructions. The expression of PWS genes in GM11715, A15 and A15-1 cells were tested by 
primers listed in Table 2.1 by regular PCR.  
2.2.2 Chromatin immunoprecipitation (ChIP) in three somatic cell hybrids 
Approximately 1×106 GM11715, A15, or A15-1 cells were plated on 35 cm2 plates with 
regular media [Dulbecco’s Modified Eagle Medium (DMEM) + 10% Fetal Bovine Serum (FBS) + 
1% penicillin-streptomycin (P/S)]. When cells reached 70-80% confluence, formaldehyde was 
added to the regular media to make a final concentration of 1% and the plates were incubated at 
37°C for 10 minutes to crosslink protein to DNA. After washing with 5 ml ice-cold PBS, another 5 
ml ice-cold PBS was added and cells were scraped from the plates using a cell lifter, put into a 15 
ml tube and sonicated to shear DNA. Samples were precleared at 4°C with protein G-
agarose/salmon sperm beads for 1 h (Millipore). Protein-DNA was immunoprecipitated using the 
ChIP assay kit (Millipore) with anti-NRF1 (from Dr. Daniel Raines), anti-H3K4me1 [Histone H3 
(mono methyl K4) antibody, Abcam, Catalog #: ab8895], anti-H3K4me3 [Anti- trimethyl-Histone 
H3 (Lys4), Millipore, Catalog #: 07-473], or anti-H3K9me2 [Anti-dimethyl- Histone H3 (Lys9), 
Millipore, Catalog #: 07-521]. Complexes were collected with Protein G agarose/salmon sperm 
beads and washed. Protein-DNA complexes were eluted off the beads and cross-links were reversed 
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by incubation at 65ºC overnight. On the next day, DNA was recovered by phenol-chloroform 
extraction and precipitated by ethanol. PCR was performed using the recovered ChIP DNA 
materials as templates and primers from Table 2.2. The PCR products were run on an agarose gel 
to examine the results.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
34 
Table 2.1. Primers for gene expression studies using somatic cell hybrids. 
Primer namea Primer 
number 
Primer sequence 
MKRN3 F RN2998 5'-CACACGAGAAAGATATGGAAC-3' 
MKRN3 R RN2856 5’-GGAATGGTTGCAATTGGAAAG-3’ 
MKRN3-AS F RN2976 5’-TCAAGTCCATCTTTGCTCCAC-3’   
MKRN3-AS R RN2977 5’-CTGTTGAGGCAGTGCTTCTG-3’    
MAGEL2 F RN2853 5’-GTGGAGGCACAGCCCTTGT-3’ 
MAGEL2 R RN2854 5’-GGAACTGCACCAACGCATT-3’ 
NDN F RN2851 5’-TGCTCCTGCAGAGTTTGGAA-3’ 
NDN R RN2852 5’-GGCCTTGACTTTTCTTGGTTAGG-3’ 
MIRH1 F RN2921 5’-ATATTGGGGCCTTCGATT-3’  
MIRH1 R RN2922 5’-ACTTGTCGAATTCCATCTGC-3’ 
PWRN1 F RN2923 5’-TGTTTCCCAGACCGTAAC-3’ 
PWRN1 R RN2924 5’-ACATCCAGTGGTAAGAAT-3’ 
C15orf2 F RN2907 5’-CACCAGCAAGCCTATGAATTCC-3’ 
C15orf2 R RN2925 5’-GTGGGGATGTGTAGACTGATGTC-3’  
U1B F RN3000 5'-AACTGTGGTCGCTGATCAATG-3' 
U1B R RN2999 5'-TCTGCGTTTGACTTGGACTTCC-3' 
U1A F RN2875 5’-GTCATTCTGCTTGCTGATCAAGA-3’ 
U1A R RN2999 5'-TCTGCGTTTGACTTGGACTTCC-3' 
SNRPN-SNURF exon 1-2 F RN3001 5'-TGACGCATCTGTCTGAGGAG-3' 
SNRPN-SNURF exon 1-2 R RN2999 5'-TCTGCGTTTGACTTGGACTTCC-3' 
SNORD107 F RN1455 5'-GGCTAGGTTCATGATGACAC-3' 
SNORD107 R RN1456 5'-GGCACACTGACTGGATTTCA-3' 
SNORD64 F RN1433 5'-GGATTTGTGATGAGCTGTGT-3' 
SNORD64 R RN1434 5'-GGACTTCAGAGTAATCACGT-3' 
SNORD109 F RN1583 5'-GGATCGATGATGAGAATAA-3' 
SNORD109 R RN1584 5'-GAACCTCAGATTGACATGT-3' 
SNORD116 class I F RN1579 5'-ATGATGATGAGTCCCC-3' 
SNORD116 class I R RN1580 5'-GACCTCAGTTCCGATGAG-3' 
SNORD116 class II F RN1581 5'-GATCGATGATGACTTCCA-3' 
SNORD116 class II R RN1582 5'-GGACCTCAGTTCGACGAG-3' 
IPW F RN3002 5'-ATGACTTCCTGGGAACTCTTC-3' 
IPW R RN2874 5’-TGGCACCAACTCAACAAATCC-3’ 
SNRPN-SNURF exon 63-65 F RN2970 5’-CTGAAGCTCAGGCCATTCCT-3’ 
SNRPN-SNURF exon 63-65 R RN2971 5’-GTCTTCCTCCAGGCTCACTG-3’ 
SNORD115 F RN1435 5’-GGGTCRATGATGAGAACCTT-3’ 
SNORD115 R RN1436 5’-GGGCCTCAGCGTAATCCTAT-3’ 
SNRPN-SNURF exon 142 F RN2972 5’-CACAGCTGACACACCCAGATATC-3’ 
SNRPN-SNURF exon 143 R RN2973 5’-CCCTGAAGTTTCCTTGAAGTTGTT-3’ 
SNRPN-SNURF exon 144 R RN3069 5’-TGAAGTGGAGGATCAGATTCCAG-3’ 
SNRPN-SNURF exon 145 R RN3070 5’-GTTACTTAATCATACAGTAAGCTG-3’  
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Table 2.1. (continued)  
Primer namea Primer 
number 
Primer sequence 
SNRPN-SNURF exon 147-148 F RN2974 5’-AGAAAAGGCGCAATGAAAGA-3’ 
SNRPN-SNURF exon 147-148 R RN2975 5’-GGAGAAGGGCCATAGACTCC-3’ 
UBE3A F RN2980 5'-AACAAGAAAGGCGCTAGAATTG-3' 
UBE3A R RN2981 5'-TAACTTTCCGGAAGCTCTGTAC-3' 
ATP10A F RN2978 5'-CCTGGCTCAACTGGATAACG-3' 
ATP10A R RN2979 5'-AACTGACGTGCCAGCTGAAG-3' 
5.8S rRNA F RN2849 5'-CGACTCTTAGCGGTGGATCA-3' 
5.8S rRNA R RN2850 5'-GACGCTCAGACAGGCGTAG-3' 
 
a Abbreviations: F: forward PCR primer; R: reverse PCR primer. Gene sequences were obtained 
from the Ensembl genome browser (http://www.ensembl.org/Homo_sapiens/Info/Index). 
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Table 2.2. Primers for ChIP studies using somatic cell hybrids. 
Primer names Primer 
number 
Primer sequence 
SNURF-SNRPN enhancer F RN2683 5’-CAGGTCTTGGAAGGCTATGTCG-3’ 
SNURF-SNRPN enhancer R RN2684 5’-CTCCCCACTGGCGGCTCTAC-3’ 
SNURF-SNRPN promoter F RN2877 5’-TGCACTGCGGCAAACAAG-3’ 
SNURF-SNRPN promoter R RN3059 5’-AGACAGATGCGTCAGG-3’ 
U1A promoter F RN2967 5’-CTGAAGCCTTTGGGATTTTCTA-3’ 
U1A promoter R RN2968 5’-AAACAGCTCCAGAGGGAAGAC-3’ 
U1A (upstream U1A promoter) F RN3266 5’-CGCCATAACCGGAAGAGATC-3’ 
U1A (upstream U1A promoter) R RN3265 5’-CCCTTTCCCCCTGCTATTTC-3’ 
U1B (upstream U1B promoter) F RN3263 5’-TGGTCTCCCGTCACCGTTT-3’ 
U1B (upstream U1B promoter) R RN3264 5’-ACTCCTAGCAGACGCCATAAGC-3’ 
NDN promoter F RN2894 5’-CCTAGATCTTCTCAGCCCAAACA-3’ 
NDN promoter R RN2895 5’-TCCATGGCGAGGCTTCAC-3’ 
CpG islet (MKRN3) F RN3033 5’-ATTAAACGCGAGTGTCCAGAAT-3’ 
CpG islet (MKRN3) R RN3034 5’-CAAACCTGTGAACTAGTCGGTGTA-3’ 
NRF1 cluster RN3006 5’-CCTTCTGGCGCATGCGCAGTCTCT-3’ 
NRF1 cluster RN2960 5’-AGTGGACTCTGCAATGCTGTAA-3’ 
MKRN3 promoter F RN3053 5’-GAAATCGTGTGAGAAGGGACTTAG-3’ 
MKRN3 promoter R RN3054 5’-CCTCTGACTGTGTGTTCCTACCTA-3’ 
MIRH1 promoter F RN3040 5’-CGTGAGTTAAGAGTGTGAAGGAGA-3’ 
MIRH1 promoter R RN3041 5’-CAAACAGTCTGCTCTGAGTCTTGT-3’ 
PWRN1 promoter F RN3581 5’-GGCGGTGAGATCTACAGGAG-3’ 
PWRN1 promoter R RN3582 5’-GTCTGGGAAACACGGAGAAATC-3’ 
MAGEL2 promoter F RN3579 5’-CAGCCTCTGATCCTGCAAATC-3’ 
MAGEL2 promoter R RN3580 5’-GTCTGCCAAGTCAGGGGAGTG-3’ 
 
a Abbreviations: F: forward PCR primer; R: reverse PCR primer. Gene sequences were obtained 
from the Ensembl genome browser (http://www.ensembl.org/Homo_sapiens/Info/Index). 
 
 
 
2.2.3 Bioinformatics and phylogenetic analyses 
Gene sequences were obtained from the Ensembl genome browser and putative NRF1 
binding sites were localized within potential gene regulatory regions by examining 5 kb upstream of 
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the TSS, exon 1, and all introns and 5 kb downstream of 3’ UTR of the gene. In this second step, 
sites matching a GCGCAYGCGC motif, allowing at most one mismatch in one “GCGC” and/or 
one mismatch in the “AY” segment (on either strand), were selected as potential NRF1 motifs.  
Second, the sequence spanning the NRF1 motif(s) was used for BLAST 
(http://www.ncbi.nlm.nih.gov/blast/Blast.cgi) searches in the non-redundant (NR) and whole 
genome shotgun (WGS) databases to determine conservation of NRF1 motif(s) across mammalian 
sequences. Sequences were aligned by ClustalW (http://www.ebi.ac.uk/Tools/clustalw2/index.html) 
and conserved motifs were highlighted and analyzed by STAMP or other bioinformatic tools.  
Genomic sequences for the M. domestica SNRPN and SNRPB’ loci were obtained by NCBI 
BLAST with the M. domestica SNRPB’ cDNA sequence (Gray et al., 1999b). Sequences spanning 
each gene were exon-masked and/or Repeatmasked [using the “mammal (other than below)” in 
“DNA source” option] and used for BLAST. M. domestica-specific repetitive sequences were then 
removed in silico when necessary. Candidate non-coding conserved sequences (NCCS) were 
subsequently analyzed further by BLAST and visual inspection. SNORD119 snoRNA gene 
sequences from different species were also obtained from NCBI BLAST searches. SNORD64, 
SNORD107, SNORD109, SNORD115 and SNORD116 human copies were obtained from the NCBI 
gene database, and other eutherian copies of SNORD64, SNORD107 and SNORD109 were obtained 
by BLAST searches in the WGS database. Names of different classes of PWS snoRNAs were used 
according to official nomenclature from PubMed. M. domestica SNRPB’ exons and introns 
sequences were obtained from the Ensembl genome browser (http://www.ensembl.org/index.html). 
All sequence was transformed into FASTA format using ReadSeq 
(http://searchlauncher.bcm.tmc.edu/seq-util/readseq.html) and alignments were performed using 
ClustalW (http://www.ebi.ac.uk/Tools/clustalw2/index.html). The alignment of SNORD116 was 
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derived from both ClusterW and Runte et al. (2001). Alignments were adjusted as needed to 
maximize parsimony.  
2.2.4 Calculation of minimum free energy in prediction of RNA-RNA interaction 
The minimum free energy of interaction for the snoRNA and predicted target RNA was 
calculated by RNAhybrid (Rehmsmeier et al., 2004), which is based on the classical RNA 
secondary structure prediction algorithm to two sequence (Zuker &Stiegler, 1981) and energy 
parameters of RNA-RNA interaction by Mathews et al. (1999). SnoRNAs and predicted 28S rRNA 
sequence were submitted in RNAhybrid (http://bibiserv.techfak.uni-
bielefeld.de/rnahybrid/submission.html) to predict the minimum free energy. 
2.2.5 Sequence cloning and analyses 
PCR primers (Table 2.3) flanking Didelphis virginiana SNORD119N and SNORD119B 
were used to clone the respective fragments from D. virginiana genomic DNA.  The two PCR 
fragments were then subcloned in to a TOPO TA vector (Invitrogen) for sequencing according to 
the manufacturer’s instructions.  
2.2.6 Marsupial, mouse and human RNA and DNA studies  
RNA was extracted from M. domestica tissue samples with Trizol (Invitrogen) followed by 
DNase I treatment (Promega). The latter step to remove DNA was critical for studies of small RNA 
expression where no introns were present. A mouse total RNA panel (10 tissues) and FirstChoiceTM 
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Human total RNA survey panel (20 tissues) were purchased from Ambion. PCR and quantitative 
(Q)RT-PCR primers (Table 2.3) were designed by the online primer design program Primer3Plus 
(http://www.bioinformatics.nl/cgi-bin/primer3plus/primer3plus.cgi) and checked by NetPrimer 
(http://www.premierbiosoft.com/netprimer/index.html). 1 μg of each human, mouse, and M. 
domestica RNA sample was reverse-transcribed (SuperScript II, Invitrogen) into cDNA using 
hexamer oligonucleotides or specific snoRNA reverse primers in a 20 μl reaction. cDNA was 
amplified by Taq DNA polymerase (Promega), using 94°C for 5 minute, 35 cycles of 94°C for 30 
seconds, 50°C (snoRNA primers)/53°C (5.8S rRNA primers)/55°C (SNRPN/SNRPB’ PCR primers) 
for 30 seconds, and 72°C for 1 minute, then followed by a 10-min final extension at 72 °C. PCR 
products were analyzed by agarose gel electrophoresis.   
2.2.7 Verification of SNORD119B and SNORD119N snoRNA specific RT-PCR assays 
by restriction enzyme fragment length variants (RFLV) 
The SNORD119B and SNORD119N snoRNA gene sequences were aligned by Clustal W. 
The HaeIII enzyme was chosen to differentiate SNORD119B snoRNA from SNORD119N snoRNA 
RT-PCR products. The enzyme digested RT-PCR products were analyzed by agarose gel 
electrophoresis.  
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Table 2.3. Primers for evolutionary studies of the PWS SNRPN locus. 
Species, target gene, and orientationa Primer Primer Sequence 
Human SNORD119 snoRNA F RN2731 5’-GCTGGATTAATGATGAGAT-3’ 
Mouse Snord119 snoRNA F RN2733 5’-GCTGGATTCATGATGAAAT-3’ 
Human/Mouse SNORD119 snoRNA R RN2732 5’-ATCTCAGAGTAATCCTGC-3’ 
M. domestica SNORD119N snoRNA F RN2734 5’-GCTGGATTGGTGATGAAACC-3’ 
M. domestica SNORD119B snoRNA F RN2736 5’-GCTGGATTAGTGATGAAACA-3’ 
M. domestica SNORD119N/B’ snoRNA R RN2735 5’-ACCTCAGAGTAATCCTGCT-3’ 
M. domestica SNRPN (exon 5) F RN2787 5’-CACAGCCAGTATCGCAGGAGC-3’ 
M. domestica SNRPN (exon 7) R RN2788 5’-CAGAGGCAGCATCACAGCAAA-3’ 
M. domestica s SNRPB’ (exon 5) F RN2789 5’-CCCAGGGAAGAGGAACTGT-3’ 
M. domestica SNRPB’ (exon 7) R RN2790 5’-GCAAGCATCTGAGCAAAGC-3’ 
Human SNRPB/B’ (exon 6) F RN2791 5’-CTGGTATGAGACCTCCTATGG-3’ 
Human SNRPB/B’ (exon 7) R RN2792 5’-CCACAAGGAGATAAAAGGACT-3’ 
Mouse Snrpb/b’ (exon 6) F RN2793 5’-CTGGCCGAGGAACTCCAAT-3’ 
Mouse Snrpb/b’ (exon 7) R RN2794 5’-GGAAGGAAACAGGCAAGGA-3’ 
Human/Mouse/ M. domestica conserved 
5.8S rRNA F 
RN2849 5’-CGACTCTTAGCGGTGGATCA-3’ 
Human/Mouse/ M. domestica conserved 
5.8S rRNA R 
RN2850 5’-GACGCTCAGACAGGCGTAG-3’ 
M. domestica GAPDH cDNA primer 
(QPCR) F 
RN3369 5’-GCCGAGTACGTTGTGGAGTCC-3’ 
M. domestica GAPDH cDNA primer 
(QPCR) R 
RN3370 5’-AGGGGGCAGAGATAATGACG-3’ 
M. domestica SNRPN (exon 5 QPCR) F RN3267 5’-AGCCAGTATCGCAGGAGCC-3’ 
M. domestica SNRPN (exon 5 QPCR) R RN3268 5’-GGTGTCCCTCTGCTCACGG-3’ 
M. domestica SNRPB’ (exon 5 QPCR) R RN3269 5’-AGCCAGCATTGCAGGGGCTC-3’ 
M. domestica SNRPB’ (exon 5 QPCR) R RN3270 5’-GGTGCCCCTCGACCCATTG-3’ 
M. domestica SNORD119N (QPCR) F RN3365 5’-GCTGGATTGGTGATGAAACCTA-3’ 
M. domestica SNORD119N (QPCR) R RN3366 5’-CCTCAGAGTAATCCTGCTGAG-3’ 
M. domestica SNORD119B (QPCR) F RN3367 5’-GCTGGATTAGTGATGAAACCTG-3’ 
M. domestica SNORD119B (QPCR) R RN3368 5’-ACCTCAGAGTAATCCTGCTAAC-3’ 
D. virginiana SNRPN (exon 5) F RN3362 5’-GCGGTTGCTGCCACAGCCAG-3’ 
D. virginiana SNRPN (exon 6) R RN3371 5'-TCCCCATTGGTGCCCCTCGAC-3' 
D. virginiana SNRPB’ (exon 5) F  RN3364 5’-GCCGCCACAGCCAGCATTGC-3’ 
D. virginiana SNRPB’ (exon 6) R RN3363 5’-AGGGGGTCTCATGCCAGGAGG-3’ 
 
a Abbreviations: F: forward PCR primer; R: reverse PCR primer. Gene sequences were obtained 
from the Ensembl genome browser (http://www.ensembl.org/Homo_sapiens/Info/Index). 
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2.2.8 Quantitative analysis of mRNA expression  
1 μg of each M. domestica RNA sample was reverse transcribed (SuperScript III, 
Invitrogen) into cDNA using hexamer oligonucleotides and oligo (dT) primers in a 20 μl reaction. 
Expression of M. domestica SNRPN, SNRPB’, SNORD119N, SNORD119B genes using respective 
primers (Table 2.3) was analyzed by quantitative real-time PCR (QPCR) in Applied Biosystems 
7300 Real Time PCR system. SYBR green (Power SYBR® Green PCR Master Mix, Applied 
Biosystems) was used as a fluorescent dye and each cDNA sample was run in triplicate to calculate 
the statistical significance of the data.  Threshold cycle (CT) was reported from the Applied 
Biosystems 7300 Real Time PCR system (Table 2.4 & 2.5). Outliers in the CT dataset were 
determined by Analyze-it for Microsoft Excel 2003 to generate an outlier box plot and the 
observations outside 1.5 interquartile ranges (IQRs) were defined as outliers. In each tissue sample, 
the ∆CT value was obtained by normalizing each gene of interest against M. domestica GAPDH 
data for each assay. The ∆∆CT value was obtained by subtracting the ∆CT values for each sample 
from the ∆CT values of GAPDH in each corresponding assay to calculate a relative ∆∆CT. All ∆∆CT 
values were converted to fold change. 2-sample independent t-test was used in Microsoft Excel 
2003 to compare the expression difference (p<0.05) between 1) SNRPN and SNRPB’; 2) 
SNORD119N and SNORD119B in each tissue sample. Comparisons of gene expression measured 
by QRT-PCR in brain and non-brain tissues between 1) SNRPN and SNRPB’; 2) SNORD119N and 
SNORD119B were made using 2-way ANOVA (SPSS v13.0) with repeated measures. 
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Table 2.4. Average CT for 5 genes in brain tissues of M. domestica a. 
CT 11wk ♀ brain 11wk ♂ brain Adult ♂ brain 
Exp 1 Exp 2 Exp 3 Exp 1 Exp 2 Exp 3 Exp 4 Exp 1 Exp 2 Exp 3 Exp 4 
SNRPN  27.64 27.39 28.47 28.83 27.18 28.86 27.15 28.48 27.98 28.90 28.67 
SNRPB’  29.00 28.59 29.82 30.23 28.02 29.47 27.88 30.57 29.46 30.72 30.20 
SNORD119N  31.67 32.21 33.14 32.39 31.30 33.01 31.75 33.26 32.91 33.07 28.76b 
SNORD119B  33.66b 35.60 35.37 31.62a 32.85 33.26 32.00 33.12a 34.13 33.24 32.80 
GAPDH  22.83 23.19 24.32 24.38 23.72 24.19 22.77 24.40 24.22 25.11 24.42 
 
 
a Abbreviation and symbols: CT: threshold cycle; wk: week; ♀: female; ♂: male; exp: experiment.  
b These 3 SNORD119B assays were ran separately with GAPDH control average CT values of 22.94, 24.67, 24.75 for 11wk ♀ brain, 
11wk ♂ brain, Adult ♂ brain, respectively. b The results from this assay were defined as outliers by Analyze-it for Microsoft Excel 
and not included in the data Figure 2.13. 
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Table 2.5. Average CT for 5 genes in non-brain tissues of M. domesticaa. 
CT Liver Spleen Kidney Muscle 
Exp 1 Exp 2 Exp 3 Exp 1 Exp 2 Exp 3 Exp 1 Exp 2 Exp 3 Exp 1 Exp 2 Exp 3 
SNRPN  25.35 24.72 24.84 25.23 25.45 25.86 29.41 28.52 28.71 25.27 27.44 24.88 
SNRPB’  24.44 23.68 23.63 23.09 23.08 23.24 28.78 27.53 27.63 25.19 27.28 24.83 
SNORD119N  29.95 29.22 29.06 28.38 28.48 28.66 32.00 29.56 31.16 31.93 38.38 33.08 
SNORD119B  32.42 31.65 31.62 29.16 29.52 29.43 33.52 33.00 32.54 35.13 38.29 38.93 
GAPDH  19.73 19.18 18.92 21.08 21.78 21.76 24.41 23.42 22.96 16.96 20.26 17.06 
 
a Abbreviation and symbols: CT: threshold cycle; exp: experiment.  
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2.3 RESULTS 
2.3.1 Expression profile of PWS genes in three somatic cell hybrids 
Expression studies showed that most PWS genes are expressed robustly in GM11715 cells 
(Figure 2.3). In contrast, the homologous mouse genes are not expressed (unpublished data). For 
A15 cells, previous studies have shown high expression of key PWS genes, including SNRPN and 
NDN (Gabriel et al., 1998).  
2.3.2 NRF1 ChIP results and chromatin status of the 2 Mb PWS region in somatic 
cell hybrids 
Our laboratory has previously demonstrated multiple functional NRF1 sites in the 2 Mb 
PWS region (Stefan et al., in preparation). In this study, I verified the NRF1 regulatory function on 
PWS genes in a mouse/human somatic cell hybrid cell line, GM11715, by performing NRF1 ChIP 
assay. As expected, since the SNURF-SNRPN-snoRNA polycistronic locus is well expressed in 
these cells, I found by ChIP assays that NRF1 binds strongly to the SNURF-SNRPN promoter and 
enhancer (Figure 2.4). NRF1 also bound to regulatory elements associated with other expressed 
genes in these cells (Figure 2.4), including the NDN promoter, the U1A promoter and strongly to an 
upstream putative enhancer, and the PWRN1 promoter (the first such confirmation), but only 
weakly to the MKRN3 enhancer (this Is not surprising since this gene is not expressed in these 
cells). I also tested the MAGEL2 promoter, a gene expressed robustly in GM11715 cells, as there 
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was a weak sequence match to the NRF1 motif but NRF1 does not bind at this element, a result that 
further helps define functional NRF1-binding motifs. Consistent with no NRF1 binding site in the 
MIRH1 promoter, there is no binding of NRF1 (Figure 2.4). Surprisingly, since MIRH1 is 
expressed at good levels in GM11715 cells, the “NRF1-cluster” (a strong Mirh1 enhancer in vitro) 
is only very weakly bound by NRF1 despite strong binding of NRF1 to the “NRF1 cluster” in SK-
N-SH neuroblastoma cells. Histone code studies have indicated that active chromatin is associated 
with H3K4me1 (Heinzman et al., 2007), and using GM11715 cells I found that all the gene 
promoters and enhancers in the PWS domain have an active chromatin status [Figure 2.5(a)]. 
Additionally, positive ChIP results using H3K4me3 and negative results with H3K9me2 further 
support the active chromatin status in this region [Figure 2.5(b) & (c)]. Nevertheless, the “NRF1 
cluster” and MKRN3 regulatory regions are only weakly positive. Therefore, we concluded that 
there are two domains in the 2 Mb PWS imprinted region: one is the U1A-SNURF-SNRPN-snoRNA 
segment which is highly expressed and strongly binds NRF1 to all promoter and enhancer elements 
in GM11715 cells, and a more proximal domain containing genes expressed at lower levels (e.g., 
NDN, MIRH1) or not at all (e.g., MKRN3) with low levels of NRF1 binding (e.g., NDN promoter, 
MKRN3 enhancer, “NRF1 cluster”). ChIP assays were also performed on both A15 and A15-1 cells 
to test the binding of NRF1 to NRF1 sites on the human chromosome 15 of PWS region. 
Unfortunately, our data showed that NRF1 also only bound weakly to the “NRF1 cluster” in the 
PWS region of A15 or A15-1 [Figure 2.6(a) & (b)].    
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Figure 2.4. NRF1 ChIP assay using GM11715 cells. Abbreviations: Ab+: antibody positive; Ab-: 
antibody negative; TI: total input; bp: base pair. 
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Figure 2.5. ChIP assays using GM11715 cells for (a) H3K4me1, (b) H3K4me3, and (c) 
H3K9me2 antibodies. Abbreviations: Ab+: antibody positive; Ab-: antibody negative; TI: total 
input; bp: base pair. 
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Figure 2.6. NRF1 ChIP assays using (a) A15 and (b) A15-1 cell lines. Abbreviations: Ab+: 
antibody positive; Ab-: antibody negative; TI: total input; bp: base pair. 
 
 
 
 
 
49 
2.3.3 Evolutionary studies of the PWS SNRPN locus and snoRNAs 
2.3.3.1 Intragenic snoRNAs in the duplicated SNRPB’ and SNRPN loci of marsupials 
In M. domestica, SNRPN and SNRPB’ are adjacent paralogs on chromosome 1 (Rapkins et al., 
2006). By sequence analysis across species, we found three conserved elements, which were in intron 
5 of SNRPN, exon 2b of SNRPB’, and intron 5 of SNRPB’ (Figure 2.7), respectively. Further analysis 
confirmed the conserved sequences in intron 5 of SNRPN and intron 5 of SNRPB’ were paralogous 
genes, both of which were C/D box snoRNAs, and their ortholog in human was named SNORD119 
(Yang et al., 2006). Because SNRPN and SNRPB’ were paralogous genes, we named the intron 5 
snoRNA in SNRPN as SNORD119N and the intron 5 snoRNA in SNRPB’ as SNORD119B. To further 
examine these results in other marsupial species, we verified the existence of the snoRNAs in 
Didelphis virginiana (Virginia opossum) by PCR cloning and in Macropus eugenii (tammar wallaby) 
by sequence BLAST (Figure 2.8).  
2.3.3.2 Molecular evolution of the SNORD119 snoRNA within SNRPB’ intron 5 in vertebrates 
Since the protein of SNRPB’, SmB’, is an indispensable protein that constitutes one of the 
major proteins in the assembly of the Sm spliceosome (Matera et al., 2007) and snoRNAs have 
important functions in rRNA modification (Maden, 2001), it was not surprising that we found 
SNRPB’ conserved across species, from yeast to eutherian mammals. SNORD119B orthologs were 
found consistently in intron 5 of the SNRPB’ gene of all analyzed eutherian mammals, reptiles, 
Xenopus tropicalis, and zebrafish, in intron 6 of the SNRPB’ gene of Atlantic salmon, but not in any 
intron of birds [Figure 2.9(a)].  
By sequence BLAST, we determined that genes (CD20-ELMO2) upstream of M. domestica 
SNRPN were syntenic to human chromosome 20q13.12 and to mouse 2H3, while those downstream 
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of M. domestica SNRPN (SNRPB’-STK35) were syntenic to human chromosome 20p13 and to 
mouse 2F3, and the block of M. domestica SNRPN was syntenic to the PWS region of human 
chromosome 15q11.2 and to mouse 7C (Table 2.6). We found large blocks of repetitive elements 
on the 5’ upstream (~47k, 96% repetitive) and 3’ downstream (~6k, 67% repetitive) sides of M. 
domestica SNRPN, respectively (Table 2.6).  
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Figure 2.7. Genetic maps of the SNRPN--SNORD119N and SNRPB’--SNORD119B loci, and 
syntenic sequences in human and mouse. Arrows indicated transcriptional direction. Red 
asterisks indicated conserved regions. 
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Figure 2.8. DNA sequence comparison of SNORD119B and SNORD119N in three species of 
metatherians, M. domestica, D. virginiana, and M. eugenii. Intron sequence is in small case, with 
exon-intron and intron-exon boundaries were in bold black and underlined. The SNORD119N and 
SNORD119B alignment is in bold blue. Box C/C’ and box D/D’ are in bold pink and the antisense 
box is in bold green. 
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Table 2.6. Analysis of the ELMO2-SNRPN-SNRPB’-TGM6 genomic interval in M. domestica. 
Region 
 
Extracted 
featurea 
Size 
(bp)a 
Repetitive Uniqu
e 
Features identified 
ELMO2-SNRPN None 47,876 96% 4% Gene promoters & FLJ13305 pseudogeneb 
SNRPN intragenic Exons, snoRNA 12,976 44% 56% TAF9 pseudogenec 
SNRPN-SNRPB’ None 6,210 67% 33% None 
SNRPB’ intragenic Exons, snoRNA 10,530 36% 64% None 
3’ of SNRPB’ None 28,470 69% 31% 3’ end of TGM6 (exon 9-12) 
 
a Size of region analyzed after extracting (masking) exons and snoRNAs. For this analysis, we masked SNRPN exons 1-7, 
SNRPB’ exons 1-7, SNRPB’ exon 2b, SNORD119N and SNORD119B sequences. 
b The SNRPN and ELMO2 promoters have only 363-bp and 659-bp unique sequence, respectively. The ELMO2 promoter has two 
elements conserved in mammals. The 1.55 kb FLJ13305 pseudogene is located 36.2-kb 5’ of SNRPN.  
c Located in SNRPN intron 4, on the complementary strand. 
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Figure 2.9. (continued below)  
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Figure 2.9. Phylogenetic analyses of the SNORD119B snoRNA. (a) Cartoon of SNRPB’ gene structure of therian mammals, 
reptiles, an amphibian and zebrafish with the SNORD119 snoRNA in intron 5, whereas the SNORD119 snoRNA is in intron 6 of 
Atlantic salmon. In contrast, the SNRPB’ gene in birds has no intragenic snoRNA. (b) Clustal W multisequence alignment of 
SNORD119 snoRNAs. Box C/C’ and box D/D’ are highlighted in bold red: from 5’ to 3’, these are box C, box D’, box C’ and box D, 
respectively. The antisense box is highlighted in bold green and is 5’ of box D. 
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2.3.3.1 Expression studies of SNORD119 orthologs and paralogs 
Expression studies by RT-PCR showed that SNORD119 snoRNA was ubiquitously 
expressed in 20 analyzed human tissues [Figure 2.10 (a)] and 10 analyzed mouse tissues [Figure 
2.10(b)]. In M. domestica, SNORD119N and SNORD119B were ubiquitously expressed in 8 tissues 
from one female animal and 4 brain tissue samples from 4 animals (11 weeks postpartum male and 
female, adult male and female, respectively) [Figure 2.11(a) & (b)]. Because SNORD119N and 
SNORD119B were highly conserved sequences (Figure 2.8) and the PCR primers for SNORD119N 
and SNORD119B only differ in two non-contiguous nucleotides, to confirm we had tested specific 
gene expression, we used HaeIII enzyme digestion on both PCR products and verified the primers 
were specific to SNORD119N and SNORD119B PCR products [Figure 2.12(b)] in M. domestica.  
By quantitative real-time PCR (QRT-PCR) studies of gene expression in M. domestica, our 
results showed that in 3 brain tissues, SNRPN was expressed at a higher level than SNRPB’ (11 
weeks postpartum female, P<0.05, and adult male, P<0.001, but not in 11 weeks postpartum male, 
P=0.116), while in the 3 non-brain tissues, liver, kidney and spleen, SNRPB’ expression was 
significantly higher than SNRPN [liver, spleen, and kidney, all P<0.05; Figure 2.13(a)]. These 
results were consistent with protein studies of SmN and SmB in mice (Gray et al., 1999b). In 
addition, in 3 of 4 female tissues (one juvenile brain and all non-brain tissues were from the same 
adult animal) analyzed, SNORD119N gene expression was significantly higher than SNORD119B 
(11 weeks postpartum female, P<0.001; liver, P<0.0001; spleen, P<0.05; but in kidney, P=0.141), 
except in two male brain samples [11 weeks postpartum male, P=0.990, and adult male, P=0.808, 
Figure 2.13(b)]. This suggests a different expression level of SNORD119N and SNORD119B in 
male versus female in M. domestica; however, larger numbers of animals would be needed to 
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further examine this possibility. By 2-way ANOVA analyses to compare gene expression in brain 
tissues, SNRPN gene expression was significantly higher than SNRPB’ [F(2, 1)=31.10, P<0.0001), 
but SNORD119N and SNORD119B gene expression was not [F(2, 1)=0.71, P=0.414) due to the 
lack of expression difference in the two male brain tissues [Figure 2.13(b)]. Similarly, 2-way 
ANOVA analyses comparing gene expression in non-brain tissues (liver, spleen and kidney) 
showed that SNRPN expressed significantly lower than SNRPB [F(2, 1)=45.08, P<0.0001] and 
SNORD119N expressed significantly lower than SNORD119B [F(2, 1)=9.08, P =0.011].  
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Figure 2.10. Expression studies of SNORD119, SNRPN and SNPRB' in human and mouse. (a) 
RT-PCR in 20 tissues from human. (b) RT-PCR in 10 tissues of mouse. Abbreviations: RT +: 
reverse transcription positive sample; RT -: reverse transcription negative control; bp: base pair. 
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Figure 2.11. Expression studies of SNORD119N, SNORD119B and their host genes in M. 
domestica. (a) RT-PCR in 8 non-brain tissues of M. domestica. (b) RT-PCR in 4 brain tissues of M. 
domestica. Adult 1 ♂: animal #J7614, male; Adult 2 ♀: animal #J7344, female; 11 wk ♀: juvenile 
M. domestica, 11 weeks postpartum, female; 11 wk ♂: juvenile M. domestica, 11 weeks 
postpartum, male. 
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Figure 2.12. Verification of SNORD119B and SNORD119N snoRNA-specific RT-PCR assays 
by restriction enzyme fragment length variants (RFLV). (a) Alignment of the snoRNA 
sequences, with the position of RT-PCR primers in blue rectangles and the recognition site for the 
HaeIII restriction enzyme in a red rectangle. (b) RFLV analysis on PCR products from RT-PCR 
using SNORD119B-specific and SNORD119N-specific primers. Abbreviations: Ta: annealing 
temperature in PCR; HaeIII +: PCR product was digested by HaeIII; HaeIII -: PCR product was  
not digested, as a negative control. 
 
61 
 
 
Figure 2.13. Expression studies of SNORD119 snoRNAs by QRT-PCR in M. domestica. 
Abbreviations: Adult ♂: animal #J7614, male; 11 wk ♀: juvenile M. domestica, 11 weeks 
postpartum, female; 11 wk ♂: juvenile M. domestica, 11 weeks postpartum, male. Liver, spleen and 
kidney were from a female adult animal #G3232. Group comparisons of (a) SNRPN and SNRPB’; 
and (b) SNORD119N and SNORD119B were calculated by 2-sample t-tests using Microsoft Excel 
2003. P values <0.05, <0.001, <0.0001 are represented by “*”, “**” and “***”, respectively. 
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2.3.3.2 Function of SNORD119 orthologs and paralogs 
As noted above, the C/D box snoRNAs have one or two 10-21 nucleotide long antisense 
elements 5’ of box C/C’, which are complementary to the mature rRNA and guide site-specific 2’-O-
methylation. Structural conservation of the core of rRNA and modification is conserved between 
Xenopus laevis and human (Maden, 1990). In the same study, by oligonucleotide fingerprinting, the 
4560 position of 28S rRNA was methylated in both human and Xenopus laevis; however, the same 
position was unmethylated in chicken 28S rRNA (Khan & Maden, 1976; Maden & Hughes, 1997, 
listed as position 4550 in their paper). When we aligned SNORD119B antisense box sequence to 
rRNA position 4560, we found the interaction was thermodynamically favorable (Figure 2.14). 
Similarly, SNORD119N antisense box was also thermodynamically favorable in aligning to the same 
position of rRNA in M. domestica. Therefore, we predicted the function of SNORD119B and 
SNORD119N is to target rRNA 4560 site for 2’-O-methylation (Figure 2.14). However, experimental 
studies are needed to test which snoRNA targets 28S rRNA in vivo. It is likely that SNORD119B is 
the common form and functions in most circumstances, while SNORD119N may function in the brain. 
Similar targeting sequence was found in human 28S by SNORD119 (Figure 2.15). Such 
interaction was thermodynamically favorable. Surprisingly, we found that SNORD115-3 was also 
thermodynamically favorable in potentially targeting the same position of 28S rRNA (Figure 2.15). 
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Figure 2.14. Predicted M. domestica 28S rRNA targeting by SNORD119B and SNORD119N. 
Box C’ and box D are shown in blue rectangles. The predicted minimum free energy of 
SNORD119B binding to M. domestica 28S rRNA is ∆G°(37°C)=-23.6 kcal/mol, and for 
SNORD119N binding to M. domestica 28S rRNA is ∆G°(37°C)=-28.3 kcal/mol. 
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Figure 2.15. Comparison of human SNORD119 and SNORD115-3 for their potential 
targeting of 28S rRNA. Box C’ and box D are shown in blue rectangles. The predicted minimum 
free energy of SNORD119 binding to 28S rRNA is ∆G°(37°C)=-28 kcal/mol, and for SNORD115-
3 binding to 28S rRNA is ∆G°(37°C)=-26.9 kcal/mol. 
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2.3.3.3 Molecular phylogeny of SNORD119 family descendants: the PWS imprinted snoRNAs 
Unlike M. domestica, in human and mouse, SNRPN is located on a different chromosome to 
SNRPB’ and forms a more complicated bicistronic locus, SNURF-SNRPN, in the PWS domain. The 
adjacent gene structure of paralogous SNRPN and SNPRB’ only exists in metherians (both M. 
domestica and D. virginiana), but not in birds, reptiles, and platypus (data not shown), indicating 
the origin of the SNRPN occurred in a common ancestor of therians.   
Downstream of the SNURF-SNRPN bicistronic locus in the PWS region, there are five 
classes of C/D-box snoRNAs in the intronic regions of extended host transcripts derived from 
alternative SNURF-SNRPN promoters (Figure 2.16). Among the five classes of PWS C/D-box 
snoRNAs, there are some copy number variances in different classes. SNORD64 and SNORD107 
each has one single copy. SNORD109 has two identical copies A and B. SNORD115 has 47 copies. 
SNORD116 has 29 copies (Figure 2.16, Cavaillé et al., 2000; Runte et al., 2001). In our analysis, 
we found that SNORD64 was highly similar to SNORD115, SNORD107 was highly similar to 
SNORD109, while SNORD115 was also related to SNORD109 or SNORD107 (Figure 2.17). The 
three sub-classes of SNORD116 are significantly more divergent to the other groups of PWS C/D-
box snoRNAs. To better assess the sequence comparison and evolutionary studies between 
SNORD119N and PWS C/D-box snoRNAs, we BLASTed human SNORD64, SNORD107 and 
SNORD109 in the WGS database in NCBI and aligned maximum matched sequences from 
difference eutherian species to the human sequences, then achieved eutherian consensus sequences 
for SNORD64, SNORD107, and SNORD109 (Figure 2.18). SNORD119N snoRNA showed identity 
to each class of PWS C/D-box snoRNAs (Figure 2.19). Combined, the information on the 
similarity between SNRPN versus the SNURF-SNRPN bicistronic locus and SNORD119N snoRNA 
versus the five classes of PWS C/D-box snoRNAs, suggested that the eutherian SNURF-SNRPN-
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snoRNA locus evolved from a common ancestor as did the metatherian SNRPN-SNORD119N 
locus. 
Based on these analyses, a gene evolutionary model (Figure 2.20) was established. In this 
model, we predicted that about 173-190 mya, the common ancestor of therians had only one copy 
of SNRPB’. The ancestral copy of SNRPB’ was duplicated to form a paralogous gene, SNRPN, 
upstream of the ancestral SNRPB’. SNRPN then became fixed evolutionarily due to gain of 
functional requirement and selective pressure. In metatherians, the adjacent paralogs of SNRPN and 
SNRPB’ remains in the same position. In a eutherian ancestor, however, SNRPN was translocated to 
another chromosome, and ontained SNURF by de novo gene formation or an unknown mechanism 
(Gray et al., 1999a; Chai et al., 2001). During the evolution from eutherian ancestor to modern 
eutherians, other chromosomal rearrangement occurred. In our model, combined with other 
evolutionary studies, MKRN3 was acquired by retrotransposition from an ancestral MKRN1 gene 
(Gray et al., 2000, 2001), and the intronless NDN and MAGEL2 were acquired by retrotransposition 
from an ancestral MAGE gene on the X chromosome and subsequent duplication (Chai et al., 2001; 
Rapkins et al., 2006). Subsequent to multiple duplication and diversification events, the SNORD119 
gene gave rise to the five classes of PWS C/D-box snoRNAs, although these have unknown 
functions. Additionally, the SNORD115 and SNORD116 C/D-box snoRNA families have 
duplicated many times to form different sub-classes (Figure 2.21 & Figure 2.2).  
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Figure 2.16. Map of PWS C/D-box snoRNAs. Circles represent protein coding genes, and ovals 
represent RNA genes. Abbreviations: IC: imprinting center; cen: centromere; tel: telomere.   
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Figure 2.17. Comparison of five classes of PWS C/D box snoRNAs. Box C/C’ and box D/D’ are highlighted in bold red: from 5’ to 
3’, these are box C, box D’, box C’ and box D, respectively. The antisense box is highlighted in bold green and is 5’ of box D.
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Figure 2.18. Multisequence alignments of SNORD64, SNORD107, and SNORD109. Box C/C’ 
and box D/D’ are highlighted in bold red: from 5’ to 3’, these are box C, box D’, box C’ and box 
D, respectively. The antisense box is highlighted in bold green and is 5’ of box D.
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Figure 2.19. Comparison of SNORD119N to five classes of PWS C/D-box snoRNAs. Box C/C’ and box D/D’ are highlighted in 
bold red: from 5’ to 3’, these are box C, box D’, box C’ and box D, respectively. The antisense box is highlighted in bold green and is 
5’ of box D. 
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Figure 2.20. Evolutionary model for the origin of the PWS imprinted domain.
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Figure 2.21. (continued below) 
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Figure 2.21. Human SNORD115 family sequence alignment and consensus sequence of each class. Box C/C’ and box D/D’ are 
highlighted in bold red: from 5’ to 3’, these are box C, box D’, box C’ and box D, respectively. The antisense box is highlighted in 
bold green and is 5’ of box D. 
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Figure 2.22. (continued below) 
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Figure 2.22. Human SNORD116 family sequence alignment and consensus sequence of each class. Box C/C’ and box D/D’ are 
highlighted in bold red: from 5’ to 3’, these are box C, box D’, box C’ and box D, respectively. The antisense box is highlighted in 
bold green and is 5’ of box D. 
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2.4 DISCUSSION 
2.4.1 NRF1 regulation of the PWS imprinted domain in somatic cell hybrids  
By ChIP assays, we have confirmed the active and repressive chromosomal domains in 
GM11715, A15 and A15-1 cells. These data showed weak binding of NRF1 to the “NRF1 
cluster” in these three somatic cell hybrids. Since our goal was to use a somatic cell hybrid with 
strong binding of NRF1 to the “NRF1 cluster” in the single copy of human chromosome 15 to 
study NRF1 regulation on the PWS region, these results indicated none of tested cell lines would 
be ideal for the “gene targeting” study of “NRF1 cluster”. However, my data provided a valuable 
resource of chromatin information on these three somatic hybrid cell lines for other work in our 
laboratory.  
2.4.2 Evolutionary insights and relationships of the PWS SNRPN imprinted locus 
and snoRNAs 
In this study, we reported novel snoRNAs in the SNRPN and SNRPB’ genes of M. 
domestica, SNORD119N and SNORD119B, respectively, and suggested that by gene duplication 
of SNRPB’ to SNRPN, SNORD119N was retained and duplicated from SNORD119B in intron 5 of 
SNRPB’. In eukaryotes, functional related genes are in clusters and can be derived from tandem 
duplication of an ancestral gene (Spitz & Duboule, 2006). Synteny between two species indicates 
the gene regions have been evolved from a common ancestral gene region (Tanaka-Fujita et al., 
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2007). For snoRNAs, duplication of a host gene can generate snoRNA paralogs (Weber, 2006, 
Zemann et al., 2006). Combining the sequence similarity of M. domestica SNORD119N versus 
each of the five classes of PWS C/D-box snoRNA genes, the sequence similarity among the five 
classes of PWS C/D-box snoRNAs, and the syntenic regions of SNRPN and SNRPB’ between 
human and M. domestica, we concluded that SNORD119N in M. domestica is derived from the 
same common ancestral snoRNA as for the five classes of PWS C/D-box snoRNA genes by 
multiple rounds of DNA duplications (Figure 2.19). Similar DNA duplication events have been 
found with multiple copies of U1 promoters in the PWS region (Färber et al., 1999). In our 
analysis, SNORD119N is more related to SNORD64 and SNORD115 (Figure 2.18). This suggests 
either a more recent evolutionary origin of these snoRNAs or possibly retention of similar 
functions. Nevertheless, the large number of duplication and diversification events in forming the 
eutherian PWS-region snoRNAs suggests dynamic evolutionary processes operate on this domain 
and have selected for evolutionarily. It will be necessary to determine the function of each of the 
PWS-region snoRNAs in order to understand what evolutionary forces might have driven these 
processes. 
Because SNURF-SNRPN is associated with the imprinting control region in the PWS 
region, our phylogenetic study on the origin of SNRPN will have important implications in 
understanding gene functions and the imprinting mechanism in the PWS region. The comparison 
of eutherian genomes and the metatherian genome (M. domestica) is highly effective in 
recognizing genes and regulatory sequence evolution. Compared to the M. domestica genome, 
higher mammals have evolved by modification of epigenetic mechanisms instead of primarily 
inventing new genes (Mikkelsen et al., 2007; Renfree, 2007). Genomic imprinting has been found 
in both eutherians and marsupials, but seems to have a different imprinting mechanism in 
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marsupials. To better understand why and how imprinting was established in phylogeny, studies 
on the imprinting mechanism in marsupials become critical. It has been described that the origin 
of SNRPN was derived from gene duplication of an ancestral SNRPB’ gene, and the expression of 
brain-specific-imprinted SmN could be compensated by a feed-back loop of SmB/B’ expression 
in order to maintain stoichimetric levels of spliceosomal components (McAllister et al., 1989; 
Gray et al., 1999b; Matera et al., 2007). The indispensability of SmB’/B/N was consistent to our 
finding that SNRPB’ existed in all species (data not shown), while SNORD119 existed in most 
species we analyzed, including all mammals, one amphibian, reptiles, and two kinds of fish. The 
constrained sequence of SNRPB’ and SNORD119 implied the functional importance of both 
genes.  
In this study, we also predicted the function of SNORD119 is to target 28S rRNA at 
position 4560 for 2’-O-methylation based on sequence alignment and thermodynamic calculation 
(Figure 2.14; Figure 2.15). Methylation modification of rRNA on position 4560 has been 
experimentally confirmed in human and X. laevis, but was not found in chicken (Khan & Maden, 
1976; Maden & Hughes, 1997, listed as position 4550). Consistent with this, SNORD119 was 
found in SNRPB’ of human and X. laevis, but not  in chicken.  
Considering evolutionary explanation for the snoRNA copies in PWS region, it can be 
traced by the sequence similarity between M. domestica SNORD119N and each of the five classes 
PWS C/D-box snoRNAs. First, PWS C/D-box snoRNAs were derived from SNORD119N by a 
series of DNA duplications after which they gained new function in brain neonatal and/or 
postnatal development. This is supported by recent studies that snoRNAs can also target pre-
mRNA modification for gene silencing and regulation (Zhao & Yu, 2008) and SNORD115 can 
target serotonin 2C receptor to regulate gene expression (Kishore & Stamm, 2006). There is a 
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growing number of snoRNA found to have tissue-specific expression pattern, most probably 
reflecting that of the host gene (Cavaillé et al., 2000; Runte et al., 2001). A PWS patient was 
found to have distal SNURF-SNRPN translocation breakpoint with no gene expression of 
SNORD116, IPW and PAR1 (Wirth et al., 2001). A mouse model with a paternal deletion from 
Snrpn to Ube3a showed a phenotype of hypotonia, growth retardation, and partial lethality (Tsai 
et al., 1999) that is similar to the neonatal presentation of PWS and other PWS mouse models. 
These data suggest that the loss of PWS C/D-box snoRNAs contributes to the disease of PWS 
(Cavaillé et al., 2000; Runte et al., 2001). Another recent study on a paternally-inherited 
Snord116 deletion mouse model showed that snoRNA deletion in the PWS region was not lethal, 
but led to growth deficiency and a mild hyperphagia (Ding et al., 2008) albeit the animals 
weighed less than control littermates. All these studies suggest there is some specific function of 
PWS C/D-box snoRNAs in neonatal to postnatal development. Alternatively, the PWS C/D-box 
snoRNAs that have high sequence similarity to SNORD119N, such as SNORD64 and SNORD115, 
may target the same position of 28S rRNA in the brain. For example, in our analysis, we 
predicted that PWS C/D-box snoRNAs SNORD115-3 could alternatively target the same position 
of 28S rRNA (Figure 2.15) during postnatal development for brain-specific function (Cavaillé et 
al., 2000; Runte et al., 2001; de los Santos et al., 2000). 
Additional analysis, in our studies, implied some of the copies in SNORD115 and 
SNORD116 may not be functional because of mutations in the box-C/C’ and box-D/D’ regions 
(Figure 2.21 & 2.22), the gene structure of which were similar to the pseudogene HBII-437 
(Runte et al., 2001).  
To summarize, our study identified the origin of the five classes PWS C/D-box snoRNAs 
by gene duplication and diversification from an ancestral host gene with its intronic snoRNA. 
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Clearly, snoRNA evolution is labile, with duplication, transposition, and loss being detected in 
different phylogenetic lineages. It remains unclear why multiple copies of PWS C/D-box 
snoRNAs exist. It may be due to dosage requirement in specific period of development and/or 
functional compensation to some loss-of-function copies, such as the ones in the classes of 
SNORD115 and SNORD116. In the long term, functional studies on the five classes of PWS C/D-
box snoRNAs will allow these questions to be addressed, which will also shed light on the role of 
the box C/D-snoRNAs in disease mechanisms of PWS.  
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3.0  REGULATORY ROLES AND MECHANISMS OF NRF1 IN CIRCADIAN 
RHYTHMS 
3.1 INTRODUCTION 
Circadian rhythms, an “internal body clock”, govern the metabolic, hormonal, 
physiological, and behavioral pace of an organism in a 24-hour period, and exist from lower 
organisms such as bacteria to higher mammals such as human (Roenneberg & Merrow, 2005). 
The central mammalian circadian pacemaker located in the suprachiasmatic nucleus (SCN) of the 
hypothalamus is entrained by light acting on retinal neurons that project to the SCN, and uses 
neuronal and hormonal mechanisms to coordinate clocks in organs throughout the body 
(Maywood et al., 2007; Takahashi et al., 2008). In addition to the SCN, peripheral organs, such as 
liver and heart, have circadian rhythms that receive output signals from the SCN (Rutter et al., 
2002; Hastings et al., 2007) and additionally can be entrained by food or energy balance 
(Mendoza, 2007).  
At the cellular level, circadian rhythms are comprised of positive and negative feedback 
loops. In this feedback system, the CLOCK and BMAL1 polypeptides form a heterodimeric 
complex which binds to an E-box (5’-CANNTG-3’) transcriptional element and functions as a 
transcriptional activator in the circadian pacemaker to regulate clock-controlled genes (CCGs, 
Steeves et al., 1999; Gekakis et al., 1998; Kondratov et al., 2003). In contrast, PER and CRY 
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polypeptides also form heterodimers and mediate the negative limb of the circadian 
transcriptional feedback loop (Sun et al., 1997; Darlington et al., 1998; Hastings et al., 2007; 
Brown et al., 2005). The increase of PER/CRY heterodimers inhibits CLOCK/BMAL1 function. 
Subsequently, PER and CRY are degraded and cycling of this system generates the circadian 
oscillations (Reppert & Weaver, 2002). Additionally, NR1D1 forms an ancillary loop to 
coordinate the pacemaker (Takahashi et al., 2008) regulating BMAL1 via REV-ERBα response 
elements (ROREs, Preitner et al., 2002; Ueda et al., 2002) and also to repress itself by 
autoregulation (Adelmant et al., 1996). The fine-tuned regulation of both loops leads CCGs 
regulated by CLOCK/BMAL1 to act under circadian control. Although many key regulatory 
genes in the circadian system have been found, there may still be some missing factors that 
coordinate the system. 
It has been suggested that DBP, a key clock output gene, plays a role in the feedback 
system for circadian rhythms (Takahashi et al., 2008). DBP contributes to activation of PER1 by 
binding to the PER1 promoter (Yamaguchi et al., 2000). Expression of DBP is driven by 
oscillations of chromatin structure that regulate the binding of CLOCK/BMAL1 to E-box motifs 
within enhancer regions located in the first and especially the second intron (Ripperger et al., 
2000; Ripperger & Schibler 2006). Indeed, deletion of two E-box motifs in intron 2 abolished the 
oscillation of DBP expression and chromatin structure in Rat-1 cells and in a mouse model 
(Ripperger et al., 2000; Ripperger & Schibler 2006). In this work, we identify a conserved NRF1 
motif within the intron 2 enhancer element of DBP. Furthermore, we identify conserved NRF1 
binding sites in the 5’ regulatory elements of 25 of 45 circadian regulatory genes, including 
CLOCK, CRY1, PER1, and NR1D1. These are functional binding sites as shown by ChIP, 
expression studies following siRNA knockdown of NRF1 mRNA levels, and transient 
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transfection assays of wildtype and mutant promoter and promoter-enhancer luciferase reporter 
constructs. Further, co-immunoprecipitation shows that NRF1 and the phosphorylated, active 
form of CLOCK interact in a molecular complex. In serum-induced NIH3T3 cells with circadian 
oscillations of Dbp and Nr1d1 mRNA, Nrf1 mRNA and protein levels show ultradian oscillations. 
Based on these results, we propose that NRF1 has a major role in activating expression of 
circadian regulatory genes from both the positive and negative feedback regulatory loops, and 
consequently is positioned to integrate many aspects of circadian biology.  
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3.2 MATERIALS AND METHODS 
3.2.1 Bioinformatics and phylogenetic analyses 
Genomic sequences for CLOCK, PER1, CRY1, DBP, NR1D1, and 45 other circadian 
regulatory genes were obtained by NCBI BLAST (http://www.ncbi.nlm.nih.gov/blast/Blast.cgi) 
with the human genes from Ensembl database. Sequences spanning each gene were exon-masked 
and/or Repeatmasked [using the “human” in “DNA source” option] and used for BLAST. The 
consensus NRF1 recognition sequence “YGCGCANGCGCR” were used for the search and 
allowed 1 nucleotide change in either “GCGC” arm. Putative NRF1 binding sites were searched 5 
kb upstream of TSS and at least 1 kb into intron 1 of 45 reported circadian regulatory genes. For 
CLOCK, PER1, CRY1, DBP, and NR1D1, all sequence was transformed into FASTA format on 
ReadSeq (http://searchlauncher.bcm.tmc.edu/seq-util/readseq.html) and the alignments were 
performed by Clustal W (http://www.ebi.ac.uk/Tools/clustalw2/index.html). Alignments were 
adjusted as needed to maximize parsimony.  
3.2.2 Gene expression studies 
RNA was extracted from SK-N-SH human neuroblastoma cells and NIH3T3 mouse 
embryonic fibroblast cells, and reversed transcribed into cDNA using SuperScript® III reverse 
transcriptase according to the manufacturer’s instruction (Invitrogen). Regular PCR was 
performed to test gene expression of 25 circadian regulatory genes using the primers in Table 3.1.  
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Table 3.1. RT-PCR primers for circadian gene expression studies (human SK-N-SH 
cells). 
 
Target gene 
(primer)a 
Primer 
number 
 
Exon 
 
Primer sequences 
CLOCK (F) RN3519 17 5’-GATAATCGTATAAACACAGTCAGTC-3’ 
CLOCK (R) RN3520 17-18 5’-GGTGTTGAGGAAGGGTCTGAG-3’                
PER1 (F) RN3521 16 5’-GTCTCTGTGGGGACCAAGAAAG-3’     
PER1 (R) RN3522 17 5’-ACTGGCTCCTTCCGTGGGGTG-3’ 
CRY1 (F) RN3523 8 5’-CTGTTGGTTTTGGTAGGAGAAC-3’      
CRY1 (R) RN3524 9 5’-ATTTTGCAGGGAAGCCTCTTAG-3’      
NR1D1 (F) RN3525 6 5’-CTTCCGTGACCTTTCTCAGC-3’   
NR1D1 (R) RN3526 7 5’-GCAAAGCGCACCATCAGCAC-3’              
WDR5 (F) RN3527 12-13 5’-TCTCTGTTACTGGTGGGAAGTGG-3’   
WDR5 (R) RN3528 13-14 5’-TGTTGAGATCACGACATCTGTGTG-3’ 
TIMELESS (F) RN3529 12-13 5’-GCTGGCAACAGTGAATGAGATG-3’      
TIMELESS (R) RN3530 13 5’-CAGGTCACGAAGGAAAGAGC-3’   
DBP (F) RN3531 3-4 5’-GAGGAGCAGAAGGATGAGAAATAC-3’   
DBP (R) RN3532 4 5’-CGCACCGATATCTGGTTCTCC-3’                 
FBXL15 (F) RN3533 3 5’-CAGAACTCCACCACCTTGACC-3’           
FBXL15 (R) RN3534 4 5’-AACGCAGCACGGGGCAGTAC-3’        
ALAS1 (F) RN3535 3 5’-GAGGATGTGCAGGAAATGAATG-3’    
ALAS1 (R) RN3536 4 5’-CCCTCCATCGGTTTTCACACT-3’          
HSF1 (F) RN3537 5 5’-CATGCCCAGCAACAGAAAGTCG-3’              
HSF1 (R) RN3538 6 5’-CTGCACCAGTGAGATCAGGAAC-3’     
CHORDC1 (F) RN3539 10-11 5’-GGGTGTGATTGATGTAAAGCG-3’   
CHORDC1 (R) RN3540 11 5’-CTGCATCGGTTCAGCTTTTCTC-3’ 
NPAS2 (F) RN3541 3 5’-CCCCAAGAGTTACCTGTCCC-3’           
NPAS2 (R) RN3542 4 5’-AGGCAGGAGCTGCTGTGTGAG-3’      
ARNTL (F) RN3543 12 5’-GTGAACGGGGAAATCAGGGTG-3’    
ARNTL (R) RN3544 12-13 5’-TAGCTGTTGCCCTCTGGTCTAC-3’      
ARNTL2 (F) RN3545 9 5’-ATGGATGCTTACCCAACTCAAAG-3’   
ARNTL2 R RN3546 10 5’-CCAGCTTCTCAAGTAACCAGTG-3’          
CRY2 (F) RN3547 8 5’-GTTCTTCCACTGCTACTGCCC-3’           
CRY2 (R) RN3548 8-9 5’-AGGTATCGCCTGATGTAGTCCC-3’      
PER2 (F) RN3549 10 5’-CCTCTCCTGGGCTACCTACC-3’               
PER2 (R) RN3550 10-11 5’-GCAGGATCTTTTTGTGGATGGC-3’             
PER3 (F) RN3551 15 5’-ATAAGCCAATGCGGTTACAGC-3’       
PER3 (R) RN3552 16 5’-GTCCAGGGCTCACAGAAGAG-3’          
BHLHB2 (F) RN3553 4 5’-GTACCTGAATAAGAAGACAACTC-3’          
BHLHB2 (R) RN3554 4-5 5’-CACATCCAAAGTTCCTTCTGTAC-3’         
BHLHB3 (F) RN3555 1-2 5’-AGATTTTATAGGACTGGACTATTC-3’              
 
 
86 
Table 3.1. (continued)
 
 
Target gene 
(primer)a 
Primer 
number 
 
Exon 
 
Primer sequences 
BHLHB3 (R) RN3556 2 5’-TGTCGTCTCGTTTCATGCTCC -3’                       
NONO (F) RN3557 5 5’-AAGAGGGACTTCCAGAGAAGCTG-3’     
NONO (R) RN3558 5-6 5’-GGGTGGCTGCTCTCGTTCCTTG-3’   
CSNK1E (F) RN3559 7 5’-GCACATCGAGAGCAAGTTCTAC-3’ 
CSNK1E (R) RN3560 8 5’-GTTGTAGTCGCCCTCAGCTC -3’            
FBXL3 (F) RN3561 3 5’-AACACTTGGACTTATTTCAACTGC-3’          
FBXL3 (R) RN3562 4 5’-GAGTTTACGAACACAACTGTCAG-3’   
CIPC (F) RN3563 2 5’-CTTGGGATGGCTGCTGCTGAG-3’   
CIPC (R) RN3564 3 5’-GGTGTTGAGGAAGGGTCTGAG-3’       
EZH2 (F) RN3565 10 5’-AAACGGGGGGAGAGAACAATG-3’ 
EZH2 (R) RN3566 10-11 5’-ACCGAGAATTTGCTTCAGAGG-3’ 
PPARGC1A (F) RN3567 11-12 5’-AGTAAATCTGCGGGATGATGGAG-3’     
PPARGC1A (R) RN3568 12 5’-TTCAAGAGCAGCAAAAGCATCAC-3’    
 
 
a Abbreviations: F: forward PCR primer; R: reverse PCR primer. Gene sequences were 
obtained from the Ensembl genome browser (http://www.ensembl.org/Homo_sapiens/Info/Index). 
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3.2.3 Chromatin immunoprecipitation (ChIP) 
Approximately 1×106 SK-N-SH cells were plated on 35 cm2 plates with regular media 
[Alpha modified MEM + 10% Fetal Bovine Serum (FBS) + 1% penicillin-streptomycin (P/S) + 
1% of 100 mM L-glutamine + 1% nonessential amino acid + 1% sodium pyruvate]. When cells 
reached 70-80% confluence, formaldehyde was added to the media to make a final concentration 
of 1% and the plates were incubated at 37°C for 10 minutes to cross-link proteins and DNA. After 
washing with 5 ml ice-cold PBS, cells were scraped from the plates in 5 ml ice-cold PBS using a 
cell lifter, put into a 15 ml tube, centrifuged, re-suspended in SDS lysis buffer (ChIP assay kit, 
Millipore) and sonicated to shear DNA. Samples were precleared with protein G-agarose/salmon 
sperm beads (Millipore). Protein-DNA complexes were immunoprecipitated with anti-NRF1 
(from Dr. Daniel Raines), anti-H3K4me1 [Histone H3 (mono methyl K4) antibody, Abcam, 
Catalog #: ab8895], anti-H3K4me3 [Anti-trimethyl-Histone H3 (Lys4), Millipore, Catalog #: 07-
473], or anti-H3K9me2 [Anti-dimethyl-Histone H3 (Lys9), Millipore, Catalog #: 07-521]. 
Complexes were collected with Protein G agarose/salmon sperm beads and washed. Protein-DNA 
complexes were eluted off the beads and cross-links were reversed by incubation with NaCl at 
65ºC overnight. On the next day, DNA was recovered by phenol-chloroform extraction and 
precipitated by ethanol. PCR was performed using the recovered immunoprecipitated DNA as 
templates and primers from Table 3.2. The PCR products were run on an agarose gel to examine 
the results.  
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Table 3.2. PCR primers for ChIP assays of circadian gene cis-regulatory elements, in 
human SK-N-SH cells or mouse Neuro2a cells. 
 
Target gene (primer)a 
Primer 
number 
 
Primer sequences 
CLOCK (F) RN3377 5’-GCCTGCAGAGCCAGATTTCG-3’ 
CLOCK (R) RN3378 5’-AAGCCGAGTCCGTGATTGCG-3’ 
CLOCK intron 1 (F) RN3379 5’-GAGTGCCGGTTGGCTTCTTG-3’ 
CLOCK intron 1 (R) RN3380 5’-CACTACCCCGCCTGTGTCCAG-3’ 
PER1 (F) RN3381 5’-CAGCTGACGTCGGTTTCCCTG-3’ 
PER1 (R) RN3382 5’-GTAGACAAAAACCTGGACACTTCC-3’ 
CRY1 (F) RN3383 5’-CTGAAGGAAACCGGACAATTTC-3’ 
CRY1 (R) RN3384 5’-GCTGAGACCCGGATGAGCAC-3’ 
NR1D1 (F) RN3387 5’-ATCACATGGTACCTGCTCCAGTG-3’ 
NR1D1 (R) RN3388 5’-GAAGTAAGTAGGTGATGGGGAGAA-3’ 
WDR5 (F) RN3389 5’-CGTAGCGCTCCTCCGAGAG-3’ 
WDR5 (R) RN3390 5’-GGACTCAGCTCGACAAGGC-3’ 
TIMELESS intron 1 (F) RN3391 5’-GAGTGAGTGTGTGGCGAGAGG-3’ 
TIMELESS intron 1 (R) RN3392 5’-GGAGACTAAGGAGCAGAGTACAG-3’ 
DBP intron 2 (F) RN3393 5’-CCCTTCCCAGCGGCACATTCC -3’ 
DBP intron 2 (R) RN3394 5’-CAGCTAAGGACACAGGTTCAGG -3’ 
FBXL15 (F) RN3395 5’-GTCTGTTCGGGCAGTCAGG-3’ 
FBXL15 (R) RN3396 5’-CAGACCCCTGCAAAGATAGAG-3’ 
ALAS1 (F) RN3397 5’-ATATCCGCAGAGCCCAAGAAG-3’ 
ALAS1 (R) RN3398 5’-CACTCAAGTCGAGAAGTCCAAAC-3’ 
CHORDC1 (F) RN3401 5’-CTGTTGTCTGGGCTCCACTTC-3’ 
CHORDC1 (R) RN3402 5’-ACGATCCGTTGCGTTTCAGG-3’ 
CIPC (F) RN3403 5’-GACGACGAGGTTGTCATGGTG-3’ 
CIPC (R) RN3404 5’-CTCCCCTACTTCCACCTCCTTTC-3’ 
EZH2 (F) RN3405 5’-GCGTCCCTTACAGCGAACCC-3’ 
EZH2 (R) RN3406 5’-CAATCGCCATCGCTTTTATTTG-3’ 
HSF (F) RN3411 5’-GCACAGCCGCTTCCGACAG-3’   
HSF (R) RN3412 5’-GCGCGTGTTGGTCCCACC-3’   
TEF (F) RN3598 5’-CGCCAATCAGGGGACACAG-3’ 
TEF (R) RN3599 5’-CGCCTCCTTCCATCGCTAC-3’ 
PPP5C (F) RN3600 5’-TCTCATTCCCTATTGGCTCTC-3’ 
PPP5C (R) RN3601 5’-GCCGCACAAGTGTCGTAAAG-3’ 
BTRC (F) RN3602 5’-CGTAGCCTCAGTTTTTTTCCTG-3’ 
BTRC (R) RN3603 5’-CGCCCTCTCTTACCTCTCAG-3’ 
 
a Abbreviations: F: forward PCR primer; R: reverse PCR primer. Gene sequences were 
obtained from the Ensembl genome browser (http://www.ensembl.org/Homo_sapiens/Info/Index 
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and http://www.ensembl.org/Mus_musculus/Info/Index). Unless indicated otherwise, all PCR 
primers are located in the promoter of the indicated gene.  
3.2.4 NRF1 siRNA assays 
NRF1 siRNA primers were designed (Brummelkamp et al., 2002; Smith et al., 2004), 
cloned into the pSUPER siRNA vector and then sequenced to confirm the correct structure. SK-
N- SH cells were sub-cultured onto 75 cm2 flasks 1 day before the nucleofection and reached 80-
90% confluence. On the day of nucleofection, 4 μg of pSUPER-NRF1 DNA were transfected into 
1×106 SK-N-SH cells using an Amaxa cuvette (Lonza) with Nucleofector® (Lonza) and the 
transfected cells were plated onto a 6-well plate. 24 hr after nucleofection, RNA was extracted 
with Trizol and treated by DNase I to remove genomic DNA. 1 μg of RNA from each sample was 
reverse transcribed into cDNA using SuperScript® III reverse transcriptase (Invitrogen) according 
to the manufacture’s instructions. RT-PCR was performed using primers for each gene (Table 
3.1) to examine gene expression with GAPDH as a negative control and NRF1 as a positive 
control to ensure effective down-regulation by siRNA.  
3.2.5 Reporter constructs and luciferase reporter assays 
Based on sequence alignments of conserved promoter sequence of CLOCK, PER1, CRY1, 
NR1D1 and DBP, and enhancer sequence of PER1 and DBP, luciferase reporter constructs were 
made by PCR cloning using primers in Table 3.3 to clone the minimal promoter (all five genes) 
and enhancer (PER1 intron 1 and DBP intron 2) sequences using genomic DNA from human SK-
N-SH cells as templates. PCR products were digested with BglII and HindIII for promoters or 
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BamHI and SalI for enhancers, and ligated products directionally into the pGL3basic vector 
(Promega). For the CLOCK promoter, NR1D1 promoter, and DBP enhancer, site-directed 
mutations in the putative NRF1 binding sites were performed using primers in Table 3.3 with a 
GeneTailor™ Site-Directed Mutagenesis Kit (Invitrogen) according to the manufacturer’s 
instruction and the mutated products were amplified by Platinum Taq DNA polymerase High 
Fidelity (Invitrogen). However, by sequence analysis, we found four unexpected mutations, which 
were introduced by PCR, in either the promoter or in the luciferase gene of the DBP-pr+enh-
NRF1 construct, and one mutation in the luciferase gene of the CLOCK-pr-mu construct. To 
correct these errors, BamHI and SalI were used to isolate the desired DBP enhancer fragment 
carrying the NRF1 site mutation, while BglII and HindIII were used to isolate the desired CLOCK 
promoter fragment with the NRF1 site mutation, and each used to generate the expected 
constructs, respectively. Both new constructs were sequenced to confirm correct insertions. To 
make the NRF1 site mutation in the putative PER1 enhancer, a minigene was designed (Table 
3.3) and synthesized by Integrated DNA Technologies, Inc. The mutated PER1 enhancer 
fragment was released from the synthetic construct and ligated into the PER1-pr following BamHI 
and SalI digestion. Subsequently, five groups of constructs were transfected into SK-N-SH human 
neuroblastoma cells in a 6-well plate or NIH3T3 cells in a 24-well plate using Lipofectamine 
2000 (Invitrogen). For each well, 1 μg of pGL3basic-derived vector containing a firefly luciferase 
gene was co-transfected with 25 ng of pRL-SV40 vector containing a Renilla luciferase gene. 
Cells were lysed 24 hr after transfection by passive lysis buffer (Promega). Luciferase activity 
was measured using a Dual-luciferase reporter assay (Promega) on a Luminometer 20/20n device 
(Turner BioSystems). For each sample, the firefly luciferase activity was normalized to Renilla 
luciferase activity. The relative luciferase activity was normalized to pGL3basic vector luciferase 
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activities. Each experiment was repeated three times to collect data for statistical analysis and 
analyzed by a two-tailed t-test. 
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Table 3.3. PCR primers and a minigene used for luciferase constructs and 
mutagenesis. 
Target gene (primer 
or oligonucleotide)a 
Primer 
number 
Primer sequences 
CLOCK promoter (F) RN3644 5’-GACTAGATCTGCGGCTCCGTGCTGCCTAAC-3’ 
CLOCK promoter (R) RN3645 5’-GAAAAAGCTTCAAGCCGAGTCCGTGATTG-3’ 
DBP promoter (F) RN3647 5’-CACAAGATCTATCAGGCAGCACGAGCAGAGC-
3’ 
DBP promoter (R) RN3648 5’-GGTTAAGCTTCCAAAGCAAACTTCTTTCGC-3’ 
DBP enhancer (F1) RN3649 5’-CTTTGGATCCCGGCACATTCCTGCGCCACG-3’ 
DBP enhancer (F2) RN3650 5’-CAATGTCGACCTAAGGACACAGGTTCAGG-3’ 
DBP enhancer (R1) RN3651 5’-CTTTGGATCCTGAGTCCTCCCATCCCTCCTC-
3’ 
DBP enhancer (R2) RN3652 5’-CAATGTCGACTGCTGACGCCTGCTTCCCTC-3’ 
NR1D1 promoter (F) RN3653 5’-CTTTAGATCTCGCAGTCCGCCCACTTTGTC-3’ 
NR1D1 promoter (R) RN3654 5’-CTTTAAGCTTCTTTTGCCCGAGCCTTTCCCTG-
3’ 
PER1 promoter (F) RN3655 5’-CACAAGATCTCTCTTCAGCCCAGCACCAGC-3’ 
PER1 promoter (R) RN3656 5’-CTTTAAGCTTTCCACCGGGCGGGCGGGGAG-3’ 
PER1 enhancer (F) RN3657 5’-TTAAGGATCCCGTTCCCCCACTTCCGCCG-3’ 
PER1 enhancer (R) RN3658 5’-CACAGTCGACCTCCAGGCTAATTTTATC-3’ 
CRY1 promoter (F1) RN3659 5’-CTTTAGATCTCTTACCCTCTGGAACGCAGC-3’ 
CRY1 promoter (F2) RN3675 5’-CTTTAGATCTCAAGCTCCCCGCATCCCC-3’ 
CRY1 promoter (R1) RN3660 5’-CCATAAGCTTTGTTTACTACACTGGCTCGG-3’ 
CRY1 promoter (R2) RN3661 5’-CCCTAAGCTTCCTCGGCCCCGCCCCCG-3’ 
CLOCK promoter 
mutation (F) 
RN3693 5’-
GTGCTGCCTAACGGGGCAAGTaaaATaaaCACCGAG
CCG-3’ 
CLOCK promoter 
mutation (R) 
RN3852 5’-ACTTGCCCCGTTAGGCAGCACGGAGCCGCGC-
3’ 
DBP enhancer 
mutation (F) 
RN3676 5’-
CTCCCATCCCTCCTCCGCGCTTCGCaaAGaaaCCTT
CAAGCG-3’ 
DBP enhancer 
mutation (R) 
RN3677 5’-
GCGAAGCGCGGAGGAGGGATGGGAGGACTCACGTGG
-3’ 
NR1D1 promoter 
mutation (F) 
RN3855 5’-
TCCCGACAGTCTTGTCGTTGaaaAGaaaCGCAAGAG
CTC-3’ 
NR1D1 promoter 
mutation (R) 
RN3856 5’-
CAACGACAAGACTGTCGGGATTTGTAGTCCACC-3’ 
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Table 3.3. (continued) 
 
Target gene (primer 
or oligonucleotide)a 
Primer 
number 
Primer sequences 
PER1 enhancer 
mutation minigene 
(sense-strand only is 
shown) 
RN3717 5’-
TTAAGGATCCCGTTCCCCCACTTCCGCCGGGAAATGG
GGGAGGGGTCGCTCCTCCCGCCCTCCTGTGGTCCCTC
CAGCAACCGCTGAGCTCAGCAGCTGACGTCGGTTTCC
CTGGCGACCGTGGCGGCGGCGGAAGCGCGTGGTGGGG
CCGCGCACGTCGGCGaaaATaaGCAGCGGGGGTGGCA
CCGCCCCCGGATAAAATTAGCCTGGAGGTCGACTGTG
-3’ 
 
 
a Abbreviations: F: forward PCR primer; R: reverse PCR primer. Gene sequences were obtained 
from the Ensembl genome browser (http://www.ensembl.org/Homo_sapiens/Info/Index). For 
primer sequences, bold and underline represent restriction enzyme sites used for cloning 
purposes, while bold, italicized lowercase letters represent mutations (shown only for the sense 
strand of oligonucleotides). Each of the five mutations generated is within an NRF1 site within 
the corresponding wildtype (WT) DNA sequence.  
 
3.2.6 Luciferase reporter assays on co-transfection of the DBP promoter-enhancer 
luciferase construct and expression vectors for CLOCK, BMAL1 and NRF1 
5×104 NIH3T3 cells were plated into a 24-well plate a day before the transfection. On the 
day of the experiment, each well was transfected with 250 ng pGL3b-DBP pr+enh construct, 25 
ng pRL vector and/or (1) 125 ng pcDNA3-HA-Clock and 125 ng pcDNA3-HA-BMAL1 (these 
expression vectors were a gift from Dr. M.P. Antoch, Roswell Park Cancer Institute, Buffalo; 
Kondratov et al., 2006); (2) 125 ng pcDNA3-NRF1-VP16 (a gift from Dr. T. Gulick; 
Ramachandran et al., 2008); and (3) 125 ng of each of the three expression vectors, using 
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Lipofectamine 2000 for 20 minutes,  the medium was changed to 500 µl/well OPTI-Medium. 24 
hr after the transfection, cells were lysed by passive lysis buffer (Promega) and luciferase activity 
was measured by a Luminometer 20/20n device (Turner BioSystems). For each sample, the firefly 
luciferase activity was normalized to Renilla luciferase activity. The relative luciferase activity 
was normalized to the luciferase activity of the pGL3basic vector. Each experiment was repeated 
three times to collect data for statistical analysis and analyzed by a two-tailed t-test.  
3.2.7 Co-immunoprecipitation 
Approximately 2×106 NIH3T3 cells were plated in 35 cm2 plates with regular medium 
[(Dulbecco’s modified Eagle medium (DMEM)+10% calf bovine serum (CBS) + 1% penicillin-
streptomycin (P/S)]. When cells reached 80% confluence, media was removed and cells were 
washed once with 5 ml ice-cold PBS/Phosphatase Inhibitors (Nuclear Complex Co-IP Kit, Active 
Motif). By adding another 5 ml ice-cold PBS/Phosphatase Inhibitors, cells were removed gently 
by a cell lifter and collected by centrifugation, and cell pellets were re-suspended in 1 ml 1× 
Hypotonic Buffer with Detergent and the cells lysed by incubation on ice for 15 min. After 
centrifugation, pellets (nuclear fraction) were re-suspended in 200 μl Complete Digestion Buffer 
with 1 μl Enzymatic Shearing Cocktails and incubated at 4°C for 90 min. To stop the reaction, 4 
μl 0.5 M EDTA was added to each sample and centrifuged at 14,000 × g at 4°C for 10 min to 
obtain supernatant. Protein concentration was measured by Bovine Gamma Globulin (BGG) 
Protein Standards assays (Pierce). Control agarose resin (Cross-linked Co-IP kit, Pierce) was used 
to pre-clear the cell lysates before immunoprecipitation. 
Anti-NRF1 (received from Dr. Daniel Reines) and anti-BMAL1 (N-20, Santa Cruz 
Biotechnology) were each cross-linked to Protein A/G Plus Agarose on Pierce Spin Column by 
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DSS solution (Cross-linked Co-IP kit, Pierce). For each co-IP reaction, 500 μg of nuclear extracts 
were diluted into a total of 600 μl IP Incubation Buffer and incubated overnight at 4°C with 
rotation. On the next day, the columns were washed and co-IP products were collected by elution 
buffer according to the manufacturer’s instruction. The antigens were then used for western blot 
analysis. Cell lysates incubated with control agarose resin overnight were used as a control 
according to the manufacturer’s instruction. 
3.2.8 Western blot 
Immunoprecipitated protein samples were loaded and separated on 4-12% Bis-Tris gels 
(BioRad, Criterion XT Precast Gel) and transferred onto a nitrocellulose membrane. IP samples 
by anti-rabbit NRF1 and anti-rabbit BMAL1 were detected on a western blot with anti-CLOCK 
(S-19, Santa Cruz Biotechnology) as a primary antibody and horseradish peroxidase (HRP) 
conjugated donkey anti-goat secondary antibody (Santa Cruz Biotechnology) as a secondary 
antibody. The membrane was detected by chemiluminescence (Western Blotting Luminol 
Reagent, Santa Cruz Biotechnology) using BioMax film. 
3.2.9 Cell cycling studies 
Using NIH3T3 cells, 1 × 106 cells were plated on 35 cm2 plates or 5 × 104 cells were 
plated on 6-well plates with regular medium [(Dulbecco’s modified Eagle medium (DMEM) + 
10% calf bovine serum (CBS) + 1% penicillin-streptomycin (P/S)]. After two days, when cells 
reach 80% confluence, cells were changed into 1% serum medium (DMEM + 1% BCS + 1% P/S) 
for 1 day. At t=0, cells were replaced with serum-rich medium (50% horse serum + DMEM + 1% 
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P/S, Balsalobre et al., 1998) for two hours. After that, cells were changed into serum-free medium 
(DMEM + 1% P/S). At each indicated time point, cells were washed by PBS, trypsinized, 
collected by centrifugation and frozen at -80°C for protein analyses or Trizol (Invitrogen) applied 
directly onto the cells, collected and frozen at -80°C for RNA analyses.  
RNAs was extracted according to the manufacturer’s instruction (miRNA kit, Qiagen) and 
treated by RNase-free DNase I (Promega) to remove genomic DNA. 1 μg of RNA sample from 
each time point was reverse transcribed by SuperScript® III reverse transcriptase (Invitrogen) into 
cDNA using hexamer oligonucleotides and oligo dT primers in a 20 μl reaction. Expression of 
Dbp, Nr1d1, and Nrf1 genes using the respective primer sets (Table 3.4) was analyzed by 
quantitative real-time PCR (QPCR) using an Applied Biosystems 7300 Real Time PCR system. 
SYBR green (Power SYBR® Green PCR Master Mix, Applied Biosystems) was used as a 
fluorescent dye and each cDNA sample was loaded in triplicate. For each sample, a ∆CT value 
was obtained by normalizing each gene of interest against GAPDH in each assay. The ∆∆CT value 
was obtained by subtracting the ∆CT values for each sample from the ∆CT values of GAPDH in 
each corresponding assay to calculate a relative ∆∆CT. All ∆∆CT values were converted to fold 
change.  
For protein analysis, nuclear extracts were obtained from each time point (Nuclear Extract 
Kit, Active Motif) and protein concentration was measured. Samples were loaded onto a Criterion 
XT 4-12% Bis-Tris Gel (Bio-Rad) for protein separation, followed by transfer to a western blot 
and subsequent detection using anti-rabbit NRF1 (received from Dr. Daniel Reines), anti-rabbit 
DBP (Santa Cruz Biotechnology), or anti-rabbit β-actin (ab8227, Abcam).   
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Table 3.4. RT-PCR primers for gene expression studies (mouse NIH3T3 cells). 
 
Target gene 
(primer)a 
Primer 
number 
 
Exon 
 
Primer sequences 
Clock (F) RN3770 7 5’-CTTAGTAATGAAGAGTTTACACAG-3’ 
Clock (R) RN3771 8 5’-TAACGAAGTTACACTCTCAGATAC-3’ 
Per1 (F) RN3772 16-17 5’-CCAAGAAAGATCCGTCGTCAGC-3’ 
Per1 (R) RN3773 17 5’-AGGGCGAGCGGGCTCAGGGT-3’ 
Cry1 (F) RN3774 8 5’-CTGTGGGTTTTGGTAGGAGGAC-3’ 
Cry1 (R) RN3524 9 5’-ATTTTGCAGGGAAGCCTCTTAG-3’      
Nr1d1 (F) RN3525 6 5’-CTTCCGTGACCTTTCTCAGC-3’   
Nr1d11 (R) RN3526 7 5’-GCAAAGCGCACCATCAGCAC-3’              
Dbp (F) RN3775 3-4 5’-CTGAGGAACAGAAGGATGAGAAG-3’ 
Dbp (R) RN3776 4 5’-ATCTGGTTCTCCTTGAGTCTTC-3’ 
Nrf1 (F) RN3807 9 5’-ATTACTCTGCTGTGGCTGATGG-3’ 
Nrf1 (R) RN3808 10 5’-CGTCGTCTGGATGGTCATTTC-3’ 
Nrf1 3’-UTR (F) RN3945 12 5'-GCCCGTGTTCCTTTGTGGTG-3' 
Nrf1 3’-UTR (R) RN3946 12 5'-GGAGAACAACACAGATTCCATGC-3’ 
Arntl (F) RN3779 12-13 5’-TACCTGTTCAAAGAAAAAAGCAG-3’    
Arntl (R) RN3780 13 5’-GGCTCATTGTCTTCGTCCAGC-3’     
Per2 (F) RN3777 10 5’-CCTCCTGGGCTATCTACCTC-3’               
Per2 (R) RN3778 11 5’-CGGTGGACAGCCTTTCGATTA-3’             
Clock alternative 
splicing (F) 
RN4066 15 5′-GCGAGAACTTGGCATTGAAGAG-3′ 
Clock alternative 
splicing (R) 
RN4067 21 5′-CTGTGTCCACTCATTACACTCTGTTG-
3′ 
 
a Abbreviations: F: forward PCR primer; R: reverse PCR primer; ex: exon; in: intron. Gene 
sequences were obtained from the Ensembl genome browser 
(http://www.ensembl.org/Mus_musculus/Info/Index).  
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3.3 RESULTS 
3.3.1 Putative NRF1 sites in 5’ regulatory elements of ~56% circadian regulatory 
genes  
To determine whether NRF1 may have a role in regulating circadian genes, we first 
identified 25 potential NRF1 target genes (Table 3.5) from bioinformatics searches of 45 
candidate genes (Table 3.5 & Table 3.6) in human and mouse genome sequences, with strong 
matches to the NRF1 canonical binding site, 5’-YGCGCANGCGCR-3’. This sequence is a 
pyrimidine (Y)-purine (R) repeating motif, with both a direct repeat and a palindrome (in each 
case, 5’-YGCGCR-3’); either of the latter two features is likely responsible for NRF1 binding 
DNA as a homodimer (Gugneja & Scarpulla, 1997; Gomez-Cuadrado et al., 1995). Prior 
biochemical footprinting studies have shown that NRF1 contacts most or all guanines on both 
strands of DNA (Virbasius & Scarpulla, 1994), and extensive phylogenetics, in vitro and in vivo 
studies in our laboratory and others (Rodriguez-Jato et al., 2005, unpublished data) are consistent 
with the essential nature of the two GCGC sub-motifs. One nucleotide substitution in one GCGC 
motif is allowed, but reduces affinity, while two substitutions prevent NRF1 binding. Only the Y, 
N, and R positions are variable, with consensus sequences at these positions increasing affinity. 
Second, for candidate NRF1 target circadian genes in human and mouse (Table 3.5), we assessed 
phylogenetic conservation by multi-sequence alignment for which the majority of identified TF 
sites were present in all or most sequenced mammalian genomes (Figure 3.1 & Appendix A), 
indicating functional importance. 
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Figure 3.1. (a) (continued below) 
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Figure 3.1. (a) (continued below) 
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Figure 3.1. (b) (continued below) 
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Figure 3.1. (b) (continued below) 
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Figure 3.1. (c) (continued below) 
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Figure 3.1. (d) (continued below)
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Figure 3.1. (d) (continued below)
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Figure 3.1. (e) (continued below)
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Figure 3.1. (f) (continued below) 
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Figure 3.1. (f) (continued below) 
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Figure 3.1. Multi-sequence alignments for (a) CLOCK promoter; (b) CRY1 promoter; (c) PER1 promoter; (d) PER1 intron 1; (e) 
NR1D1 promoter; (f) DBP promoter; and (g) DBP intron 2 enhancer. Consensus sequences for CLOCK/BMAL1 (E-box) and NRF1 
motifs are highlighted in pink and red, respectively.  
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Table 3.5. NRF1 targets include 25 genes encoding core, output, or input circadian 
regulators. 
Gene NRF1 
site 
Human 
chromosome 
Circadian regulatory 
function 
Circadian 
reference 
CLOCK Promoter, 
Intron 1 
4q12 
 
bHLH TF; forms heterodimer 
with BMAL1; binds to E-box to 
activate gene expression; part of 
positive limb of circadian 
rhythms; possesses histone 
acetyltransferase activity 
Steeves et al., 
1999; Hirayama 
et al., 2007; 
Kondratov et 
al., 2003 
PER1 Intron 1 17p13.1 Negative regulator of circadian 
rhythms; heterodimerizes with 
CRY1; PER1 expression is 
activated by CLOCK/BMAL1 
via binding to a promoter E-box 
element 
Motzkus et al., 
2007 
CRY1 Promoter 12q23.3 A photoreceptor; as of PER1 Griffin et al., 
1999; 
Etchegaray et 
al., 2003; Ueda 
et al., 2005; 
Langmesser et 
al., 2008 
NR1D1b Promoter 17q21.1 Encodes an orphan nuclear 
receptor; activated by CLOCK 
and BMAL1 and repressed by 
PER and CRY; a heme sensor 
that coordinates metabolic and 
circadian pathways 
Preitner et al., 
2002; Yin et al., 
2007 
DBP Intron 2 19q13.33 A member of PAR bZIP TFs; 
DBP gene expression regulated 
by CLOCK/BMAL1 complex  
Ripperger & 
Schibler U, 
2006; 
Stratmann et 
al., 2010 
BTRCa Promoter 10q24.32 Part of the E3 ubiquitin ligase 
complex,  mediates PER1 and 
PER2 degradation 
Shirogane et al., 
2005; Reischl et 
al., 2007;  
PPP5C Promoter 19q13.3 Part of an E3 ubiquitin ligase 
complex,  mediates PER1 and 
PER2 degradation 
Partch et al., 
2006 
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Table 3.5. (continued) 
 
Gene NRF1 
site 
Human 
chromosome 
Circadian regulatory 
function 
Circadian 
reference 
FBXL15 Promoter 10q24.32 Protein phosphatase 5; activates 
the kinase activity of CKIε 
(encoded by CSNK1E) by 
preventing autophosphorylation  
Koh et al., 2006 
WDR5 Promoter 9q34.2 A component of the histone 
methyltransferase complex; 
involved in H3K4 methylation; 
associates with PER1 
Brown et al., 
2005; Schuetz 
et al., 2006; 
TIMELESS Intron 1 12q13.3 Interacts with CLOCK in 
circadian rhythms; interacts 
with Chk1 and the ATR-ATRIP 
complex in cell cycle 
checkpoints  
Unsal-Kacmaz 
et al., 2005 
TEF Promoter 22q13.2 PAR bZip protein; circadian 
output gene and TF similar to 
DBP  
Fonjallaz et al., 
1996 
HSF1 Promoter 8q24.3 Activates expression of heat 
shock proteins by thermal 
stress; maintains physiological 
homeostasis of circadian 
rhythms  
Reinke et al., 
2008; Kim et 
al., 2005 
EZH2 Promoter 7q36.1 A polycomb group enzyme; a 
component of CLOCK/BMAL1 
complex; can bind to di- or 
trimethylation of H3K27 on 
Per1 and Per2 promoters; 
enhances mCRY-mediated 
transcriptional repression 
Etchegaray et 
al., 2006; 
CIPC Promoter 14p24.3 Additional negative-feedback 
regulator to CLOCK/BMAL1 
Zhao et al., 
2007 
CHORDC1 Promoter 11q14.3 A potential transcription 
regulator during development 
and has circadian expression 
pattern in mammalian brain  
Gerstner & 
Landry, 2007 
ALAS1 Promoter 3p21.2 Regulated by CLOCK; rate 
limiting enzyme in heme 
biosynthesis  
Kaasik & Lee, 
2004; 
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Table 3.5. (continued) 
 
Gene NRF1 
site 
Human 
chromosome 
Circadian regulatory 
function 
Circadian 
reference 
FMR1 Promoter Xq27.3 homolog dfmr1 (Drosophila) 
mutant shows erratic locomotor 
activity; Fmr1 KO mice have a 
shorter running period in 12 hr 
dark-12 hr dark cycles  
Dockendorff et 
al., 2002; Inoue 
et al., 2002; 
Zhang et al., 
2008;  
FXR2 Promoter 17p13.1 Autosomal homolog of FMR1, 
similar function as FMR1 
Zhang et al., 
2008 
CSNK1E Intron 1 22q13.1 A member of the casein kinase I 
(CKI) gene family; 
phosphorylates PER, CRY, and 
BMAL1 
Eide et al., 
2002; 
Etchegaray  et 
al., 2009 
NR1D2b Intron 1 3p24.2 Belongs to REV-ERB family, 
as for NR1D1, uses heme as a 
ligand 
Raghuram  et 
al., 2007; Liu et 
al., 2008;  
CREM Promoter 10p11.21 a bZIP TF that binds to the 
cAMP responsive element, 
encodes the transcriptional 
repressor ICER, whose levels in 
SCN is regulated by light and 
expressed at high level during 
the night 
Stehle et al., 
1993; Foulkes, 
et al., 1996; 
MYBBP1A Promoter 17p13.3 Interacts with mCRY1, co-
repressor of PER2 promoter 
Hara et al., 
2009 
RAB3A Intron 1 19p13.2 A ras-associated binding 
protein; mutation of mouse 
gene shows abnormal circadian 
period  
Kapfhamer et 
al., 2002 
ATF5 Intron 1 19q13.3 Activating transcription factor 
5; regulated by 
CLOCK/BMAL1  
Lemos et al., 
2007 
PROK2 Promoter 3p13 A circadian output gene 
expressed in the SCN;   
predominantly entrained by 
endogenous clock, and light is a 
modulator for its rhythmic 
expression 
Cheng et al., 
2002; Cheng et 
al., 2005 
 
a NR1D1 is also known as REV-ERBα, NR1D2 as REV-ERBß, and BTRC as ß-TrCP1.  
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3.3.2 NRF1 binds to 5’ regulatory elements of a subset of genes involved in 
circadian regulation and regulates their gene expression 
To test if the predicted NRF1 targets are functional, ChIP assay was used to examine in 
vivo binding of NRF1 in human SK-N-SH neuroblastoma cells. Using antibody against NRF1 in 
ChIP, we showed that NRF1 bound to all predicted targets for 16 tested genes, including CLOCK, 
PER1, CRY1, DBP and NR1D1 (Figure 3.2).  
Similarly, to test the transcriptional regulatory role of NRF1, we used a pSUPER siRNA 
plasmid (Brummelkamp et al., 2002; Smith et al., 2004) that expresses a shRNA targeting NRF1 
exon 2 to knockdown NRF1 mRNA levels. By knockdown of NRF1 mRNA to ~50% levels, we 
found that all predicted target genes have reduced mRNA levels, including CLOCK, PER1, CRY1, 
DBP, and NR1D1, but not those for the GAPDH control (Figure 3.3). Surprisingly, we observed 
significant knockdown of BMAL1 mRNA levels (Figure 3.3). BMAL1 is not predicted to be a 
direct target of NRF1 based on the lack of a canonical NRF1 site from ~50 kb upstream of the 
BMAL1 TSS, all intronic sequence, through ~50 kb downstream of the 3’-UTR. This observation 
indicates the possibility of a secondary effect on BMAL1, although an unknown mechanism by 
which NRF1 can regulate the circadian system cannot be excluded.       
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Table 3.6. 21 genes encoding core, output, or input circadian regulators that do not 
have promoter or intragenic canonical NRF1 sites. 
Genea NRF1 
site 
Human 
chromosome 
Circadian regulatory 
function 
Reference 
BMAL1 none 11p15.2 Heterodimerizes with CLOCK Hirayama et al., 
2007 
CRY2 none 11p11.2 Paralog of CRY1 Griffin et al., 1999; 
Langmesser et al., 
2008 
PER2 none 2q37.3 Paralog of PER1 von Schantz  et al., 
2006; Kaasik & 
Lee, 2004 
PER3 none 1p36.23 Paralog of PER1 von Schantz  et al., 
2006 
NPAS2 none 2q11.2 CLOCK-related; 
heterodimerizes with BMAL1 
Kaasik & Lee, 
2004; 
BMAL2 none 12p11.23 Heterodimerizes with CLOCK, 
paralog of BMAL1 
Sasaki et al., 2009; 
Shi et al., 2010 
DEC1 none 3p26.1 bHLH TF; interacts with 
ARNTL and suppresses 
CLOCK/BMAL1 complex 
Sato et al., 2004; 
Butler et al., 2004; 
Li et al., 2003; 
Honma et al., 2002 
DEC2 none 12p12.1 bHLH TF; interacts with 
BMAL1 and suppresses 
CLOCK/BMAL1 complex; 
expression is mediated by 
DEC1 
Noshiro et al., 
2004; Butler et al., 
2004 
FBXL3 none 13q22.3 Forms SCF ubiquitin ligase 
complexes with Skp1 and cullin 
proteins to ubiquitinate and 
degrade CRY1 and CRY2 
Busino et al., 2007; 
NONO none Xq13.1 Associates with PER; acts as a 
bridge between the 
CREB/TORC complex and 
RNA polymerase II 
Brown et al., 2005; 
Amelio et al., 2007; 
PPARGC1A none 4p15.2 A transcriptional coactivator 
regulates genes involved in 
energy metabolism; stimulates 
BMAL1, NR1D1, NRF1 and 
NRF2 (GABP) 
Liu et al., 2007 
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Table 3.6. (continued) 
 
Genea NRF1 
site 
Human 
chromosome 
Circadian regulatory 
function 
Reference 
RORA none 15q22.2 A retinoid-related orphan 
receptor; activates BMAL1 
transcriptional activity through 
RORA binding box 
Akashi & Takumi, 
2005 
RORC none 1q21 Also a retinoid-related orphan 
receptor; mostly expressed in 
skeletal muscle 
Hirose et al., 1994 
CSNK1D none 17q25 A member of the casein kinase I 
(CKI) gene family; maintains 
24 hr circadian cycle length by 
phosphorylation regulation of 
PER proteins 
Etchegaray et al., 
2009 
AANAT none 17q25 An acetyltransferase; a 
penultimate enzyme in 
melatonin synthesis, regulated 
by cAMP-dependent 
phosphorylation 
Hintermann et al., 
1996; Coon et al., 
2001 
HLF none 17q22 A member of the PAR TF 
family; a clock output gene 
Young et al., 2001; 
Young et al., 2002 
CCRN4L none 4q31.1 Also known as Nocturnin in 
mouse; a deadenylase in 
circadian output pathways 
Garbarino-Pico et 
al., 2007; Green et 
al., 2007 
E4BP4 none 9q22 Phosphorylation regulation by 
CSNK1D;  negatively regulates 
expression of Per2 
Doi et al., 2004; 
Ohno et al., 2007 
CSNK2A1 none 20p13 A subunit of casein kinase II 
(CK2); CK2 phosphorylates 
PER2 and regulates PER2 
stability with CSNK1E 
Tsuchiya et al., 
2009 
CSNK2A2 none 16q21 Also a subunit of casein kinase 
II, as for CSNK2A1 
Tsuchiya et al., 
2009 
CSNK2B none 6p21.3 Also a subunit of casein kinase 
II, as for CSNK2A1 
Akten et al., 2003; 
Tsuchiya et al., 
2009 
 
a BMAL1 is also known as ARNTL, BMAL2 as ARNTL2, DEC1 as BHLHB2, DEC2 as BHLHB3, 
PPARGC1A as PGC-1α, CCRN4L as NOCTURNIN, E4BP4 as NFIL3, CSNK2A1 as CSK2alpha, 
CSNK2A2 as CSK2alpha’, and CSNK2B as CSK2beta.  
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Figure 3.2. NRF1 ChIP assays using SK-N-SH neuroblastoma cells. SNURF-SNRPN enhancer 
is a positive control. Abbreviations: Ab+: antibody positive; Ab-: antibody negative; TI: total input 
of DNA; H2O: PCR negative control; bp: base pair.  
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Figure 3.3. NRF1 siRNA assays using SK-N-SH neuroblastoma cells. GAPDH is a negative 
control. Mock: no siRNA transfection negative control. siRNA: NRF1 siRNA transfection; H2O: 
PCR negative control; bp: base pair. 
 
 
3.3.3 NRF1 regulates expression through the promoters of CLOCK, CRY1 and 
NR1D1, and the enhancers of PER1 and DBP 
To test the function of NRF1 sites in the 5’ regulatory regions of major circadian 
regulatory genes, luciferase reporter constructs for CLOCK, PER1, CRY1, NR1D1 and DBP were 
made using the conserved promoter sequences of CLOCK, DBP, CRY1, PER1, and NR1D1, and 
the conserved enhancer sequences of DBP and PER1 [Figure 3.4(a), Figure 3.1].  
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For the CLOCK promoter, two luciferase constructs were made in pGL3basic [Figure 
3.4(b)], one with 2 intact NRF1 sites (CLOCK-pr) and the other with a site-specific mutation in 
the second NRF1 site [CLOCK-pr-mu, Figure 3.4(a)]. As expected, mutation of the second 
NRF1 site in the promoter significantly reduces the luciferase activity compared to the intact 
promoter construct in transfected SK-N-SH neuroblastoma cells [Figure 3.4(b)].  
For the CRY1 promoter, three constructs have been made [Figure 3.4(c)] with variation in 
the size of the promoter. Compared to the full-length CRY1 promoter (CRY1-pr), the luciferase 
construct CRY1-pr-s2 with a deletion of just the NRF1 site has significantly reduced the 
luciferase activity (by ~30%, P<0.01), indicating that NRF1 is a transcription activator of the 
CRY1 promoter.  To examine the effects on transcriptional activity of loss of E-box motif (Ueda 
et al., 2005), as well as NF-Y and Sp1 sites, in the CRY1 promoter, we also made a short version 
of CRY1 promoter with only the NRF1 and NF-Y site [CRY1-pr-s1, Figure 3.4(c)]. Surprisingly, 
this construct showed a much higher activity than the full-length of CRY1 promoter construct. 
Two potential mechanisms can explain this observation. First, either or both of two, long 
conserved blocks of sequence 5’ to the E-box [Figure 3.1(b)] could bind a repressor of CRY1 
transcription, which would be removed in the CRY1-pr-s1 construct. Alternatively, the increased 
activity of this construct versus the full-length construct may be due to shortening the distance 
from the NRF1 and NF-Y sites to the TSS. Indeed, the most common position of the NRF1 motif 
in genome-wide bioinformatics analyses is centered at 62-nt 5’ of the TSS (Xie et al., 2005), so 
the NRF1 site in the CRY1-pr-s1 construct is likely to be in a more optimal position compared to 
the position in the wildtype CRY1 promoter construct. 
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Figure 3.4. (continued below)
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Figure 3.4. Luciferase reporter assays of 5’ regulatory elements of CLOCK, CRY1, PER1, 
NR1D1 and DBP. (a) Gene structure for CLOCK, CRY1, PER1, NR1D1 and DBP, with sequence 
and location of NRF1 putative binding sites. For NRF1 sites, red represents nucleotides matching  
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to the NRF1 consensus recognition site and green represents less optimal nucleotides. Luciferase 
reporter assays for (b) the CLOCK gene promoter in SK-N-SH neuroblastoma cells, (c) the CRY1 
gene promoter in SK-N-SH neuroblastoma cells, (d) the PER1 gene 5’ regulatory element in SK-
N-SH neuroblastoma cells, (e) the NR1D1 gene promoter in NIH3T3 cells and (f) the DBP gene 
5’ regulatory element in NIH3T3 cells. P<0.05: *; P<0.01: **; P<0.001: ***. 
 
 
 
Similarly, PER1 5’ regulatory elements were cloned into the luciferase vectors [Figure 
3.4(d)]. Compared to the PER1 promoter construct (PER1-pr), the luciferase activity of a 
construct (PER1-pr+enh) carring the PER1 promoter with an intact putative intron 1 enhancer 
increased by approximately 5.9-fold [P<0.001, Figure 3.4(d)] in transfected SK-N-SH 
neuroblastoma cells. This result confirms our hypothesis that the PER1 intron 1 NRF1 site is 
within an enhancer element for PER1 promoter activity. Not surprisingly, a single site-directed 
mutation of the NRF1 binding site in the PER1 enhancer (PER1-pr+enh-mu construct) 
significantly reduced luciferase activity by approximately 70%, compared to the intact promoter 
and enhancer construct [P<0.001, Figure 3.4(d)]. 
For the NR1D1 promoter, two luciferase constructs were made [Figure 3.4(e)], one with 
two intact NRF1 sites (NR1D1-pr) and the other with a site-specific mutation of the first NRF1 
site (NR1D1-mu). As expected, the construct with the NRF1 site mutation has significantly 
reduced the luciferase activity by approximately 60% compared to the intact promoter construct 
in transfected NIH3T3 cells [P<0.001, Figure 3.4(e)]. 
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Previously, two E-box elements in intron 2 of DBP were shown to be critical for circadian 
transcriptional regulation of this gene in the SCN by CLOCK/BMAL1 (Ripperger et al., 2000; 
Ripperger and Schibler, 2006). Deletion of the two E-box elements and sequence in between in 
Rat-1 cell line and in a mouse model showed loss of circadian mRNA expression of DBP 
compared to the wildtype and altered histone modification at the chromatin level. By 
bioinformatics analyses, we found a conserved, putative NRF1 site between the two E-box 
elements in intron 2 of DBP [Figure 3.4(a), (f), Figure 3.1(g)]. To test the role of the NRF1 site 
in this region, we cloned the DBP promoter alone (DBP-pr construct) and with the enhancer 
element (DBP-pr+enh) into a pGL3basic luciferase reporter vector. As expeced, the DBP 
promoter construct is functional and has increased the luciferase activity by 34-fold (P<0.01) 
compared to the pGL3basic vector, while the enhancer construct (DBP-pr+enh) has increased the 
transcriptional activity another 3-fold to the DBP promoter construct [overall 102-fold compared 
to the pGL3basic, P<0.001, Figure 3.4(f)]. Deletion of each individual (DBP-pr+enh-E1, DBP-
pr+enh-E2) or both E-boxes (DBP-pr+enh-E1-E2) within the enhancer significantly reduced 
luciferase and hence enhancer activity by 38%, 32%, and 47%, respectively [P<0.001, P<0.001, 
P<0.001, respectively, Figure 3.4(f)].  Interestingly, mutation of the NRF1 binding site with both 
E-boxes intact (DBP-pr+enh-NRF1) reduced DBP enhancer activity to a greater extent [by 52%, 
P<0.0001, Figure 3.4(f)] than mutation of either E-box motif and at least as much as mutations of 
both E-boxes [Figure 3.4(f)]. These data provide strong evidence that NRF1 acts as an activator 
of the DBP gene enhancer.  
As a complementary approach, we used the intact DBP promoter+enhancer luciferase 
construct (DBP-pr+enh) and co-transfected with expression vectors for NRF1 (NRF1-VP16; 
Ramachandran et al., 2008), CLOCK and BMAL1 (Kondratov et al., 2006). CLOCK and 
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BMAL1 increased luciferase activity of the DBP-pr+enh construct by ~18-fold (P<0.001, Figure 
3.5). Similarly, NRF1 alone or in combination with CLOCK and BMAL1 increased luciferase 
activity of the DBP-pr+enh construct by ~14 and ~21 fold, respectively (P<0.001, Figure 3.5). 
These data demonstrate that NRF1 as well as the CLOCK-BMAL1 heterodimer activate the DBP 
intron 2 enhancer. 
Taken together, luciferase reporter assays have demonstrated that NRF1 is a major 
transcriptional activator for CLOCK, CRY1, and NR1D1 though promoter target sites. Similarly, 
NRF1 acts as a major regulator of PER1 and DBP transcription through intronic enhancer sites.  
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Figure 3.5. Co-transfection of the DBP promoter+enhancer luciferase construct with 
expression vectors for CLOCK, BMAL1 and NRF1. P<0.001: ***. 
 
 
 
125 
3.3.4 NRF1 and the CLOCK/BMAL1 heterodimer are in a molecular complex 
We have shown that NRF1 binds spatially close to two CLOCK/BMAL1 binding sites in 
the DBP intron 2 enhancer and together NRF1 and CLOCK/BMAL1 co-regulate this DBP 
circadian enhancer. Therefore, we hypothesize that NRF1 interacts with CLOCK/BMAL1 in a 
molecular complex, and that CLOCK may acetylate NRF1 with deacetylation by SIRT1. In 
support of this hypothesis are the following observations: 1) CLOCK is known to acetylate 
histone H3, histone H4, and BMAL1 (Doi et al, 2006; Hirayama et al, 2007); 2) SIRT1 is known 
to associate with CLOCK/BMAL1 and to promote the deacetylation of histone H3, BMAL1, and 
PER2 (Asher et al, 2008; Nakahata et al, 2008) and 3) in vitro acetylation of NRF1 by pCAF 
(p300/CBP-associated factor) enhances its function (Izumi et al., 2003), suggesting that NRF1 
acetylation in vivo may contribute to its mechanism of action at least at a subset of cis-regulatory 
elements that it targets.  
The acetylated lysine residue(s) in NRF1 [Figure 3.6(a)] are not known (Izumi et al, 
2003), and other HAT enzymes, including CLOCK, might be relevant for NRF1 acetylation in 
vivo. Few targets of the CLOCK [Figure 3.6(b)] HAT enzymatic function have been identified 
(Doi et al., 2006; Hirayama et al., 2007). For histone H3, it is lysine 14 (K14) that is acetylated 
[Doi et al, 2006, Figure 3.6(c)], while phosphorylation of histone H3 at S10 (which is induced by 
light, Crosio et al, 2000) enhances acetylation at K14 (Doi et al., 2006). For BMAL1, it is K537 
(mouse) that is acetylated [Figure 3.6(c)], whereas the acetylated lysines in histone H4 have not 
been identified (Doi et al., 2006). Our comparison of histone H3 and BMAL1 amino acid 
sequences around the CLOCK-acetylated lysine identified a shared SXGGK motif with similar 
motifs present in a region of more extended similarity between histone H4 and NRF1 [SXGRGK; 
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Figure 3.6(c)]. This observation predicts lysine 221 in NRF1 as a candidate for potential CLOCK 
acetylation. 
To test this hypothesis, co-immunoprecipitation was performed to examine a potential 
interaction between NRF1 and CLOCK. We used antibodies against NRF1 and, as a positive 
control, antibodies against BMAL1 for immunoprecipitation and then detected CLOCK proteins 
on a western blot [Figure 3.6(d)]. As expected (Lee et al., 2001; Tamaru et al., 2003; Kondratov 
et al., 2006), BMAL1 co-immunoprecipitated both native and phosphorylated CLOCK-isoforms 
from nuclear extracts. Intriguingly, NRF1 not only co-immunoprecipitated both CLOCK 
isoforms, but preferentially associated with the phosphorylated, active form of CLOCK [Figure 
3.6(d)]. Besides full length CLOCK and phosphorylated CLOCK isoforms, we detected a low 
level of a smaller CLOCK protein in nuclear extract, in NRF1-IP and BMAL1-IP samples 
[Figure 3.6(d)]. According to previous studies, a smaller Clock mRNA isoform was found in 
mouse with alternative splicing of exon 18, which leads to an in-frame 30 amino acid deletion 
(King et al., 1997). Using primers located in exons 15 and 21 (Table 3.4), RT-PCR was 
performed using cDNA from NIH3T3 cells (see below). As expected, we found two RT-PCR 
bands [Figure 3.6(e)], the sizes which match the more abundant full-length and the less abundant 
alternatively spliced (lacking exon 18) Clock mRNA isoforms. Therefore, all three protein bands 
detected by western analysis are different isoforms of CLOCK. 
127 
 
 
Figure 3.6. Co-immunoprecipition of NRF1 or BMAL1 and CLOCK, as detected by western 
blot. (a) Structure of the conserved NRF1 polypeptide. NRF1 from human (H), mouse (M), and 
chicken (C) are 99-100% identical over the entire sequence. The position of structural domains is 
indicated, including nuclear localization signal (NLS, pink vertical box), DNA binding (dark blue 
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horizontal box), dimerization (black horizontal bar) an transcriptional activation (grey box) 
domains. NRF1 has 5 serine residues that are phosphorylated (P). Modified from Scarpulla 
(2008). (b) Structure of the CLOCK polypeptide from mouse (M) showing functional motifs. (c) 
Amino acid alignment of CLOCK-targeted acetylation motifs in histone H3 and BMAL1, and 
similar motifs in histone H4 and NRF1. The acetylated lysine in H3 and BMAL1 have green 
shading, with residues present in all 4 sequences in green, blue or yellow shading, while gray 
shading denotes amino acids present in 2 or 3 of the sequences. (d) Detection of CLOCK protein 
on a western blot, showing native CLOCK, phosphorylated CLOCK (P-CLOCK), and a low level 
of CLOCK resulting from alternatively spliced (alt. spliced) Clock mRNA (see e). Abbreviations: 
IP: immunoprecipitation; nuclear extract: total protein extract from nucleus; negative control: the 
negative control in immunoprecipitation uses control agarose resin. (e) RT-PCR analysis of full-
length (762-bp) and alternatively-spliced (672-bp) Clock mRNA isoforms. Each lane shows RT-
PCR products from NIH3T3 cell cDNA derived from different time points after serum-shock. 
 
 
3.3.5 Ultradian oscillations of Nrf1 mRNA and NRF1 protein in serum-shocked 
NIH3T3 cells 
It has been reported that a subset of clock genes can be synchronized and subsequently 
undergo at least two circadian oscillation cycles in cell line models (Balsalobre et al., 1998; 2000; 
Earnest & Cassone, 2005). To test if Nrf1 mRNA levels oscillate in a circadian or other fashion, 
we used serum-shocked NIH3T3 cells, an established model to synchronize circadian cycles of a 
subset of clock genes (Osland et al., 2010). As expected, both Dbp and Nr1d1 showed typical 
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rhythmic expression in this cell model, with the peak phase at 24 hr and 20 hr, respectively, after 
serum-shock [Figure 3.7(a)&(b), Balsalobre et al., 1998], while Clock and Per1 mRNA levels 
did not cycle (data not shown). These findings are consistent with previous reports with respect to 
peaks and phases of oscillation and oscillatory behavior of mRNAs encoding known circadian 
regulators (Balsalobre et al., 1998; Osland et al., 2010). Interestingly, Nrf1 mRNA levels 
oscillated [Figure 3.7(c)], with the peak phase at 16 hr and 32 hr, respectively, after serum-shock, 
indicating an ultradian rhythm (~16 hr; Hughes et al., 2009). At the protein level, NRF1 showed a 
similar ultradian rhythm as for mRNA levels, when compared to the positive control (DBP) and 
the β-actin negative control [Figure 3.7(d) & (e)]. As we have shown that NRF1 controls 
expression of circadian regulatory genes in both the positive and negative feedback loops, it is not 
surprising that NRF1 does not cycle in a typical circadian manner. Indeed, even at the nadir of 
Nrf1 mRNA and NRF1 protein levels, there are still significant levels present in these cells under 
these conditions [Figure 3.7(c),(e)]. Further studies are needed to determine if NRF1 levels 
oscillate in vivo in the SCN and other tissues. 
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Figure 3.7. NRF1 mRNA and protein expression levels in serum-shocked NIH3T3 cells. (a) 
mRNA expression levels of Dbp. (b) mRNA expression levels of Nr1d1. (c) mRNA expression 
levels of Nrf1. Three different biological replicates are shown. (d) Protein expression of DBP and 
NRF1 detected on western blot. β-actin was used as a control. (e) Quantification of protein 
amounts in each lane for NRF1 normalized to β-actin, using Image J software. 
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3.4 DISCUSSION 
In this study, for the first time NRF1 has been demonstrated to positively regulate 
numerous circadian genes, including core regulatory genes and CCGs with regulatory roles 
(Figure 3.2-3.4, 3.8, Table 3.3). Overall, ~56% of these genes are targets of NRF1 regulation. 
Furthermore, NRF1 and the active, phosphorylated CLOCK polypeptide interact in a molecular 
complex. These observations indicate a significant impact of NRF1 on circadian biology. In 
particular, we used numerous molecular genetic methods to show that NRF1 positively regulates 
transcriptional activity of CLOCK, CRY1, and NR1D1 through promoter sites, as well as PER1 
and DBP through enhancer sites (Figure 3.8). Intriguingly, we also observed that BMAL1, which 
was not predicted to be a direct target of NRF1, had down-regulated mRNA levels in NRF1 
siRNA assays. This could be caused by down-regulation of other NRF1 target genes in the 
circadian system that encode regulators of BMAL1 expression (Table 3.3, Figure 3.8) or an 
unknown circadian factor that is also under NRF1 regulation and remains to be identified. If 
additional circadian regulatory genes that are not direct targets if NRF1 show a similar secondary 
effect, then the role of NRF1 in the circadian network would be extremely broad.  
NRF1 was first identified with a major role in activating nuclear genes encoding 
mitochondrial functions and biogenesis (Virbasius et al., 1993; Scarpulla, 2008), in cell cycle 
regulation (Cam et al., 2004; Patti et al., 2003), neuronal development and function (Chang et al., 
2005; Yang et al., 2006; Liang& Wong-Riley, 2006, Smith et al., 2004), in Prader-Willi 
syndrome (Stefan M, et al., in preparation; Chapter 2), and is implicated in diabetes (Patti et al., 
2003; Mootha et al., 2003; Gaulton et al., 2008; Liu et al., 2008; He et al., 2008). Studies of 
NRF1 orthologs have shown that loss of Nrf1 function in zebrafish is embryonic lethal and leads 
to a specific loss of photoreceptor neurons and their precursors (Becker et al., 1998). As circadian 
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rhythms are entrained by light through retinal afferents to the SCN (Rutter et al., 2002), NRF1 
could regulate the process of light entrainment and neuronal connections to the SCN, although 
this hypothesis remains to be examined. Additionally, a serum shock induces circadian gene 
expression in cell lines (Balsalobre et al., 1998), and NRF1 is in an inactive state in serum-starved 
cells but becomes active (phosphorylated) with serum addition (Gugneja & Scarpulla, 1997). 
Finally, in the peripheral system, PPARGC1A, a transcriptional coactivator to NRF1 and other 
TFs in mitochondrial metabolism, is rhythmically expressed in the mouse liver and skeletal 
muscle, and may play a role in metabolic adaptations to the daily circadian cycle (Liu et al., 
2007). These observations are consistent with our findings that NRF1 has major regulatory roles 
in the circadian system. 
The molecular mechanism of circadian transcriptional regulation is best understood for the 
DBP gene, highly expressed and strongly rhythmic in the SCN and peripheral tissues such as the 
liver (Lopez-Molina et al., 1997; Yan et al., 2000), which involves the rhythmic binding of 
CLOCK/BMAL1 heterodimers to E-box elements in an intron 2 enhancer in coordination with 
rhythmic changes in histone modification (Ripperger et al., 2000; Ripperger & Schibler 2006; 
Kiyohara et al., 2008). Additionally, CRY1 can also be recruited to the non-canonical E-box in 
the DBP and cause delay phrase of DBP expression in liver (Stratmann et al., 2010). In this study, 
we further dissected the cis-acting DBP enhancer and identified a significant involvement of 
NRF1, in which the NRF1 site closely flanks the two E-boxes in intron 2 of DBP [Figure 3.1(g)].  
Indeed, NRF1 affects the amplitude of transcriptional activity due to DBP enhancer activity to the 
same degree as the effect triggered by CLOCK/BMAL1 heterodimers in unstimulated NIH3T3 
cells [Figure 3.4(f) & Figure 3.5]. Although in transfection experiments the combination of 
NRF1, CLOCK and BMAL1 was not dramatically additive, it is possible that the DBP 
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transcriptional capacity in the luciferase reporter system is saturated by NRF1 alone or CLOCK-
BMAL1 alone. Alternatively, NRF1 and CLOCK/BMAL1 may have independent roles in 
activation of DBP enhancer function. The latter seems unlikely given that we have identified 
NRF1 and the active CLOCK transcription factor in a molecular complex, making it likely that 
NRF1 and CLOCK function together in a complementary manner. Interestingly, the amplitude of 
transcriptional activity (Dibner et al., 2009; O’Neill, 2009) plays a role in the period of the 
circadian clock, so NRF1 may contribute to this aspect of circadian function by its ability to 
strongly activate transcription through enhancer and promoter mechanisms.  
By protein immunoprecipitation studies we have shown that NRF1 and CLOCK/BMAL1 
interact in a molecular complex, and it is striking that NRF1 preferentially interacts with the 
phosphorylated, active isoform of CLOCK in the nucleus [Figure 5(c); Lee et al., 2001; Tamaru 
et al., 2003; Shim et al., 2007]. It is known that the status of CLOCK phosphorylation is dynamic, 
with phosphorylation of CLOCK associated with its translocation from the cytoplasm to the 
nucleus (Kondratov et al., 2003; Shim et al., 2007) and an enhancement of its E-box binding 
ability, whereas hyperphosphorylation decreases protein stability of CLOCK (Yoshitane et al., 
2009; Spengler et al., 2009). Furthermore, many factors can transiently interact with 
CLOCK/BMAL1 for specific functions, for example, CIPC-mediated CLOCK phosphorylation 
(Yoshitane et al., 2009), SIRT1-mediated deacetylation of BMAL1 and PER2 (Asher et al., 2008; 
Nakahata et al., 2008; Masri & Sassone-Corsi, 2010), and MLL1 (mixed lineage leukemia-1)-
mediated methylation of H3K4 (Masri & Sassone-Corsi, 2010). Therefore, it is plausible that the 
interaction between NRF1 and CLOCK/BMAL1 also occurs in a transient manner at the promoter 
or enhancer elements of a subset of genes involved in circadian rhythms. 
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Interestingly, our data showed that peak levels of NRF1 mRNA and protein oscillate with 
an ~16 hr ultradian rhythm (~1.5th harmonic cycle, Hughes et al., 2009) in serum-shocked 
NIH3T3 cells [Figure 3.7(c)]. It is not surprising that NRF1 levels oscillate, as in other work (see 
Chapter 4), we found that NRF1 is autoregulated by a feed-forward mechanism, although the 
mechanism of negative feedback regulation recquisite for an oscillatory system is not known. One 
candidate would be a repressive transcriptional mechanism (see Chapter 4). Another mechanism 
that could negatively regulate NRF1 mRNA and protein levels would be miRNA targeting, and 
our recent studies have found that miR-182 and miR-96 are involved in down-regulation of NRF1 
(B. J. Henson, R. D. Nicholls, unpublished data). This is intriguing as the miR-182/miR-96 family 
of miRNAs has been suggested to show circadian expression in retinal neurons (Xu et al., 2007) 
although more recent studies suggest that the oscillatory activation of miR-182/miR-96 in retinal 
photoreceptor neurons is due to activation by light with rapid turnover in the dark (Krol et al., 
2010). These and additional mechanisms acting in retinal (Becker et al., 1998) and/or SCN 
neurons could thus play a role in regulation of NRF1 and subsequent circadian regulation of 
downstream NRF1 target genes. Combined with our data showing that NRF1 targets include 
genes from both positive and negative feedback loops (Table 3.3), we propose that the circadian 
system can interpret the oscillating levels of NRF1 and its interaction with the CLOCK/BMAL1 
complex to regulate the affinity and binding at cis-regulatory elements of target genes to integrate 
the regulatory networks of both the positive and negative circadian feedback loops.  
Genome-wide microarray analyses have shown that 10-15% of genes are CCGs with 
circadian expression and that many of these genes are involved in metabolism and energy balance 
(Reppert & Weaver, 2002; Mendoza, 2007; Masri & Sassone-Corsi, 2010). Interestingly, energy 
balance in the body is sensed and regulated by the AMP-activated protein kinase (AMPK, Hardie, 
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2008; Spasic et al., 2009; Richter et al., 2009; Lim et al., 2010), which regulates the circadian 
clock through phosphorylation and stability of CRY1 and entrains circadian function to 
metabolism (Lamia et al., 2009; Suter & Schibler, 2009). AMPK also activates NRF1-pathways 
(Bergeron et al., 2001; Garcia-Roves et al., 2008), and provides a link between energy balance, 
diabetes (Hardie, 2008), exercise (Ojuka et al., 2004), and NRF1 levels and activity (Timmons et 
al., 2006; Wright et al., 2007). Additionally, PPARGC1A is one of several co-activators for 
NRF1, particularly for nuclear genes encoding mitochondrial functions (Scarpulla, 2008), and 
PPARGC1A is known to play a key role in integration of circadian function (Liu et al., 2007) and 
metabolism (Cunningham et al., 2007). Collectively, this provides a link of NRF1 to energy 
balance and metabolism, each of which can critically influence circadian rhythms.  
In vertebrates, light entrains the developing circadian clock via photoreceptive retinal 
ganglion cells that express melanopsin and that project to the SCN (Vallone et al., 2007). 
Intriguingly, mutation of NRF1 ortholog in zebrafish demonstrated an essential role in 
development of all types of photoreceptors (Becker et al., 1998). The NRF1 ortholog in fly (EWG) 
is also essential for neuronal development (DeSimone & White, 1993). Supporting evidence from 
the Allen brain atlas (Jones et al., 2009) by in situ hybridization shows enriched expression of 
Nrf1 in the SCN of the hypothalamus in mouse, as well as hypothalamic nuclei involved in the 
regulation of feeding, and other non-hypothalamic neuronal structures. This observation, 
combined with our data showing NRF1 contributes to enhancer function of the SCN-specific DBP 
enhancer (Ripperger et al., 2000), as well as other key genes for SCN circadian function such as 
CLOCK, PER1, CRY1, NR1D1, and others, supports a hypothesis for a role of NRF1 in gene 
regulation of the central pacemaker of circadian rhythms. Future studies will determine the roles 
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and mechanisms of action of NRF1 in establishment and/or function of neural and molecular 
pathways underlying circadian rhythms.  
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Figure 3.8. Summary of NRF1 regulation in the circadian system. The model depicts the canonical clock mechanism involving 
positive and negative feedback loops comprised of CLOCK/BMAL1 heterodimers binding to E-box elements in target genes and 
subsequent repression of these pathways by PER/CRY heterodimers. NR1D1 provides an ancillary feedback loop, while DBP encodes 
an output regulatory TF and also regulates PER1. Post-translational regulation by phosphorylation and protein degradation are not 
shown for simplicity. NRF1 regulation occurs for many components of the circadian regulatory hierarchy. 
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4.0  ADDITIONAL MECHANISMS AND SYSTEMS OF NRF1 REGULATION 
4.1 INTRODUCTION 
4.1.1 Hereditary spastic paraplegia 
Hereditary spastic paraplegias (HSP) are neurodegenerative disorders characterized 
primarily by progressive spasticity in the lower limbs due to axonal degeneration of the 
corticospinal tract (CST). Other neural-related clinical features include progressive symmetric 
spasticity of lower extremities, often but not always with muscle weakness, and increased 
stiffness, hyperreflexia, extensor plantar responses and, in some cases, bladder disturbances and 
vibratory sense impairment (Depienne et al., 2007; Fink 2009). Dominant inheritance accounts 
for ~70% of HSP and mutations in one gene, SPAST (SPG4), occur in about 40% of these cases. 
However, to date, 45 autosomal dominant, recessive and X-linked gene loci are chromosomally 
linked to HSP pathogenesis, with etiological gene mutations identified for only 22 of these 
(Depienne et al., 2007; Salinas et al., 2008; Dion et al., 2009; Fink, 2009). Selection of new 
candidate genes that affect function and trafficking in long axons is difficult as known hereditary 
spastic paraplegia (HSP) genes encode proteins involved in a multitude of biochemical pathways 
including known or potential roles in mitochondria, microtubules, anterograde transport, 
endosomal, endoplasmic reticulum (ER) and Golgi, as well as additional functions such as 
cytoplasmic, gap junction, and myelin sheath or Schwann cell function (Salinas et al., 2008; Dion 
et al., 2009; Park et al., 2010).  
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Our knowledge of cis-binding motifs and role of NRF1 in transcriptional regulation in the 
PWS region (Chapter 2) provided a basis for initially examining SPG6 (NIPA1, on human 
chromosome 15q11.2), followed by the Spastin (SPG4) gene promoter since SPG4 is most 
frequently involved in spastic paraplegia. Having identified potential NRF1 binding sites in the 
promoters of these two genes (see Results), we extended our analyses to all 22 cloned HSP loci. 
We hypothesize that HSP loci are co-regulated by a common GRN in order to determine proper 
spatiotemporal expression patterns in the motor cortex to accomplish specific CST functions.  
4.1.2 NRF1 autoregulation 
NRF1 is known to be crucial for the expression of nuclear genes that encode 
mitochondrial products (Scarpulla, 2008), genes in cell cycle regulation (Morrish et al., 2003; 
Cam et al., 2004), development (Chen et al., 1997; Efiok & Safer, 2000; Moriuchi et al., 1997; 
Solecki et al., 2000) and neural functions (Chang & Huang, 2004; Smith et al., 2004; Chang et al., 
2005; Yang et al., 2006). Indeed, loss of Nrf1 function is lethal across the animal kingdom 
(Chapter 1.1.1). Previous reports have shown that some TFs are autoregulated by binding to their 
own promoters. For example, NR1D1 has a Rev-erbα response element (RORE) on its own 
promoter [Figure 3.1(e)], which has been shown to mediate transcriptional repression when 
NR1D1 protein level goes up in an in vitro system, implying this gene is potentially autoregulated 
(Adelmant et al., 1996). YY1 has a cluster of YY1 binding sites on its intron 1 as a transcriptional 
activator (Kim et al., 2009). When exogenous YY1 was overexpressed in an induced cell line, 
endogenous YY1 protein level went down to maintain homeostasis through regulation by the 
cluster of YY1 sites intron 1, proving the mechanism of YY1 autoregulation (Kim et al., 2009). 
These data suggested a TF autoregulatory system is functioned by a transcriptional feedback loop 
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to repress its own expression. Intriguingly, we found two highly conserved NRF1 sites in the 5’ 
regulatory region and one site in intron 1 of the NRF1 gene (Figure 4.1). All putative NRF1 sites 
are highly conserved from fish to human (Figure 4.1). Therefore, we hypothesize that NRF1 
autoregulates its own transcriptional activity. 
4.1.3 NRF1 binding site studies 
As mentioned in Chapter 1.1.4, several genome-wide studies by bioinformatics analysis or 
experiments (ChIP-chip) have revealed that approximately 5-6% of the genes are regulated by 
NRF1. Functional NRF1 binding sites have been confirmed experimentally with sequence 
variance of 1 nucleotide in either GCGC and/or 1 nucleotide in the AY segment (Stefan et al., in 
preparation, Figure 2.2 & 3.1). These studies also suggested that multiple NRF1 binding sites 
may also increase binding affinity by cooperative binding even if individual recognition motifs 
may not be optimal.  
To further study the parameters that affect NRF1 binding ability, an artificial model has 
been designed. In this model, six minigenes have been synthesized in pIDTSMART vectors (IDT), 
each containing 10, 8, 6, 4, 2, or 1 copies of NRF1 consensus recognition sites. These minigenes 
were subcloned from the pIDTSMART plasmids into the promoter position of a modified 
pGL3basic luciferase reporter vector. Subsequently, these series of pGL3basic-derived vectors 
were transfected into SK-N-SH neuroblastoma cells to compare the luciferase activities. These 
studies will not only improve bioinformatics methods for identification of functional NRF1 sites 
genome-wide, in any animal species, but will also provide critical knowledge and reagents to aid 
structural analyses of NRF1 as well as the generation of novel reagents for future in vivo 
functional studies. 
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Figure 4.1. Multi-sequence alignment of the NRF1 promoter-exon 1-intron 1 region. NRF1 sites are highlighted in bold red. A 
YY1 site is highlighted in bold pink. Sp1 sites are highlighted in bold purple. The exon/intron boundary is highlighted in bold blue. 
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4.2 MATERIALS AND METHODS 
4.2.1 Bioinformatics and phylogenetic analyses 
NRF1 sites were predicted using bioinformatics by matches on either strand to the 
consensus binding motif 5’-yGCGCANGCGCr-3’, allowing one mismatch in one but not both 
GCGC motifs (y = t or c; r = a or g; neither of these two positions is required but generates a more 
optimal motif). Sites with one mismatch in one GCGC motif are defined as an NRF1-like site (L); 
various substitutions lead to differing affinity for NRF1 as determined experimentally (e.g., 
ACGC remains high affinity with strong binding of NRF1, but GCCC has little or no affinity, 
although multiple NRF1 or NRF1-like sites in a promoter can increase the binding extent at even 
weaker sites). 
4.2.2 Gene expression studies 
RNA was extracted from human SK-N-SH neuroblastoma cells with Trizol (Invitrogen) 
according to the manufactuer’s protocol. DNase I treatment was performed to remove DNA 
contaminants from each RNA sample. Based on RNA concentration, determined using a 
spectrophotometer, 1 µg of RNA from each sample was transcribed into cDNA by SuperScript® 
III reverse transcriptase according to the manufacturer’s protocol (Invitrogen). Regular PCR was 
performed to test gene expression of a subset of HSP genes using primers from Table 4.1.  
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Table 4.1. Human QPCR primers for HSP genes. 
Target gene (primer)a Primer number Exon Primer sequences 
SPG3A F RN3632 7-8 5’-TCAAGGTCTCAGGGAACCAGC-3’ 
SPG3A R RN3633 8 5’-CCAGGATGAGGTAGCAGAAAAC-3’ 
SPG4 F RN3430 15 5'-GACTGATGGATACTCAGGAAG-3' 
SPG4 R RN3431 16 5'-GGCAGACATATTCTTCACCTG-3' 
SPG5 F RN3613 4 5'-TTTCCCATCCACCTCACCAG-3' 
SPG5 R RN3614 5 5'-CCCGGTCTCTGAACTGAGAG-3' 
SPG6 F RN3024 4 5'-GCTCCGTCGTGCTGATTAT-3' 
SPG6 R RN3025 5 5'-AGGTAGCCCACAAACACTGG-3' 
SPG7 F RN3428 15 5'-GGTGAAGCAGTTTGGGATGG-3' 
SPG7 R RN3429 16 5'-CTTGGCCACCAGCAGTCTTG-3' 
SPG8 F RN3432 27 5'-GCCAGTTTATCTGCTCCACG-3' 
SPG8 R RN3433 28 5'-GCACCCACAACATCTGCAGG-3' 
SPG10 F RN3634 9-10 5’-CTGGCTGAGGGCACTAAAAG-3’ 
SPG10 R RN3635 10 5’-TGAGCAACAGATGAACATAGTC-3’ 
SPG11 F RN3624 7 5'-GCTGATGGACTGTATTCTGG-3' 
SPG11 R RN3625 8 5'-AATCTGGAACAAAATCGTAGGC-3' 
SPG13 F RN3434 10 5'-GATGCATTCCAGCCTTGGAC-3' 
SPG13 R RN3435 11 5'-CAAAGATCCTTCAACACCTGC-3' 
SPG15 F RN3636 4 5’-TTGTACTGGAGAAATGGTTGGC-3’ 
SPG15 R RN3637 5 5’-TCTGACAATAAAAGAAACTCAAGC-3’ 
SPG17 F RN3638 5 5’-CCTCCTGCTATTTGGCTTTGC-3’ 
SPG17 R RN3639 6 5’-CTGTGGATCTCAATGATCGCTC-3’ 
SPG20 F RN3438 7 5'-CATGTCAAGAAGCATGGAAGC-3' 
SPG20 R RN3439 8 5'-AGCTGCACATTCCAATCCTTG-3' 
SPG21 F RN3640 3 5’-GCTCTGACTGGATGGGGTTAC-3’ 
SPG21 R RN3641 4 5’-CTGAATCCATCACAGAACTCG-3’ 
SPG31 F RN3642 3 5’-GCACTTTTCACCACAGCAGAG-3’ 
SPG31 R RN3643 4 5’-TTAGTTCATAATAGAATGGAAACC-3’ 
SPG33 F RN3436 7 5'-CGGGTTCCTGAGCAAGAATG-3' 
SPG33 R RN3437 8 5'-TGAGAAGGTGGCCGAGCAG-3' 
 
a Abbreviations: F: forward PCR primer; R: reverse PCR primer. Gene sequences were obtained 
from the Ensembl genome browser (http://www.ensembl.org/Homo_sapiens/Info/Index). 
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4.2.3 Chromatin immunoprecipitation (ChIP) 
Approximately 1×106 SK-N-SH neuroblastoma cells or marsupial cells were plated on 35 
cm2 plates with regular medium [medium for SK-N-SH cells: Alpha modified MEM + 10% FBS 
+ 1% penicillin-streptomycin (P/S) + 1% 100 mM L-glutamine + 1% nonessential amino acid + 
1% sodium pyruvate; medium for marsupial cells: DMEM+10% FBS + 1% penicillin-
streptomycin (P/S)]. When cells reached 70-80% confluence, formaldehyde was added into the 
regular media to make the final concentration of 1% and the plates were incubated at 37°C for 10 
minutes to cross link protein to DNA. After washing with 5 ml ice cold PBS once, another 5 ml 
ice cold PBS was added, cells were scraped from the plates by a cell lifter, put into a 15 ml tube, 
centrifuged, re-suspended in SDS lysis buffer (ChIP assay kit, Millipore), and sonicated to shear 
DNA. Samples were precleared with protein G-agarose/salmon sperm beads (Millipore). Protein-
DNA complexes were immunoprecipitated with anti-NRF1 (from Dr. Daniel Raines, Smith et al., 
2004) or anti-YY1 (Santa Cruz Biotechnology, sc-1703X). Complexes were collected with 
Protein G agarose/salmon sperm beads and washed. Protein-DNA complexes were eluted off the 
beads and cross-links were reversed by incubation with NaCl at 65ºC overnight. On the next day, 
DNA was recovered by phenol-chloroform extraction and precipitated by ethanol. PCR was 
performed using the recovered immunoprecipitated DNA materials as templates and primers from 
Table 4.2 and Table 4.3. The PCR products were run on an agarose gel to examine the results.  
4.2.4 NRF1 siRNA assays 
NRF1 siRNA primers were designed (Brummelkamp et al., 2002; Smith et al., 2004), 
cloned into the pSUPER siRNA vector and then sequenced to confirm the correct structure. SK-
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N- SH cells were sub-cultured onto 75 cm2 flasks 1 day before the nucleofection and reached 80-
90% confluence. On the day of nucleofection, 4 μg of pSUPER-NRF1 DNA were transfected into 
1×106 SK-N-SH cells using an Amaxa cuvette (Lonza) with Nucleofector® (Lonza) and the 
transfected cells were plated onto a 6-well plate. 24 hr after nucleofection, RNA was extracted 
with Trizol and treated by DNase I to remove genomic DNA contaminants. 1 μg of RNA from 
each sample was reverse transcribed into cDNA using SuperScript® III reverse transcriptase 
(Invitrogen) according to the manufacture’s instruction. PCR was performed using primers for 
each gene (Table 4.1) to examine gene expression with GAPDH as a negative control and NRF1 
as a positive control to ensure effective down regulation by siRNA.  
 
Table 4.2. Human ChIP primers for HSP genes. 
Target gene (primer)a Primer number Primer sequences 
SPG5 F RN3511 5'-TTGCTTGTCCGGCGCACCAG -3' 
SPG5 R RN3512 5'-TCCCCTCGCCATCTGGGTC-3' 
SPG6 F RN3630 5'-CCCCTCTTCCTGCTCCTCC-3' 
SPG6 R RN3631 5'-CACCAGGCTCGACACGACG-3' 
SPG7 F RN3464 5'-TCAGGCAGCCACGAGGTAGAC-3' 
SPG7 R RN3465 5'-AGCAGCAGCACGGCCATGTTG-3' 
SPG11 F RN3622 5'-ACGAATGGAATCGACCGGAG-3' 
SPG11 R RN3623 5'-CTTCCTCTGCAGCCATCTTG-3' 
 
a Abbreviations: F: forward PCR primer; R: reverse PCR primer. Gene sequences were obtained 
from the Ensembl genome browser (http://www.ensembl.org/Homo_sapiens/Info/Index). 
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Table 4.3. ChIP primers for the NRF1 promoter. 
Target gene (primer)a Primer 
number 
Primer sequences 
Human NRF1promoter F RN3511 5'-TTGCTTGTCCGGCGCACCAG -3' 
Human NRF1 promoter R RN3512 5'-TCCCCTCGCCATCTGGGTC-3' 
Human SNURF-SNRPN enhancer F RN2683 5'-CAGGTCTTGGAAGGCTATGTCG-3' 
Human SNURF-SNRPN enhancer R RN2684 5'-CTCCCCACTGGCGGCTCTAC-3' 
Marsupial Nrf1 promoter F RN3464 5'-TCAGGCAGCCACGAGGTAGAC-3' 
Marsupial Nrf1 promoter R RN3465 5'-AGCAGCAGCACGGCCATGTTG-3' 
Marsupial Snrpb promoter F RN3751 5'-AATAAGAAACAATGAATATGTGAGG-3' 
Marsupial Snrpb promoter R RN3752 5'-CACGACAAAACGGTCCGACTG-3' 
Marsupial Tfam promoter F RN3622 5'-ACGAATGGAATCGACCGGAG-3' 
Marsupial Tfam promoter R RN3623 5'-CTTCCTCTGCAGCCATCTTG-3' 
 
a Abbreviations: F: forward PCR primer; R: reverse PCR primer. Gene sequences were obtained 
from the Ensembl genome browser (http://www.ensembl.org/Homo_sapiens/Info/Index). 
 
4.2.5 Reporter constructs and luciferase reporter assays 
The minimal promoters of SPG4 and SPG6 were cloned by PCR into a pGL3-enhancer 
(pGL3e) luciferase vector using primers from Table 4.4. Either the pGL3e-SPG4 or -SPG6 
promoter construct was transfected into mammalian cells with 1) control siRNA; 2) siRNA 
targeting luciferase mRNA; or 3) siRNA targeting NRF1 mRNA.   
Based on sequence alignments of conserved promoter sequence of NRF1, luciferase 
reporter constructs were made by PCR cloning using primers in Table 4.5 to clone the minimal 
promoter sequence using genomic DNA from human SK-N-SH cells as template. PCR products 
were digested with BglII and HindIII for promoters or BamHI and SalI for enhancers, and the 
respective products ligated directionally into the pGL3basic vector (Promega). Site directed 
mutations were performed using primers in Table 4.5 with the GeneTailor™ Site-Directed 
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Mutagenesis Kit (Invitrogen) according to manufacturer’s instruction, and the mutated products 
were amplified by Platinum Taq DNA polymerase High Fidelity (Invitrogen). Each construct was 
sequenced to verify correct inserts. 
To study the parameters that affect NRF1 binding ability, six minigenes were synthesized 
in pIDTSMART vectors (by Integrated DNA Technology, Inc.), each containing 10, 8, 6, 4, 2, or 
1 copies of NRF1 consensus recognition sites (Table 4.6). These minigenes were subcloned from 
the pIDTSMART plasmids into the promoter position of a modified pGL3basic luciferase 
reporter vector (Figure 4.6).  
SK-N-SH cells were grown in a 6-well cell culture plate at a concentration of 1.8×105 
cells/well and each well cultured in 2 ml cell medium. When the cells reached 90% confluence, 1 
µg of each construct was transfected along with the pRL vector (Promega), a second luciferase 
vector used for normalization in the Dual-Luciferase® Reporter Assay System (Promega), with 
Lipofectamine 2000 (Invitrogen) into the cells. 24 hr after transfection, cell medium was removed 
from the cell culture, and washed once with PBS. 500 µl passive lysis buffer (Promega) was 
applied to each well and the culture plate was rocked at room temperature for 15 min. The lysates 
were then collected into a 1.5 ml tube and 100 µl LARII (Promega; freshly prepared for each 
luciferase assay) was added. The first luciferase activity reading was measured on a 20/20n 
luminometer (Turner Biosystem). Subsequently, 100 µl Stop & Glo® reagent (Promega) was 
added which allows the measurement of a second luciferase activity (Renilla) reading to 
normalize the results. The luciferase assay was repeated independently three times to test 
statistical significance by a student’s t-test. 
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Table 4.4. Primers for SPG4 and SPG6 promoter luciferase constructs 
Target gene (primer)a Primer 
number 
Primer sequencesb 
Human Spastin (SPG4) pr F  RN3470 5'-GCTTACGCGTTGAGCCGAACTGCACATTGG-3' 
Human Spastin (SPG4) pr R  RN3471 5'-CATACTCGAGGTCTCAGGAGCTCCGCACTG-3' 
Human NIPA1  (SPG6) pr F  RN3472 5'-GCTTACGCGTGCCCGCGCCTCCCGGTCACC-3' 
Human NIPA1  (SPG6) pr R  RN3473 5'-CATACTCGAGGCAGCTGCAGTCCCCATTCC-3' 
 
a Abbreviations: pr: promoter; F: forward PCR primer; R: reverse PCR primer. Gene sequences 
were obtained from the Ensembl genome browser 
(http://www.ensembl.org/Homo_sapiens/Info/Index). 
b Enzyme digestion sites are in bold and underlined. 
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Table 4.5. Primers for NRF1 promoter luciferase constructs 
Target gene (primer)a Primer 
number 
Primer sequences 
NRF1 sub-cloning primers into 
pGL3-basic promoter site F 
RN3622 5'-TCCAAGATCTGACCTCCTCATCATGGCGG-3' 
NRF1 sub-cloning primers into 
pGL3-basic promoter site R 
RN3623 5'-AATTAAGCTTCTCAGAGCGGCTGCGCTAC-3' 
NRF1 promoter YY1 mutation 
minigene for luciferase reporter 
assays 
RN3846 5'-AGATCTgacctcctcatcatggcggcggccgggcggggaagccgggccgtgcgt 
cgcgtgcgtgccctctccctcccctccccctcctcggcggcggcggcggcggcagaa 
gcggcagcgctcgcAaAATccgctggtggcaggaggctgcgaggagccggcgcggtc 
gcagtctccacggcgcaggcccacggtagcgcagccgctctgagAAGCTT-3' 
NRF1 promoter 5’ NRF1-like 
mutation minigene for luciferase 
reporter assays 
RN3847 5'-AGATCTgacctcctcatcatggcggcggccgggcggggaagccgggccgtgcgt 
cgcgtgcgtgccctctccctcccctccccctcctcggcggcggcggcggcggcagaa 
gcggcagcgctcgccattgccgctggtggcaggaggctgcgaggagccggcgcggtc 
gcagtctccacggAATaggAccacggtagcgcagccgctctgagAAGCTT-3' 
NRF1 promoter 3’ NRF1-like 
mutation minigene for luciferase 
reporter assays 
RN3848 5'-AGATCTgacctcctcatcatggcggcggccgggcggggaagccgggccgtgcgt 
cgcgtgcgtgccctctccctcccctccccctcctcggcggcggcggcggcggcagaa 
gcggcagcgctcgccattgccgctggtggcaggaggctgcgaggagccggcgcggtc 
gcagtctccacggcgcaggcccacggtagAATagccActctgagAAGCTT-3' 
NRF1 promoter 5’ & 3’ NRF1-
like mutations minigene for 
luciferase reporter assays 
RN3849 5'-AGATCTgacctcctcatcatggcggcggccgggcggggaagccgggccgtgcgt 
cgcgtgcgtgccctctccctcccctccccctcctcggcggcggcggcggcggcagaa 
gcggcagcgctcgccattgccgctggtggcaggaggctgcgaggagccggcgcggtc 
gcagtctccacggAATaggAccacggtagAATagccActctgagAAGCTT-3' 
 
a Abbreviations: F: forward PCR primer; R: reverse PCR primer. Gene sequences were obtained from the Ensembl genome browser 
(http://www.ensembl.org/Homo_sapiens/Info/Index). 
b Enzyme digestion sites are in bold and underlined. YY1 site is in bold pink. NRF1 site is in bold red. Mutated nucleotides are in 
uppercase.  
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Table 4.6. Minigenes for NRF1 tandem arrays in luciferase constructs. 
Minigenes with copy 
numbera 
Primer 
number 
Primer sequencesb 
NRF1 site tandem array (10 
copies) in a 230-bp mini gene 
RN3755 5’-TTAACTCGAGCGCGCATGCGCACCTCTGGGCCGTCGCATGCGCACCAGTCTAGCCG 
CGCAGGCGCGCTAGTCAGGCTGCGCATGCGCGCCATTGCCTGTGCGCAAGCGCGCTACT 
CGCACTGCGCATGCGCACCTTTGCATGGGCGCCTGCGCACAATGGTCTGCGCGCAGGCG 
CACACGTCAGACTGCGCAGGCGTGCACGTCGGGCGGCGCATGCGCAAGATCTTGTG-3’ 
NRF1 site tandem array (8 
copies) in a 186-bp mini gene 
RN3756 5’-TTAACTCGAGCGCGCATGCGCACCTCTGGGCCGTCGCATGCGCACCAGTCTAGCCG 
CGCAGGCGCGCTAGTCAGGCTGCGCATGCGCGCCATTGCCTGTGCGCAAGCGCGCTACT 
CGCACTGCGCATGCGCACCTTTGCATGGGCGCCTGCGCACAATGGTCTGCGCGCAGGCG 
CAAGATCTTGTG-3’ 
NRF1 site tandem array (6 
copies) in a 142-bp mini gene 
RN3757 5’-TTAACTCGAGCGCGCATGCGCACCTCTGGGCCGTCGCATGCGCACCAGTCTAGCCG 
CGCAGGCGCGCTAGTCAGGCTGCGCATGCGCGCCATTGCCTGTGCGCAAGCGCGCTACT 
CGCACTGCGCATGCGCAAGATCTTGTG-3’  
NRF1 site tandem array (4 
copies) in a 98-bp mini gene 
RN3758 5’-TTAACTCGAGCGCGCATGCGCACCTCTGGGCCGTCGCATGCGCACCAGTCTAGCCG 
CGCAGGCGCGCTAGTCAGGCTGCGCATGCGCGAGATCTTGTG-3’ 
NRF1 site tandem array (2 
copies) in a 54-bp mini gene 
RN3759 5’-TTAACTCGAGCGCGCATGCGCACCTCTGGGCCGTCGCATGCGCAAGATCTTGTG-
3’  
NRF1 site tandem array (1 
copy) in a 32-bp mini gene 
RN3760 5’-TTAACTCGAGCGCGCATGCGCAAGATCTTGTG-3’ 
 
a NRF1 binding sequences are experimentally confirmed NRF1 binding sites or high affinity sites based on the consensus sequence: 
5’-YGCGCANGCGCR-3’. DNase I footprint assay showed that at least 4 nucleotides on flanking sequence was needed for NRF1 
binding (Virbasius & Scarpulla, 1994). 
b NRF1 sites are in bold red. Enzyme digestion sites are in bold and underlined. 
151 
4.3 RESULTS 
4.3.1 NRF1 regulates hereditary spastic paraplegia genes in trans 
In this study, we have identified potential NRF1 binding sites in the promoters a total of 
10 known HSP loci with putative NRF1 binding sites in the 5’ regulatory region (Table 4.7). 
Importantly, the putative NRF1 binding sites in the promoters of most of the HSP loci were 
evolutionary conserved in all eutherian mammals, and for some sites in a marsupial (M. 
domestica) and a monotreme (platypus) (examples are shown in Figure 4.2 for SPG4, SPG5, 
SPG6 and SPG7). Evolutionary maintenance of so-called “phylogenetic footprints” provides 
strong evidence that a DNA-binding protein recognizes that sequence. In several of the HSP gene 
promoters, such as for SPG6 and SPG7, putative NRF1 and Sp1 (a TF binding at most “CpG-
island” of mammalian gene promoters) motifs were the only predicted conserved binding sites 
and for others, such as SPG5 and SPG4, the putative NRF1 binding site(s) were the main 
conserved binding sites, attesting to the likely significance of NRF1 regulation. 
To show that NRF1 physically binds in vivo at these regulatory elements, we used ChIP in 
a human neuroblastoma cell line, SK-N-SH, that robustly expresses mRNA for all investigated 
HSP genes (Figure 4.3; data not shown). The ChIP assay confirmed that NRF1 binds specifically 
and robustly to the promoters at all predicted sites for HSP genes in human SK-N-SH cells 
(examples are shown in Figure 4.4, summarized in Table 4.5). Similarly, ChIP assays were 
performed in mouse Neuro2A cells and NRF1 binds robustly to all predicted sites for mouse 
orthologs of HSP genes (data not shown). NRF1 regulation of HSP loci within neuronal-like cells 
was further confirmed by knocking down the steady-state level of endogenous NRF1 mRNA 
using silencing RNA (siRNA) studies. The siRNA treatment was effective, knocking down the 
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NRF1 mRNA level dramatically but not affecting the mRNA level of a control gene, GAPDH 
(Figure 4.5). Indeed, all tested HSP loci having NRF1 motifs that bind the TF in ChIP assays 
demonstrated a major reduction in mRNA levels in the NRF1 siRNA-treated cells (Figure 4.5). 
Utilizing luciferase reporter vectors, further assays of transcriptional promoter function 
have been employed to molecularly dissect the transcriptional mechanisms for HSP gene 
promoters. Functional promoters will drive transcription, with the degree of light produced a 
marker of the amount of luciferase enzyme produced and hence of transcriptional activation levels. 
We did this for the evolutionary conserved segments of the SPG4 and SPG6 promoters (Figure 
4.6), with high levels of promoter activity found [Figure 4.6(b) & (c), control siRNA columns]. 
Using co-transfection with a siRNA targeting the luciferase mRNA, promoter activity was 
significantly down-regulated [Figure 4.6(b), (c)], while both SPG4 and SPG6 promoter activity 
was essentially abolished using siRNA targeting the endogenous NRF1 mRNA [Figure 4.6(b), 
(c)].These results confirm the phylogenetic predictions, that NRF1 provides the major regulatory 
activity at these promoters.  
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Table 4.7. Summary of HSP loci with NRF1 regulation. 
HSP locus (Gene) Human 
Chra 
Presence of putative 
NRF1 site by 
bioinformaticsb 
Function ChIP 
confirmation in 
SK-N-SH cells 
SPG4 (SPASTIN) 2p22 + Cytosolic microtubule severing protein, with 
AAA and MIT domains  
Yes 
SPG5 (CYP7B1) 8q12.3 + (intron 1) Cytochrome p450 enzyme, cholesterol and 
steroid metabolism 
Yes 
SPG6 (NIPA1) 15q11.2 + Transporter; in ER and endosome membranes Yes 
SPG7 
(PARAPLEGIN) 
16q24.3 +++ Mitochondrial protein, AAA ATPase domain 
 
Yes 
SPG8c 
(STRUMPELLIN) 
8q24 + Protein function unknown, contains spectrin 
domains, involved in motor-neuron outgrowth  
 
Yes 
SPG11 
(SPATACSIN) 
15q15.3-
q21.1 
La Not known (proposed TM domains not verified 
by our analyses) 
Yes 
SPG13 (HSP60) 2q24-
q34 
++L Mitochondrial chaperonin, heat shock protein Yes (proximal 
and distal) 
SPG20 (SPARTIN) 13q12.3 + MIT domain, endosomal protein Yes 
SPG33 (ZFYVE27) 10q24.2 + Promotes neurite formation, involved in 
membrane traffic events 
Yes 
SPG42 (SLC22A1) 3q25.31 _d Acetyl-CoA transporter Not tested 
 
a Abbreviations: chr: chromosome; L: NRF1-like site (sites with one mismatch in one GCGC motif are defined as NRF1 like site). 
b All confirmation of NRF1 sites was by ChIP analysis using human SK-N-SH and mouse Neuro2A neuroblastoma cell lines, and for 
SPG4 and SPG6 also by luciferase reporter promoter analyses. In addition, NRF1 regulation of all these genes was seen using siRNA 
that targeted and knocked down the level of NRF1 mRNA in human SK-N-SH neuroblastoma cells. 
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c No NRF1 site occurs in the 5’ regulatory region in rodents; the NRF1 site in human SPG8 and NRF1-like site in SPG11 are 
conserved in all other non-rodent sequenced mammalian genomes. 
d No NRF1 site in the 5’ regulatory region in primates; a site in mouse Spg42 is conserved in all other sequenced mammalian 
genomes. 
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Figure 4.2. (a) (continued below) 
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Figure 4.2. (b), (c) (continued below)
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Figure 4.2. Evolutionary conserved NRF1 binding motifs in 5’ regulatory regions of HSP loci. Multi-sequence alignments were 
generated using Clustal W with manual adjustments, and representative examples are shown (* = conserved nucleotides): (a) SPG4, (b) 
SPG5, (c) SPG6, and (d) SPG7. In (c), z (36-nt) and Z (28-nt) are species-specific insertions in M. domestica and platypus, 
respectively; in (d), x is a 31-nt insertion in the rabbit. 
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Figure 4.3. HSP gene expression studies in human SK-N-SH cells. bp: base pair. H2O is PCR 
control. 
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Figure 4.4. NRF1 binds at HSP gene promoters in human SK-N-SH cells by ChIP. Antibody 
positive is shown as Ab+, controls are no antibody (Ab-), total input (TI) DNA is for PCR 
positive control, H2O is PCR negative control, and the positive ChIP control is the SNURF-
SNRPN enhancer (Rodriguez-Jato et al., 2005). 
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Figure 4.5. siRNA targeting NRF1 mRNA knocks down HSP gene expression. SK-N-SH cells 
were transfected with pSUPER-NRF1 siRNA or mock transfected as a control, with qualitative 
analysis of gene expression including a negative control (GAPDH). The GAPDH mRNA level is 
unaffected by NRF1 siRNA, whereas the mRNA levels for NRF1 and all shown HSP genes are 
reduced by the siRNA treatment (including two mRNA splice isoforms for SPG33). 
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Figure 4.6. siRNA targeting the NRF1 mRNA ablates SPG4 and SPG6 promoter function. A 
pGL3e-SPGx-promoter [x = 4 or 6; constructs are shown in (a)] plasmid and a siRNA plasmid 
(either targeting an Arl2 control, Luc, or NRF1) were co-transfected into SK-N-SH cells. 
Luciferase activities were measured for the (b) SPG4 promoter and (c) SPG6 promoter. *, P < 
0.05, for the control siRNA versus test siRNA (targeting Luc or NRF1). 
 
 
4.3.2 NRF1 autoregulates and enhances transcriptional activity 
Since we found evolutionary conserved potential NRF1 binding sites in the 5’ regulatory 
region of the gene, we then used molecular assays to confirm these findings. First, to test whether 
NRF1 binds this region, we used a ChIP assay and confirmed that NRF1 binds this site in the 
human SK-N-SH neuroblastoma cell line [Figure 4.7(a)], in the mouse Neuro2A neuroblastoma 
cell line (data not shown), and to the conserved, homologous region in a marsupial fibroblast cell 
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line [Figure 4.7(b)]. As shown by phylogenetically conserved motifs (Figure 4.1), YY1 is 
another conserved binding motif we found in the promoter of NRF1. Similarly, we used ChIP to 
confirm that YY1 binds to the NRF1 promoter in SK-N-SH cells [Figure 4.7(c)] and Neuro2A 
cells (data not shown).  
Next, we used luciferase reporter assays to test the degree of effects that each TF has on 
the regulation of NRF1. We cloned a minimal NRF1 promoter-exon 1 sequence, including one 
Sp1 site, two NRF1 sites and one YY1 site, into a pGL3basic luciferase vector and generated 
mutations of 1) each and 2) both NRF1 sites, as well as 3) the YY1 site (Figure 4.8). Then, we 
co-transfected each pGL3basic derived construct with a Renilla luciferase vector as an internal 
control into a human peripheral neuronal precursor cell line, Flp-In 293 cells. As shown in Figure 
4.8, the WT NRF1 promoter-exon 1 promoter significantly increased luciferase activity by 87-
fold compared to the empty vector (P<0.001), indicating a functional promoter construct. The 
promoter activities of all mutant constructs had a dramatic decrease in luciferase activity when 
compared to the WT construct (Figure 4.8). Specifically, when the YY1 site was mutated, the 
luciferase activity decreased by 67% or 29-fold (P<0.05). Mutation of either 5’- or 3’-NRF1 site 
decreased luciferase activity to 58% or 51-fold (P<0.05) and to 55% or 48-fold (P<0.05), 
respectively; whereas mutations of both NRF1 sites decreased luciferase activity to 44% or 39-
fold (P<0.05). These results indicate that both NRF1 sites have a significant effect on regulating 
its own promoter to increase transcriptional activity. Nevertheless, the two NRF1 sites do not 
synergize in transcriptional activity, suggesting that only one NRF1 homodimer binds this region 
in its own promoter. This is probably due to the spacing between the two NRF1 sites in this 
region that is too small (4 nucleotides apart, Figure 4.1) for two NRF1 homodimers to bind 
163 
efficiently, since a minimum of 8 nucleotides between two NRF1 sites are needed (Virbasius & 
Scarpulla, 1994). 
 
 
 
 
 
 
Figure 4.7. ChIP studies of the NRF1 promoter-exon 1 region. (a) NRF1 ChIP in SK-N-SH 
cells. (b) NRF1 ChIP in marsupial cells. (c) YY1 ChIP in SK-N-SH cells. Antibody positive is 
Ab+, controls are no antibody (Ab), total input (TI) DNA is for PCR positive control, H2O is PCR 
negative control, and the positive ChIP control is the SNURF-SNRPN enhancer (Rodriguez-Jato et 
al., 2005). 
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Figure 4.8. Luciferase reporter assays for NRF1 promoter activity. NRF1 promoter (pr) luciferase constructs (left) showing TF 
binding sites (Sp1, YY1, NRF1) and mutations (mu; X) in TF sites. Luciferase reporters assays (right). *, P < 0.05 
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4.3.3 Relationship between number of NRF1 sites and promoter activity 
Luciferase reporter vectors with 10, 8, 6, 4, 2, or 1 copies of NRF1 binding sites were 
cloned into a modified pGL3basic vector to test how the number of NRF1 sites affect the level of 
transcriptional activity. The results indicated that these artificial NRF1-only sequences provided 
significant promoter function, and that luciferase activity increased as the number of NRF1 sites 
was increased [Figure 4.9(a)]. However, the relationship between the number of NRF1 sites in 
the promoter and effect on activating transcription was not purely linear [Figure 4.9(a)]. In this 
system, two NRF1 sites had 6-fold increased luciferase activity compared to one NRF1 site, while 
doubling to four NRF1 sites increased activity a further 14-fold (80-fold over a single NRF1 site). 
For unknown reasons, increasing to six or eight NRF1 sites had only no or small effect on 
luciferase activity, respectively, whereas ten NRF1 sites had a 2-fold further increase in promoter 
activity compared to eight NRF1 sites and for a total of 245-fold that of a single NRF1 site 
[Figure 4.9(a)]. In testing the correlation between the number of NRF1 sites versus the level of 
transcriptional activity, there was a strong correlation [correlation=0.94, Figure 4.9(b)]. In Excel, 
such data was plotted and fitted the best to a polynomial regression with order of 2 [R2=0.9224, 
Figure 4.9(b)]. Therefore, I conclude that the number of NRF1 sites has positive effect in 
activating transcriptional activity of a promoter in the luciferase reporter system.   
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Figure 4.9. Luciferase reporter assays for NRF1 binding site tandem arrays. (a) NRF1 tandem array luciferase constructs (left). 
Luciferase reporters assays (right). *, P < 0.05; **, P < 0.001; *, P < 0.0001.  (b) Correlation between relative luciferase activity 
versus the number of NRF1 sites. 
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4.4 DISCUSSION 
4.4.1 NRF1 regulates spastic paraplegia genes in trans 
By bioinformatics analysis and molecular assays, we have shown that NRF1 regulates 
many HSP genes. Our findings suggest that NRF1 may contribute significantly to gene regulation 
in the cortical neurons that extend corticospinal axons which degenerate in HSP. As would be 
expected, in some of these HSP gene promoters, there are also other conserved TF binding sites. 
For example, there is a highly conserved site for SOX4 and SOX11 in the SPG4 promoter 
[Figure 4.2(a)]. Mutation of this site significantly reduced luciferase activity while activity of the 
SPG4 promoter was significantly increased with SOX11 overexpression (B. Henson, R.D. 
Nicholls, personal communication).  
As well as transcriptional regulation, it has become increasingly clear that a major 
additional regulatory mechanism exists in cells with modulation of mRNA stability and/or the 
level of translation of an mRNA by a novel functional class of very small RNA molecules termed 
microRNAs (miRNAs; Rivera & Bennett, 2010). Typically, mature, processed miRNAs are 
single-stranded RNAs 20-25 nucleotides in length (Chi et al., 2009). Mechanistically, miRNAs 
base-pair with their RNA targets, beginning with a 6-8 nucleotide “seed” sequence localized at 
the 5’ end of a miRNA (Chi et al., 2009). The “seed” provides sufficient specificity for each 
miRNA to potentially regulate several hundred mRNAs with a range of less than 100 to over 
1000 targets (Chi et al., 2009). Other members in our laboratory have shown that the miR-
183/96/182 family miRNAs target sites in one-third of HSP mRNAs (B. Henson, R.D. Nicholls, 
personal communication). This provides further insight into the GRNs for HSP genes. An 
understanding of transcriptional plus miRNA regulatory signatures may help to identify and rank 
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the top candidate genes within large chromosomal domains linked to more than 20 uncloned HSP 
chromosomal regions (Blackstone et al., 2011). 
4.4.2 NRF1 autoregulation 
By phylogenetic analysis, we showed that NRF1 and YY1 binding sites in the NRF1 
promoter are within a functionally selected region over the past ~450 million years (Figure 4.1). 
These NRF1 and YY1 sites are also conserved in Ciona species (data not shown), among the most 
primitive vertebrates; further attesting to the importance of these regulatory features. Our 
molecular results demonstrated that NRF1 acts by a feed-forward mechanism to regulate its own 
transcriptional activity in a positive way. Based on the results from luciferase reporter assays, 
YY1 is also a transcriptional activator for the NRF1 promoter. Since Sp1 is a common 
transcriptional activator in most mammalian promoters of the CpG-rich class (Pugh & Tjian, 
1990), we hypothesize that there must be a negative mechanism of TF regulation associated with 
the NRF1 promoter to repress its gene expression. Within intron 1 of NRF1, a conserved DNA 
element corresponds to a putative C/EBP (CCAAT/enhancer-binding protein) site (Figure 4.1). It 
was reported that C/EBP can either be a transcriptional activator (Landschulz et al., 1988) or 
repressor (Pei & Shih, 1990). Therefore, the next step in better understanding the transcriptional 
regulation of the NRF1 gene is to test if C/EBP is the TF that binds to this site and whether this 
site positively or negatively regulates NRF1 transcription. To further assess the complex question 
of how NRF1 regulates itself in vivo, it will be interesting to overexpress NRF1 protein in a cell 
line model and investigate how the increase of NRF1 protein level affects the transcription of 
NRF1 mRNA to maintain homeostasis of the NRF1 protein levels. 
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4.4.3 Relationship between number of NRF1 sites and promoter activity 
Here, I reported that number of NRF1 sites in an artificial promoter has a positive role in 
regulating transcriptional activity. Indeed, similar natural clusters of NRF1 sites occur in 
transcriptional regulatory sequences. For example, SPG7 promoter has 1 (bat) to 6 (small 
Madagascar hedgehog) NRF1 sites [Figure 4.2(d)], SPG4 promoter has up to 3 NRF1 sites 
[Figure 4.2(a)], “NRF1 cluster” enhancer in the PWS domain has 4 sites (Figure 2.2), and 5’ 
regulatory regions of other candidate genes have various number of NRF1 sites, e.g., EIF5A 
(eukaryotic translation initiation factor 5A, 7 NRF1 sites), MAP2K7 (mitogen-activated protein 
kinase kinase 7, 4 NRF1 sites), etc (data not shown).  
Numerous studies have found that spacing between TF binding sites is also a critical 
determinant of gene expression (Vilen et al., 1991; Nolte et al., 2006; Cheung et al., 2007; 
Larsson et al., 2007). Therefore, it provides another direction in exploring the structure and 
affinity of NRF1 binding. The artificial NRF1 site arrays discussed above or the “NRF1 cluster” 
enhancer element from the PWS domain would provide suitable reagents to alter the spacing of 
the NRF1 sites to assess the effect on promoter or enhancer activity in in vitro luciferase studies. 
Similarly, the parameters of match to consensus NRF1 recognition sequence could also be studied 
in this assay system, since the structure of NRF1 has not been determined, such studies could 
provide insights into the properties of DNA binding by NRF1.  
This study has served as a prelude to a future goal of determining the structure of NRF1, 
the mode of binding to target sites, and changes in affinity for different targets. In the long term, 
such studies may help to develop small molecule regulators of NRF1 function as drugs in diseases 
involving NRF1 deregulation, including diabetes, obesity, cancer and neurological diseases.  
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5.0  CONCLUSIONS AND FUTURE STUDIES 
5.1 CONCLUSIONS 
A GRN is a central processing unit in a living cell. GRN are composed of a collection 
of DNA segments which interact with each other by RNAs or proteins through intracellular 
and/or extracellular signals, thereby governing the rates at which genes in the network are 
transcribed into mRNA (Macneil & Walhout, 2011). A major class of regulators in a GRN is TF 
(Macneil & Walhout, 2011). The binding of TFs to specific DNA elements provides a major 
mechanism in the fundamental basis of a GRN (MacQuarrie et al., 2011). Other components in a 
GRN include RNA regulators, e.g., miRNA and lincRNA (long intergenic noncoding RNA, Wang 
et al., 2011), and chromatin factors, such as histone modifications (Macneil & Walhout, 2011). 
For over half a century, studies have been focused on TF regulation in order to study GRN (Chen 
& Rajewsky, 2007). The development of computational analysis in biological fields enables a 
preliminary scan for TF binding sites in the human genome, for which the biological importance 
can initially be tested by molecular phylogenetic analysis due to the wealth of animal whole 
genome sequences. The advent of new molecular techniques, such as ChIP–chip and ChIP-seq, 
allows more efficient direct experimental confirmation of bioinformatics results (Pareek et al., 
2011). Other technologies, such as siRNA knockdown of an mRNA encoding a TF and hence of 
protein levels, or TF overexpression, followed by whole genome RNA analyses by expression 
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microarrays or RNA-seq (a next generation sequencing approach) also provide confirmation by 
dysregulation of expression of target genes for a specific TF. High throughput technologies in 
experimental model systems are now allowing assessment of more than one factor at a time in 
system approaches (Pareek et al., 2011). 
In my research projects, I tried to make good use of both bioinformatics analysis and 
experimental techniques to elucidate the mechanisms and functional roles of NRF1 binding sites 
in the human genome. In particular, I have focused on NRF1 regulation in the 2 Mb PWS domain 
and the circadian system. In addition, I started to explore the function of NRF1 in regulating HSP 
genes and its own autoregulation. NRF1 binding sites were found in 5-6% of the promoters in the 
human genome by bioinformatics searches and ChIP-chip studies (Cam et al., 2004; FitzGerald et 
al., 2004; Xi et al., 2007). It is known that many nuclear genes encoding mitochondrial products 
are regulated by NRF1 (Scarpulla, 2008). In our laboratory, bioinformatics analysis and molecular 
studies showed that NRF1 is overrepresented in the three systems we studied. NRF regulates 83% 
of the genes in the 2 Mb PWS region, 56% in circadian regulatory genes, and 45% in HSP genes 
(Figure 5.1). My studies have provided important evidence on NRF1 binding elements and initial 
studies towards identifying GRNs that involve NRF1.  
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Figure 5.1. Systems with enrichment of transcriptional regulation by NRF1 in the human 
genome. 
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5.2 FUTURE STUDIES 
For future work, we should not only focus on the study of specific TF binding sites such 
as NRF1, but also on cis-regulatory modules, that include binding sites for NRF1 and other TFs 
with which it may co-regulate different classes of genes. In Chapter 2, an original goal was to 
use somatic cell hybrids for a gene targeting experiment in order to study the mechanism of the 
“NRF1 cluster”, a putative cis-regulatory module with enhancer function, on long-range 
regulation of the 2 Mb PWS-imprinted domain. Although my studies in somatic hybrid cells 
showed that none of these cell lines were suitable for gene targeting of the “NRF1 cluster” due to 
a lack of active chromatin at this site in these cells, the somatic cell hybrids studies nevertheless 
provided gene expression and chromatin configuration profiles of NRF1 binding and histone 
methylation for understanding gene regulation over the 2 Mb imprinted PWS domain. Optimally, 
the cis-regulatory role(s) of the “NRF1 cluster” can be investigated by gene targeting in mouse 
embryonic stem cells and subsequent analysis in knockout mice, to determine the extent to which 
this element is required for active chromatin an how many of the genes it regulates in a neural-
specific manner within the PWS-orthologous domain in the mouse.  
In the study of circadian rhythms, my work indicates that NRF1 acts as a potential master 
regulator of this complex system with targets in both the positive and negative feedback 
regulatory loops. It will be crucial to study how NRF1 interacts with CLOCK/BMAL1 
heterodimers in a molecular complex and regulates the expression of other circadian regulatory 
genes. In addition, studies of activity patterns, sleep, and metabolism in Nrf1 +/- heterozygous 
mice compared to WT controls will be of significant interest. Identification of overrepresented 
motifs in sequences associated with NRF1-regulated elements in circadian regulatory genes can 
help to identify additional potential TFs that may interact and/or function with NRF1 in the 
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circadian system. Other future studies would examine the role of NRF1 in SCN neurons and 
neuronal input and/or output pathways to the central circadian regulator.  
My studies of NRF1 binding sites in HSP genes have provided substantial data for our 
laboratory to continue studies of the function of NRF1 in this complicated neural system. Recent 
studies have confirmed that another TF, SOX11, regulates SPG4 (see Figure 4.2) along with 
NRF1 (B.J. Henson, R.D. Nicholls, unpublished data). Further, our laboratory has also identified 
overrepresented miRNA target sites in HSP mRNAs, predicting that the miR-96/-182 family 
miRNAs target nine HSP loci, an 8.5- to 11.5-fold increase over expectation (B.J. Henson, R.D. 
Nicholls, unpublished data). To date, our laboratory has confirmed miR-96/-182 regulation of 
SPG4, SPG6, SPG1, and of NRF1, with dynamic regulatory effects on mRNA and translation 
levels depending on cellular conditions. This work has therefore identified major TF and miRNA 
regulators within GRN important for neuronal function and maintenance of motor cortex axons 
that extend along the corticospinal tracts that degenerate in HSP. Future studies will identify 
additional transcriptional and miRNA regulatory elements for known HSP genes, and our 
laboratory plans to use the NRF1 + miR-96/-182 regulatory signature to identify and rank the top 
candidate genes within large chromosomal domains linked to uncloned HSP loci to aid 
identification of the disease genes. In the long term, this research program is identifying new 
functional elements for mutation studies in HSP, will provide a streamlined set of candidate genes 
for more rapid and cheaper identification of uncloned HSP genes, and may provide new targets 
for novel therapeutic approaches in neurodegenerative diseases. 
Obesity and diabetes are prominent public health issues in the USA and worldwide, and 
are associated with cardiovascular and other diseases (Lowell & Shulman, 2005; Keller, 2006; 
Kouris-Blazos&Wahlqvist, 2007). It has been suggested that variation in genetic loci and 
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environmental factors have additive effects on metabolic and mitochondrial pathways in type II 
diabetes (Lowell & Shulman, 2005). Intriguingly, many genes encoding mitochondrial functions 
and regulators, including NRF1, have decreased expression in muscle from type II diabetes 
patients (Patti et al., 2003). A recent study has suggested genetic polymorphisms linked to NRF1 
could be a susceptibility factor for type II diabetes possibly by conferring abnormalities in 
triglyceride metabolism (Liu et al., 2008). Also, studies in our laboratory have found that NRF1 is 
a master regulator of gene expression in the PWS region (Stefan et al., in preparation), a 
neurobehavioral disorder associated with childhood onset of severe obesity, and that NRF1 
regulates multiple genes involved in type II diabetes (M. Stefan, R.D. Nicholls, unpublished data). 
Furthermore, regulatory genes in circadian rhythms are also implicated in diabetes and obesity 
(Bass & Takahashi, 2010; Huang et al., 2011). Therefore, a better understanding of NRF1 target 
genes and pathways may provide important insights into the biological pathways and 
pathogenesis of diabetes, obesity, and other human disease not yet studied in detail (e.g., cancer), 
in addition to the roles that we have defined for NRF1 regulation in PWS, HSP, and circadian 
function.  
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APPENDIX 
[MULTI-SEQUENCE ALIGNMENTS FOR 20 CIRCADIAN REGULATORY GENE PROMOTERS OR ENHANCERS] 
(a) BTRC promoter (ChIP); (b) PPP5C promoter (ChIP); (c) FBXL15 promoter (ChIP); (d) WDR5 promoter (ChIP); (e) 
TIMELESS intron 1 (ChIP); (f) TEF promoter (ChIP); (g) HSF1 promoter (ChIP); (h) EZH2 promoter (ChIP); (i) CIPC promoter 
(ChIP); (j) CHORDC1 promoter (ChIP);  (k) ALAS1 promoter (ChIP, pub); (l) FMR1 promoter (pub); (m) FXR2 promoter (pub); (n) 
CSNK1E intron 1 (no exp); (o) NR1D2 intron 1 (no exp); (p) CREM promoter (no exp); (q) MYBBP1A promoter (no exp); (r) RAB3A 
intron 1 (no exp); (s) ATF5 intron 1 (no exp); and (t) PROK2 promoter (no exp). Consensus sequences for CLOCK/BMAL1 (E-box), NRF1, 
NF-Y, RORE, DBP, and Sp1 motifs are highlighted in pink, red, green, orange, brown, and purple, respectively. ChIP indicates those cis-
regulatory elements that we have shown bind NRF1 in SK-N-SH cells (see Figure 3.2). Previous publications (pub) have established that NRF1 
regulates three of these promoters (for ALAS1, FMR1, and FXR2) but we present here expanded multisequence alignments. For seven genes, no 
experimental (no exp) data has been obtained, other than the phylogenetic conservation presented here.  
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